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Fatal cancer disease accounts for a leading cause of deaths worldwide: approximately 1 in 
every 7 deaths is cancer-related1,2. Cancer progression occurs as a multi-step process which 
includes growth of a locally confined primary tumor, the onset of cancer cell invasion and 
subsequent dissemination to distant organs giving rise to metastatic lesions3–5 (Fig. 1). 90% 
of cancer related deaths are caused by development of distant metastases, however the 
mechanisms of distant metastasis formation are poorly understood and preventive therapy to 
inhibit or delay metastatic cancer progression is lacking6,7. Studying the metastatic cascade 
and associated mechanisms underlying therapy failure is thus of utmost importance to gain the 
insight needed for development of efficient therapies for all cancer stages to decrease overall 
mortality rate. Focusing on this aim in this thesis mechanisms underlying progression and 
therapy response of two mesenchymal tumor types (i.e. soft tissue sarcoma and melanoma) 
were investigated, with a particular focus on integrins and their role in the metastatic cascade 
and as mediators of therapeutic resistance. 
ECM
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Figure 1. Steps of metastatic cancer progression.
At the primary site, invading cancer cells leave the growing tumor lesion eventually intravasating into local 
blood vessels. As CTCs in the blood stream cancer cells reach distant organs followed by extravasation. 
Outgrowth to macroscopic metastases is often preceded by a phase of growth arrest and persistence 
(dormancy). 
Modified from: Alexander, S. & Friedl, P. Cancer invasion and resistance: Interconnected processes of 
disease progression and therapy failure. Trends Mol. Med. 18, 13–26 (2012).
Cancer development and progression as a multi-step process
Initiation of primary tumor growth
Underlying cause for the development of a primary tumor are genomic alterations, including 
either inherited mutations or newly acquired defects developed among others as consequence 
of aging, exposure to mutagens (e.g. UV irradiation, toxins, tobacco smoke) and/or secondary 
to chronic inflammation8–12. If these alterations affect proto-onco- and/or tumor suppressor 
genes, cellular pathways usually balancing survival, proliferation and apoptosis become 
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12  |  Chapter 1
deregulated, eventually resulting in an abnormally growing cell mass, which can arise from 
essentially every tissue type in the human body13,14.
The most common cancer types are of epithelial or mesenchymal origin15,16. Epithelial tissue 
lining the body surface or cavities and glands is characterized by apical-basal polarization and 
strong cell-cell coherence17. In contrast, mesenchymal cells are individual, unpolarized and 
motile with a fibroblast-like shape and surrounded by an extracellular matrix (ECM) to constitute 
connective tissues including bone, cartilage and blood18. Primary tumors developing from 
these two tissue types initially maintain these basal characteristics, though with continuing 
progression and the onset of invasion dedifferentiation and phenotype switches may occur, 
shaping both, morphology of the primary lesion and the mode of invasion19,20. 
Cancer invasion 
The onset of cancer invasion constitutes the first step of the metastatic cascade4 (Fig. 1). 
Prerequisite for cancer cell invasion is that cells become mobile to detach and migrate out of 
the primary tumor into the surrounding tissue and, dependent on the environment and cancer 
type, the ability to remodel ECM and basement membrane in order to condition the tissue 
microenvironment, clear the migration path and penetrate the tissue4,21. Whereas mesenchymal 
cells intrinsically exhibit a motile phenotype and low cellular adhesion which facilitates invasion, 
for epithelial tumors it was assumed that upon exposure to extrinsic factors individual cells 
become reprogrammed and undergo an epithelial to mesenchymal transition (EMT) to lower 
cell-cell adhesion and gain motility for subsequent invasive behavior22. However, with the 
discovery of collective migration patterns and advanced expression profiling techniques it 
became clear that EMT is not a prerequisite for invasion and metastasis of epithelial cancer 
cells23–25. Thus currently cancer cell invasion modes are classified in two main categories i.e. 
individual cell migration and multicellular collective migration (Fig. 1,2), with or without EMT 
signature including partial EMT20,26.
Cells lacking cell-cell adhesion invade as single cells using either mesenchymal or amoeboid 
migration strategies20 (Fig. 2). During mesenchymal invasion cells are rather elongated or 
spindle-shaped caused by high levels of cell-ECM adhesion and the establishment of focal 
adhesions at the leading edge needed to propel the cell body forward27 (Fig.2). In contrast, 
amoeboid cells appear rounded and are not dependent on cell-matrix adhesions but 
movement relies on cortical actomyosin contractility and the presence of a confined interface 
and sufficient space between tissue structures27 (Fig.2). 
Collective invasion is executed by cells retaining their cell-cell junctions, thus migrating as 
cohesive multicellular clusters or strands along or through tissue structures20,28,29 (Fig.2). The 
migrating collective develops a polarized structure with pulling leader cells at the front and 
pushing follower cells in the rear part, facilitated by a supracellular organization of the actin 
cytoskeleton helping to generate protrusion and traction forces necessary for displacement 
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of the cell cluster while maintaining cellular junctions30–32. Chapter 2 describes which general 
guidance principles become employed during collective migration to efficiently coordinate 
processes like collective cancer invasion. Individual cells which are not or just transiently 
connected via stable cellular junctions but follow the same gradient or share the same 
migration path resemble a collective migration pattern. Though, unlike collectively invading 
cells, each cell is able to generate individual traction forces on the matrix and therefore this 
type of movement is described as multicellular streaming20,33 (Fig. 2).
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Figure 2. Modes of cancer cell invasion.
Whereas for single-cell migration modes junctions between cancer cells are dispensable, during 
multicellular streaming weak, transient junctions might form. In contrast, all collective migration modes 
rely on strong cell-cell cohesion between cancer cells. Red lines represent cellular junctions.
Modified from: Friedl, P., Locker, J., Sahai, E. & Segall, J. E. Classifying collective cancer cell invasion. 
Nat. Cell Biol. 14, 777–83 (2012).
Based on their intrinsic property of strong cell-cell cohesion, collective invasion is mainly 
attributed to epithelial cancers whereas mesenchymal tumor cells with a lower tendency to 
adhere to each other are expected to show a rather single cell invasion pattern or multicellular 
streaming34. However, as shown in in vitro and in vivo model systems as well as through 
histological analysis of patient samples28,35–37, also these type of cancer cells are able to migrate 
collectively. In chapter 3 the tissue determinants underlying this plasticity behavior were 
investigated in vitro using 3D collagen matrices, identifying ECM porosity and confinement 
as major factors determining the invasion mode of mesenchymal tumor cells. The switch to 
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14  |  Chapter 1
collective invasion went along with increasing ECM confinement, supporting the concept of 
cell jamming as mechanism underlying a collective migration pattern of mesenchymal cancer 
cells.
Metastasis formation
Regardless of whether invading individually or collectively, during metastatic cancer 
progression disseminating cancer cells will eventually enter the vasculature to circulate with 
the blood, where they can be detected as circulating tumor cells (CTCs)38 (Fig. 1). CTCs are 
considered as indicator for ongoing dissemination of cancer cells and used as prognostic 
marker39. The rate-limiting steps between intravasation and metastatic outgrowth are (i) 
survival of cancer cells in the blood stream, (ii) adherence to the vessel wall and subsequent 
extravasation at a distant site and (iii) survival and onset of proliferation at the metastatic site4. 
Compared to single cells, collective invasion and subsequent dissemination of multicellular 
clusters (collective metastasis) clearly enhances the efficiency of metastatic seeding as it 
increases survival in the blood stream and in the “foreign” metastatic environment40–42. 
Furthermore, primary tumors have the ability of premetastatic conditioning: via secretion of 
tumor-derived factors and bone marrow-derived cells stimulated by the primary tumor, future 
metastatic sites become modified to create an environment that facilitates homing and thus 
survival and proliferation of disseminated cancer cells3,43. However, despite these adaptations 
of cancer cells to overcome the rate-limiting steps, just 0.1% of all CTCs succeed in efficient 
metastatic outgrowth44,45 (Fig. 1). Thus, as such metastasis formation is a quite inefficient 
process but nevertheless the most fatal step in progressing cancer disease, especially 
because disseminated cancer cell can remain dormant for decades till growing out to form 
established metastatic lesions46.
Sarcoma and melanoma cell lines
The findings described in this thesis focus on two types of malignant mesenchymal tumors 
i.e soft tissue sarcoma and melanoma, represented by the HT-1080 sarcoma and MV3 
melanoma cell line. 
HT-1080 sarcoma 
Sarcoma comprise a class of malignant tumors originating from a mesenchymal cell type, likely 
a stromal stem cell47. The classification of this cancer type has recently been updated based 
on new and improved genetic and histological findings48,49. The HT-1080 sarcoma cell line has 
been generated in 1972 from a biopsy of a “poorly differentiated highly malignant fibrosarcoma” 
growing adjacent to the acetabulum50. While back then the term “fibrosarcoma” included any 
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sarcoma containing fibroblasts which constituted 60-70% of all sarcoma diagnoses51 based 
on the current WHO classification a “fibrosarcoma” excludes the presence of any other 
line or differentiation pattern but fibroblasts, making this diagnosis quite rare nowadays49. 
Therefore most likely the HT-1080 cell line is not derived from a “true” fibrosarcoma but rather 
needs to be classified as “undifferentiated high-grade pleomorphic sarcoma” according to the 
new guidelines49. Morphologically HT-1080 sarcoma cultures include typical mesenchymal 
elongated and spindle-shaped cells with a small subset of rounded cells50. The cells express 
wildtype TP5352 which partially matches the status in human lesions where TP53 alterations 
occur but are not obligatory53,54. Instead, growth of the tumor and cell line was/is driven by an 
activated NRAS oncogene55, an alteration not frequently described for this type of sarcoma in 
which however generally no common driver mutations have been identified yet53,54.
MV3 melanoma
A melanoma is a skin cancer which develops from the malignant transformation of 
melanocytes, the melanin-producing cells residing in the bottom layer (stratum basale) of the 
epidermis56. Melanocytes originate from the neural crest, a cell layer deriving from the neuro-
ectoderm during embryonic vertebrate development giving rise to several cell lineages57. In 
the developing embryo, neural crest cells undergo an EMT to delaminate from the neuro-
ectoderm and move towards the skin followed by melanocyte differentiation58. As part of the 
epidermis melanocytes reside between keratinocytes but upon malignant transformation they 
downregulate E-cadherin based cell-cell junctions and recapitulate the developmental EMT 
program; therefore invading melanoma is classified as a mesenchymal cancer type59. The MV3 
melanoma cell line has been derived in 1990 from a human melanoma lymph node metastasis 
of which cells were subcutaneously implanted into a nude mouse and grown there for three 
passages before taking them into culture60. MV3 cells exhibit predominantly mesenchymal 
morphology with the presence of triangular and elongated cells and a small subset of rounded 
cells60. Genetically, MV3 melanoma cells are incompletely characterized; their TP53 status is 
wildtype61 and they do not contain a BRAFV600E mutation62 which is common to more than 
50% of all melanoma cases63, however whether they carry another type of BRAF mutation or 
belong to another melanoma suptype63 has not been determined yet.
Genotoxic cancer therapy and resistance
In addition to metastasis formation, (disseminated) cancer cells which cope with and survive 
therapeutic approaches are a major factor accounting for cancer-related deaths1,2,64. The 
most broadly used anti-cancer therapies include genotoxic chemo- and radiotherapy which 
target the high proliferation rate of most cancer cells by damaging the DNA and/or interfering 
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with DNA replication and proliferation such that cells eventually may undergo apoptosis65–67. 
However, either intrinsically before treatment or acquired during and after treatment (secondary 
resistance), a majority of cancers develop resistance to the applied therapy resulting in 
progressing or relapsing disease68,69. Therefore the study of cancer resistance mechanisms is 
of central importance to identify new therapeutic targets and improve current cancer therapy 
approaches.
Chemotherapy
Chemotherapeutic agents are non-specific poisons that are given systemically which has the 
advantage of principally reaching every cancer cell in the body though simultaneously also 
healthy cells may be harmed66. The four main types of chemotherapy include (i) alkylating 
agents (e.g. cisplatin) which directly damage DNA by covalently crosslinking the double strands, 
(ii) antimetabolites (e.g. methotrexate) inhibiting DNA and RNA synthesis, (iii) topoisomerase 
inhibitors (e.g. doxorubicin) precluding the removal of supercoils during DNA replication and 
(iv) anti-microtubule agents (e.g. taxanes) which interfere with either microtubule synthesis or 
disassembly and thereby inhibit completion of mitosis70,71. 
Radiotherapy
In contrast to chemotherapy which affects the process of proliferation at different levels, 
radiation therapy works by only introducing DNA double strand breaks of which the amount 
needs to be above a certain threshold to activate apoptosis signaling rather than DNA repair 
and subsequent cell survival72. However, as advantage compared to systemic chemotherapy, 
irradiation allows local application resulting in locally limited and reduced systemic adverse 
effects65. 
Therapeutic resistance
Numerous cell-intrinsic and acquired mechanisms accounting for cancer resistance to 
chemo- and radiotherapy have already been identified68, among which (i) genomic alterations 
malignant cells might have acquired73,74; (ii) interaction with the tumor micro-environment 
including stromal cells (e.g. fibroblasts endothelial and immune cells), ECM components and 
chemical factors (e.g. growth factors or cytokines) and subsequent stimulation of (dependence) 
receptors like integrins, receptor tyrosine kinases or hormone receptors75–80; (iii) metabolic 
perturbation as consequence of hypoxia, which has been described as major mediator of 
radioresistance as cancer cells switch towards glycolysis leading to lactate production and 
hypoxia-inducible factor 1 (HIF-1) activation81–83 and (iv) intratumor heterogeneity including 
the presence of slow-proliferating cells with stem cell-like properties often associated with 
EMT84–89. 
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1
Eventually each resistance mechanism engages intracellular pathways and effector functions 
which confer survival advantages68. These include stimulation of pro-survival and proliferation 
pathways like the phosphatidylinositide 3-kinase (PI3K)-Akt cascade and overruling or 
silencing of pro-apoptotic signals, both often accompanied by deregulation of the DNA 
damage response with either enhanced repair or tolerance to DNA lesions and inactivation of 
cell cycle checkpoints, allowing proliferation despite damaged DNA or abnormal mitoses68,69,90. 
As consequence, cancer cell subsets may be sensitive to the cytotoxic treatment causing 
the tumor lesion to shrink, however the persistence of resistant subsets, or even individual 
cell clones, is sufficient to nullify therapy success when growing out as resistant cancer 
relapse64,91,92. 
Strategies to overcome resistance mechanisms are already included into current therapy 
regimens67,93,94, among which the targeting of integrin adhesion receptors, which are 
considered as high potential target in cancer therapy69,95,96. Chapter 4 and 5 in this thesis 
focus on this type of cell-matrix adhesion molecules, investigating their role in metastasis and 
radioresistance of mesenchymal tumor types. 
Integrins and their role in cancer progression and therapeutic resistance
Cell adhesion to extracellular tissue structures is a substantial process underlying the 
development of tissue structures and organs97. Besides providing stable anchorage, cell- 
ECM interactions can be highly dynamic and undergo cyclic turnover during mesenchymal 
cell migration: the leading edge develops transient anchors needed to build up the traction 
force which eventually will propel the cell body forward98,99. Beyond their mechanical functions, 
cell-ECM adhesion systems provide important signaling functions stimulating cell growth, 
differentiation and survival100,101. Accordingly, cells lacking sufficient contact to ECM are 
prone to undergo apoptosis, a process called anoikis102, unless they acquired the ability to 
survive independent of any anchorage. Anoikis resistance has been described as hallmark 
of (metastatic) cancer and is driven by the constitutive activation or suppression of survival 
and proapoptotic signaling respectively, mediated by e.g. oncongene expression, continuous 
growth factor stimulation or multicellular aggregate formation101. 
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Figure 3. Pro-migratory and pro-survival signaling events initiated upon integrin-ECM interaction.
The linker molecules α-actinin, filamin and talin directly connect the cytoplasmic integrin tail to the actin 
cytoskeleton ensuring strong adhesion to the matrix. Activated Rho GTPases stimulate actin assembly 
and contractility, altogether facilitating migration. 
FAK becomes activated upon binding to the cytoplasmic integrin tail, recruiting and activating multiple 
signaling molecules eventually feeding into pro-survival pathways and inhibiting apoptosis.
Integrins as adhesion receptors and signaling hubs
Integrins are heterodimeric transmembrane receptors composed of an α- and β-subunit 
mediating attachment of cells to various ECM structures including the most abundant ECM 
components as well as cell surface receptors103. Different integrin subtypes show unique 
substrate preference with β1 and β3 integrins accounting for interaction with collagens, 
laminin, fibronectin and fibrillin, main constituents of interstitial ECM and basement membrane 
and thus important substrates during cancer cell dissemination28,29,103–107. 
After ligand binding, the short cytoplasmic integrin domain, which lacks any enzymatic 
function, is the center of integrin-mediated anchorage and outside-in signaling cascades, by 
recruiting various adaptor and signaling molecules108,109 (Fig. 3). Via the linker proteins talin, 
alpha-actinin and filamin the cytoplasmic tail of integrin β subunits becomes connected to the 
actin cytoskeleton which is essential for the establishment of stable cell-ECM junctions108,109 
(Fig. 3). Integrin-dependent downstream signaling depends upon focal adhesion kinase 
(FAK), which becomes recruited and binds the β integrin cytoplasmic tail upon integrin ligand 
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engagement108–110. Subsequent conformational changes of FAK allow its autophosphorylation 
at tyrosine 397 followed by interaction with the SH2 domain of Src kinase and its activation108–110. 
The activated FAK/Src complex then serves as origin for diverging downstream signaling 
cascades including activation of Jun amino-terminal kinase (JNK), nuclear factor κB 
(NFκB), extracellular signal-regulated kinase (ERK), mitogen-activated protein kinase 
(MAPK), phosphatidylinositide 3-kinase (PI3K) and Rho-family GTPases101,108–111. Whereas 
Rho GTPases especially regulate the assembly and contractility of actin filaments112, the 
other pathways, in particular ERK- and PI3K –mediated signaling, promote cell survival by 
activation of pro-proliferation targets or inhibition of pro-apoptotic signaling, both essential 
processes to counteract anoikis108,113,114 (Fig. 3). Furthermore, lateral interactions between 
integrin heterodimers and growth factor receptors for ligands like epidermal growth factor 
(EGF), fibroblast growth factor (FGF) or vascular endothelial growth factor (VEGF) support 
activation of growth factor receptor tyrosine kinases and efficient stimulation of growth factor-
mediated cell growth and proliferation96,115. Additionally, integrin engagement controls intricate 
signaling networks regulating cell functions like motility, shape, polarity, cell-cell adhesion and 
differentiation116,117. Thus beyond the formal appearance as cell-ECM adhesion molecules, 
integrins control a complex network of various signaling mechanisms feeding into numerous 
cellular pathways. Consequently, integrins constitute integral parts of the metastatic cascade 
and can function as mediators of therapeutic resistance69,95,96,118–121. 
Integrins and the metastatic cascade
Each step of the metastatic cascade depends on various types and strength of cellular 
adhesion to the surrounding matrix and survival cues, mediated by integrins and other adhesion 
receptors118,120. Chapter 4 summarizes the known functions of integrin subsets for each step 
of the metastatic cascade, which subsequently were tested in vivo in sarcoma and melanoma 
xenografts in mice monitored by intravital microscopy, analysis of CTCs and the onset of 
spontaneous metastasis. The results show that growth of the primary and metastatic lesions 
was integrin dependent but that metastasis formation as such did not become abrogated 
after blocking all available integrin subsets. Rather integrin-independent dissemination was 
even more efficient relative to the tumor size, which contradicts the generally accepted notion 
that integrins are indispensable for cancer cell dissemination120. Thus, despite the dominant 
role of integrins probing individual steps of the metastatic cascade and their significance 
for tumor growth, interference with integrins may not suffice to block metastatic cancer cell 
dissemination.
Integrins as mediators of therapeutic resistance
Being often upregulated in various cancer types and based on their function in pro-survival 
and thus resistance signaling, integrins have been pursued as therapeutic targets in 
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preclinical and clinical studies100,117,121,122, which however failed to inhibit metastatic growth 
as endpoint123,124. Chapter 5 describes the discovery of collective invasion-associated, 
integrin-dependent radioresistance in two mesenchymal xenograft models. To overcome this 
resistance phenotype, the study addresses compensation by alternative integrin subsets in 
providing partial resistance, a likely rate-limiting process typically not addressed in preclinical 
integrin targeting studies. As outcome, by interfering with the two most abundant integrin 
chains in mesenchymal cells, β1 and β3 integrins, previously resistant tumor fractions became 
fully sensitive to radiation therapy and successfully eliminated. These preclinical data suggest 
that therapeutic targeting of multiple integrins might increase the efficacy of integrin-targeted 
therapies.
Addressing lack of knowledge
The molecular adaptations resulting in metastatic plasticity and environment-induced 
resistance development are complex and likely depend upon local signals present in tissue 
niches125. Important insights on the signals involved in metastasis and resistance development 
were obtained by studies which systemically apply genomic and expression profiling to patient-
derived cancer specimens126,127. As potential shortcoming, the samples used for these studies 
often contain only a small subset of the entire (metastatic) lesion making it difficult to assign 
tumor niches and the environmental context. Therefore experimental models are needed where 
each step of the metastatic cascade as well as therapeutic responses and stromal context 
can be monitored accompanied by simultaneous sampling for (epi)genomic and expression 
profiling. Chapter 6 describes the establishment of a microscopy-based microdissection 
approach for live 3D tumor samples to separately isolate tumor core and invasion zone 
of sarcoma and melanoma xenografts, followed by differential expression profiling using 
RNAseq. This approach will be suited for detailed molecular characterization of the two tumor 
sub-regions to unravel mechanisms underlying integrin-independent invasion (chapter 4) and 
integrin-dependent, invasion-associated radioresistance (chapter 5), but also to generally 
identify microenvironemental re-programming events modulating therapy response and 
invasive properties. In addition to profiling of CTCs, image-based 3D microdissection of cells 
during metastatic progression will further help to define molecular changes during each step 
of the metastatic cascade, ideally using single-cell profiling techniques128. This strategy may 
facilitate the identification of new therapeutic targets to further improve therapy for sarcoma, 
melanoma and possibly other mesenchymal cancer types. 
Chapter 7 summarizes results and emerging concepts described in this thesis and discusses 
their implications for understanding cancer cell dissemination resistance development. 
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Collective cell migration results from the establishment and maintenance of collective 
polarization, mechanocoupling, and cytoskeletal kinetics. The guidance of collective 
cell migration depends on a reciprocal process between cell-intrinsic multicellular 
organization with leader-follower cell behavior and results in mechanosensory 
integration of extracellular guidance cues. Important guidance mechanisms include 
chemotaxis, haptotaxis, durotaxis and strain-induced mechanosensing to move cell 
groups along interfaces and paths of least resistance. Additional guidance mechanisms 
steering cell groups during specialized conditions comprise electrotaxis and passive 
drift. To form higher-order cell and tissue structures during morphogenesis and cancer 
invasion, these guidance principles act in parallel and are integrated for collective 
adaptation and shaping of varying tissue environments. We review mechanochemical 
and electrical inputs and multi-parameter signal integration underlying collective 
guidance, decision making, and outcome.
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Moving cell groups
Collective cell migration is a fundamental process that enables the coordinated movement 
of groups of cells that remain connected via cell-cell junctions1–3. Collective cell movements 
support the formation and morphological re-shaping of larger tissue structures during 
the morphogenesis of ducts, glands and vessels, as well as epithelial homeostasis and 
regeneration2,4,5. In addition, when reinitiated in mature tissue during neoplasia, collective 
movements contribute to cancer invasion and, likely, metastasis1,6–9. 
During collective migration, cell-cell junctions secure supracellular adhesion, polarization, 
and mechanocoupling required to sense and integrate external guidance cues and further 
share signal processing and force transmission across the migrating collective (Box1). By 
connecting the actin cytoskeleton across multiple cell bodies, cell-cell junctions form the basis 
for integrating the forces generated by individual cells within groups and their supracellular 
front-rear polarity10. Furthermore, cell-cell coupling determines collective functions beyond 
migration, such as “purse-string” contraction and closure of epithelial gaps and tissue folding11.
The mechanisms guiding individually migrating cells are well understood and include both 
chemical guidance by chemotactic soluble factors or haptotactic tissue-anchored factors 
and physical guidance12–14. These guidance mechanisms apply in principle also to collective 
movements. However, in addition to single-cell migration which results from processing of 
extracellular input within a single cell body, collective movement also involves intercellular 
integration of guiding signals to steer and maintain the migration of a cohesive cell group15. 
This includes cell-intrinsic prerequisites like the establishment of leader-follower polarization, 
supracellular mechanocoupling, and external mechanical, chemical and/or electrical stimuli 
to steer collective movements (Table 1). Here, we summarize cell-intrinsic and extracellular 
mechanisms of polarity and guidance in collective cell migration. The astounding variability 
of how different cell groups integrate converging and/or opposing guidance inputs in complex 
environments reveals collective cell migration as a versatile and adaptive example of 
multicellular decision making and plasticity.
Collective polarity by leader-follower behaviors
The guidance of collective migration often involves the coordination between two functionally 
distinct populations, leader and follower cells. Leader cells localize at the front of a moving 
group, where they receive guidance signals and instruct, with cell-cell junctions at their rear, 
follower cells into directional migration through chemical and/or mechanical signaling16,17 
(Fig. 1A). By acquiring a leading edge towards the substrate, including protruding actin-
based structures like lamellipodia or filopodia, and specialized gene expression and signaling 
programs17,18, leader cells secure front-rear polarity and guidance along or into tissue 
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structures. Examples of well-defined leader cells are tip cells in the developing insect trachea 
or mammalian sprouting vessels18. As mechanism underlying tip-cell selection and collective 
sprouting, extracellular guidance signals by morphogens and chemokines induce receptor 
tyrosine kinase signaling. This causes tip cell selection in cell-subsets and inhibits tip-cell 
fate in adjacent cells, then called followers, by negative feedback signaling through Delta-
Notch interaction18. Similar leader-follower segregation can be achieved in 2D cell sheets, 
where mechanical signals induce leaders cells at the front, which through subsequent Delta-
dependent negative feedback signaling, inhibit leader formation in neighboring cells17. Leader 
cell functions may be also be adopted transiently, with yet-to-be-defined characteristics, such 
as in the developing mammary gland, where multicellular leaders rapidly exchange position4.
The extracellular inputs and downstream intracellular signals that define and maintain 
leader cells are probably cell-type and tissue-context specific (Table 1). These include 
mitogen-activated protein kinase (MAPK) / extracellular signal-regulated kinase (ERK), focal 
adhesion kinase (FAK), phosphoinositide-3-kinase (PI3K)/Akt, Src kinases, Notch and Rho-
GTPases. The early activation of these pathways contributes to the intrinsic bipolarity in 
leader cells 3,19–23. As an example, the activation of Rho-GTPases (mainly Rac) at the anterior 
cell part regulates actin polymerization, actomyosin-based contractility, coupling and force 
transmission to stabilize integrin-mediated focal adhesions and thus defines leader cell 
motility20,24,25. Conversely, the rear of the leader cell retains cell-cell junctions and junction-
derived signals, which locally silence Rho/Rock signaling and downregulate actomyosin 
contractility26–29. Compared with the formation of protrusions at the leader cell, near cell-cell 
junctions protrusions are usually minimized and mechanical coupling is secured in a process 
termed contact inhibition of locomotion (CIL)3,30 (Table 1). 
Table 1: Diversity of guidance cues and signaling in collective movements
Guidance 
principle
Cell type/
Environment
Steering mechanism Refs.
Cell-intrinsic Epithelial monolayer in 
scratch wound assay
Spatially constrained ERK activation 
in leader cells
19
Epithelial monolayer on 
collagen I matrix
Activation of Rac, PI3K/upregula-tion 
of β1-integrin in leader cells
20
Cranial neural crest cell 
migra-tion in developing 
Xenopus 
N-cadherin mediated CIL and 
supracellular polarization
82
Contact guidance 
(1D)
Fibroblast streams on 1D 
fibrillar patterns
Uniaxial lamella, alignment of actin 
cytoskeleton (single cells)
54
Contact guidance 
(2D)
Epithelial monolayer in gap 
closure assay/single cells on 
micropatterned substrates
Interaction with substrate at free edge 
induces reorientation of cell polarity 
and front cell polarization
11,43
MDCKa cells seeded on a 
fibronectin-coated cylindrical 
wire
Circumferential alignment of the 
actin cytoskeleton and multiple focal 
adhesions for movement along curved 
substrate
47
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Contact guidance 
(3D)
Tumor cell spheroids in 
collagenI matrix
Generation of linear confined tracks 
by matrix degradation; haptokinesis
46,56,116,119,121
Contact guidance 
(1D-3D)
Melanoma invasion in mouse 
dermis
Movement along space defined by 
interfaces in tissue
50
Haptotaxis Mammary epithelium 
organoids in different ECM
Guidance by fibrillar collagen but not 
amorphous Matrigel environment
136
Epidermal wound healing Guidance by laminin 5 newly 
deposited by leading keratinocytes 
onto dermal collagen
63
Dictyostelium discoideum 
aggregation and migration
Slime sheath produced by leader 
cells that provides traction support for 
followers
137
Haptorepulsion Neural crest and placodal 
cells in developing Xenopus 
N-cadherin mediated repulsion 
between neural crest and placodal 
cells
69
Durotaxis Spreading of sarcoma cells 
on substrates with varying 
rigidtity
Improved collective coordination on 
rigid substrates (by improved cell-cell 
cohesion)
75
Collective drift Circulating tumor cell clusters 
in breast cancer metastasis
Passive drift with blood or interstitial 
fluid flow
6,76
Fluid-flow 
sensing
Pronephric cells in developing 
zebrafish 
Migration against flow, sensing 
of shear stress probably by 
mechanosensitive focal adhesion 
proteins and Fak signaling
79,138
Endothelial cells exposed to 
fluid flow in vitro
Migration with flow, sensing of shear 
stress probably by mechanosensitive 
focal adhesion proteins
78,139
Chemoattraction Border cell migration in 
developing Drosophila 
Leader cell induction by PVF1; Rac1 
activation
110,140
Endothelial cells in sprouting 
angiogenesis in vitro
VEGF-induced tip cell differentiation; 
ANG1b promoted cell-cell junctions
105
Posterior line primordium in 
developing zebrafish
Self-generated SDF-1 gradient due 
to differential expression of activating 
CXCR4c in the front and CXCR7 
decoy receptor in the rear
90–92
B and T-cell lymphoma in flow 
chamber
Clustering and collective migration 
induced by CCL19d and SDF-1 
gradient
93
Chemorepulsion Gastrulation in chick embryo Movement of mesendoderm cells out 
of primitive streak due to repulsive 
FGF8 signal
95,141
Electrotaxis Epithelial monolayer Electric field, migration towards anode 
or cathode
100,101,103
aMadin-Darby Canine Kidney, bAngiopoietin-1, cChemokine receptor type 4, dChemokine (C-C motif) 
ligand 19
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Principles of force generation in collective guidance
The anterior traction forces generated by the leader cell towards the substrate are balanced 
by tensile forces at the cell-cell junctions with follower cells at the rear. Follower cells can also 
engage in cell-substrate traction forces, possibly as consequence of “cryptic lamellipodia“ 
that protrude underneath the neighbor cell31 and transmit forces across a longer distance 
and multiple cell bodies within moving cell sheets32,33 (Fig. 1A). However, to what extent 
cryptic lamellipodia generate force to propel collective movement remains under debate33,34. 
Thus, both leader and, to lesser extent, follower cells generate traction force towards the 
substrate, which is balanced with the forces extending across cell-cell bodies. Collectively, an 
integrated mechanocoupling program within the leader cell reinforces outward polarization, 
cyclic actomyosin coupling, force transmission, and negative feedback signaling to follower 
cells to guide the cell group.
Beyond active pulling toward the substrate, mechanical pushing may be imposed by 
neighboring cells, either by volume increase after mitosis or when cells become jammed in a 
confined environment9,35 (Fig. 1B). Together, pushing from the rear and pulling from the front 
synergize and contribute to collective coordination and displacement. 
Alongside collective front-rear force transmission, moving cell groups process directional 
information by intra-and intercellular signaling. Along cell-cell junctions, signaling is exerted by 
the adhesion molecules themselves, including mainly cadherins32,36,37 (Box 1). In addition, forces 
transmitted at cell-cell junctions may induce conformational changes in mechanoresponsive 
molecules, including vinculin or filamin and thereby trigger signaling events38–40. Lastly, moving 
cell groups maintain cell-cell communication via gap junction proteins (connexins); however, 
how signaling propagation via gap junctions contributes to polarity and mechanical connection 
between moving cells remains unclear41. 
Consequently, beyond leader-follower behavior, collective migration relies on integrated 
mechanocoupling and guidance throughout the cell group. 
Topographic guidance 
The structural and molecular organization of tissue provides important cues for collective 
guidance. Cell groups interact with the extracellular matrix (ECM) and molecules bound 
by the ECM and/or resident cells; thereby they sense, interpret and follow the topography 
of their environment, termed contact guidance or, when mediated by specific adhesion 
receptors, termed haptokinesis42. In the event that these physical and/or molecular cues are 
inhomogeneous and act as a gradient, directional sensing causes intracellular signal polarity 
and movement along the gradient, termed duro- or haptotaxis, respectively43.
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Figure 1. Cell-intrinsic mechanisms for collective cell guidance.
Leader-follower cell polarization and force generation/transduction in a migrating cell group. A) By 
interacting with and exerting pulling force on the ECM, leader cells generate a gradient of traction 
force toward the substrate and between neighbor cells (upper panel). Follower cells may form “cryptic 
lamellipodia” that anchor to the ECM and might contribute additional traction forces in the moving cell 
collective (lower panel). B) Cells undergoing mitosis can exert lateral pushing on neighboring cells, 
leading to cell displacement and eventually movement through group expansion, with forward pushing of 
leader cells and rearward pushing toward follower cells.
Contact guidance/haptokinesis
Contact guidance and haptokinesis result from cells orienting their length axis and movement 
along topographic cues provided by the anisotropy of the encountered environment44,45. To 
enable haptokinesis, adhesion-receptors engage with the substrate and thereby “sense” 
and mechanically couple to topographic cues42,46. These can be ECM components, including 
collagen fibers or basement membrane, or complex tissue structures such as nerve tracks, 
muscle fibers, or fat cells. To a varying degree, these structures are respected by moving cells 
and cell groups and therefore serve both a guiding and a barrier function shielding adjacent 
environments from moving cells47–50. Given the complexity of moving cell groups, it remains 
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unclear when and which cell subsets exert active haptokinesis and when and which cells 
become passively dragged or carried along the restricted route.
The topography of the guiding structure, and hence the responding cytoskeletal organization, 
can be 1D, 2D, or 3D. Each topography supports alignment of adhesion sites in parallel 
orientation to the substrate, followed by longitudinal adaptation of the actin cytoskeleton and 
thus cell shape and migration direction51,52. 1D topography is provided by a spatially narrow 
ligand with near-linear orientation, such as a single collagen fiber or stripe-like ligand decorating 
a surface, which discourages cells to move next to each other. For 1D migration, cells are 
required to align their adhesion sites in a string-like fashion as narrow as the ligand, resulting 
in well-defined, usually chain-like movement along this single cue53,54 (Fig. 2A and Table 1). 
A 2D surface, such as the plane of a cell culture dish in vitro or basement membrane lining a 
blood vessel in vivo, provides space for topographically unrestricted spreading of adhesion 
sites underneath the entire cell body and cell group, to perform 2D haptokinesis along the 
surface as multicellular sheet. Because the substrate provides lateral space, in contrast to 1D 
migration, moving cell sheets typically exhibit lateral turns and interspersed lateral rotational 
movements of cells within the group 34,47,55 (Fig. 2B and Table 1). Collective 3D haptokinesis 
occurs when cell groups follow 3D topographic cues, which provide both guidance and bi- 
or multi-lateral confinement. Examples of aligned 3D tissue include continuous sheet-like 
2D interfaces present between muscle fibers or larger nerves and discontinuous networks 
formed by ECM fibrils or cell structures, such as neuronal filaments50,56 (Fig. 2C,D and Table 
1). As a “2.5D” intermediate, a groove or angled surface (e.g. along the edge of a cell culture 
dish) provides bilateral guidance whereby apical confinement is lacking 57,58 (Fig. 2E). Thus, in 
1D, 2D, and 2.5D haptokinesis adhesion systems guide directionality, whereas 3D guidance 
additionally follows the path of least resistance defined by multilateral and space-confining 
extracellular structures49.
Haptotaxis and repulsion 
Whereas haptokinesis describes adhesion receptor-dependent migration along an isotropic 
substrate, haptotaxis combines principles of physical and chemical guidance by directing 
migration along a gradient of immobilized ligand59. Ligand gradients can result from different 
levels or distributions of ECM proteins including collagens, fibronectin, and laminins, matrix-
bound cytokines and chemoattractants, and/or adhesion molecules present on encountered 
cells (e.g. cadherins, cell adhesion molecules (CAMs) (Box 1)). Cells usually orient their 
migration toward increasing availability of adhesion sites (Fig. 2F and Table 1); however, cell 
movement may also orient towards decreasing ligand density depending on the cell type and 
adhesion receptors involved60,61.
With haptotaxis as the primary event, leader cells can reinforce or oppose collective haptotactic 
guidance at four levels: (i) sensing and responding to the guidance cue; (ii) deposition of ECM 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Collective Cell Migration: Guidance Principles and Hierachies  |  35
2
components and de-novo creation of adhesion sites62,63; (iii) removal of adhesion sites by 
matrix degradation56,64; and (iv) paracrine signaling via deposition of cytokines/chemokines 
while remodeling the matrix65. With the latter three, cell-derived tissue modifications, leader 
cells provide secondary guidance cues for the follower cells (Table 1). 
Cell guidance away from an encountered structure is termed repulsion. Haptokinetic repulsion 
can be mediated through direct cell-cell communication, for instance by interaction of Eph 
receptor tyrosine kinase with membrane-bound associated ephrin ligands on neighboring 
cells66,67, or through downstream signaling events of other cell-cell adhesion molecules, 
including N-cadherin68,69 (Table 1). Repulsive downstream signaling leads to inhibition of Rac, 
disassembly of focal adhesions, and collapse of cell protrusions followed by reorientation 
of the cell in the opposite direction69. In addition, repulsion results from Rho-dependent 
contractility at cell boundaries, which prevents stable cell junctions and supports cell and 
tissue separation68.
Box 1: Mechanocoupling along cell-cell junctions
Cell-cell connections in collectively migrating cell groups involve homophilic 
interactions mediated by cadherin adhesion receptors (adherens junctions) together 
with demosomal proteins, tight junction constituents, gap junctions, and homophilic or 
heterophilic interactions between immunoglobulin family members, including activated 
leukocyte adhesion molecule (ALCAM), neural cell adhesion molecule (N-CAM) or L1 
cell adhesion molecule (L1-CAM) and Ephrins/Eph receptors25,114,126–128. Most, if not all, 
adhesion receptors contribute to cell-cell contact mediated signaling (e.g. PI3K/Akt, 
FAK, ERK, Rho-GTPases)129–132. Cadherins and desmosomal and tight junction proteins 
additionally provide stabilization of cell-cell connectivity133. In particular, these junctions 
form a mechano-transducing bridge to neighboring cells via cytoskeletal linkages at their 
cytoplasmic site, which underlies the supracellular organization of the actin cytoskeleton 
and actomysion cables that bridge across junctions10,134. It is likely that multiple adhesion 
mechanisms cooperate in a hierarchical manner to process guidance information and 
provide mechano-sensory integration and force coupling during collective migration. 
In addition, although cell-cell junctions provide mechanically stable connections, at 
the molecular level adhesion sites and cytoskeletal connections are dynamic and 
are constantly remodeled to secure both mechanical connection as well as junctional 
flexibility135.
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Durotaxis 
The directional response of moving cells in response to a stiffness gradient of the substrate is 
termed durotaxis, with positive (i.e. toward high stiffness), negative (i.e. toward low stiffness), 
or perpendicular (i.e. along a corridor of unchanged stiffness) orientation and directionality70,71 
(Fig. 2G). Positive durotaxis is prevalent in fibroblasts that migrate towards regions of highest 
rigidity when placed on a matrix of varying stiffness72 and results from graded mechanosensory 
signaling, including integrin-mediated focal adhesions and traction generation via myosin-II 
mediated contractility73,74. Suggestive of differential stiffness sensing, collective migration of 
sarcoma cell sheets is enhanced on stiffer substrates compared with soft substrates75 (Table 
1). However, the mechanisms by which cell groups integrate stiffness gradients for direction 
sensing remain to be explored. 
Fluid flow and shear stress 
Directional fluid flow, experienced by cell groups inside perfused vessels or in the urinary 
tract, can guide cells by several mechanisms. Collective drift occurs when cell groups enter 
perfused vessels, where detached cells can become passively dragged along in the direction 
of the flow and disseminate with blood or lymph flow or with fluids present in the peritoneal or 
pleural cavitiy6,76 (Fig. 2H and Table 1).
Flow-imposed shear stress can also be translated by adherent cells into directional information 
through molecular sensors of shear stress. These sensors include mechanosensitive focal 
adhesion proteins, G-protein coupled receptors, transient receptor potential (TRP) ion 
channels, and primary cilia77. As a consequence, migrating cells may move with or against the 
flow78,79 (Fig. 2I and Table 1). 
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Figure 2. Collective guidance by topographic and mechanical cues.
Individual modules are displayed in which live-tissue context might occur concurrently. (A-E) Gui-dance 
dimensions of collective migration by substrate topography. Cell groups migrate via contact guidance/
haptokinesis along substrate of varying shape and order. F) Haptotaxis is induced by gradients of 
adhesion sites (upper panel) or substrate-bound molecules (mainly cytokines, lower panel), which 
combines principles of mechanical and chemical guidance in the same process. G) Cell groups may 
exert durotaxis and mechanically sense and follow gradients of matrix stiffness, a process dependent on 
adhesion signaling and actomyosin. (H,I) Collective guidance by fluid flow. Cell groups either undergo 
passive collective drift (H) or sense the fluid-flow imposed shear stress to steer migration either along 
(upper panel) or against the flow (lower panel) (I). 
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Chemical guidance through chemotaxis 
Cell guidance via soluble chemical cues is termed chemotaxis and can be either attracting 
or repelling. Chemoattraction is the chemotactic movement along a gradient of soluble 
chemical stimuli including chemokines and cytokines but also altered pH or reactive oxygen 
species (ROS)80. Based on fluid drift and convection, this results in rapid but temporally limited 
molecular gradients, in contrast to the temporally and spatially more sustained signals provided 
by haptotaxis and haptorepulsion. Receptor binding and activation by chemotactic molecules 
induces local downstream signaling and cytoskeletal protrusions followed by cell polarization 
and movement toward the zone with the highest chemoattractant availability81. In response 
to a chemoattractant gradient, supracellular polarity is reinforced by preferential activation of 
signaling pathways in leading cell rows, which stimulates the pro-migratory signaling of leader 
cells and stabilizes cell polarity and cell-cell cohesion82,83. 
Collective chemoattraction is an essential guidance mechanism in developmental processes 
but also a powerful tool in experimental systems to direct collective migration84. Chemotaxis 
is typically a paracrine mechanism, through diffusive molecules secreted by other cells 
nearby85,86, but also may be induced or maintained by the cells themselves80,87 (Fig. 3A). Cell 
collectives can establish a self-generated chemokine gradient along the migrating group 
by (i) releasing a migration-enhancing factor near the front, which positively feeds-back on 
leader cells88; (ii) releasing chemokine-degrading enzymes that diffuse along the cell group 
and gradually clear chemokines along the length axis of the group89; and/or (iii) expressing 
migration-inducing receptors in the leading cell group and decoy receptors in the rear that 
bind, internalize, and thereby remove chemokines thus limiting their activity in follower and 
trailing cells87 (Fig. 3A and Table 1). This self-generation of a chemotactic gradient induces 
supracellular polarity, which is required for directional migration of the zebrafish lateral line90–
92. The scavenger chemokine receptor type 7 (CXCR7), which is preferentially expressed by 
the rear of the moving group, sequesters tissue-derived chemoattractant stromal cell derived 
factor-1 (SDF-1) and generates a front-rear SDF-1 gradient that guides collective migration 
through chemokine receptor type 4 (CXCR4) signaling90–92. 
Taking these findings together, collective chemotaxis includes a remarkable diversity of 
chemokine and signal processing across multiple cell bodies. Beyond guidance, chemotactic 
signaling can reinforce cell-cell adhesion and cell clustering, which can induce collective 
migration of cells that otherwise tend to migrate individually93,94 (Table 1). 
Chemorepulsion describes the movement away from a source of soluble chemical stimuli. 
Similar to chemoattraction, receptor binding by chemotactic molecules induces local signaling, 
whereby pro-migratory protrusions form at the pole of the cell, or cell group, opposed to 
receptor engagement85,86. Chemorepulsion in collective migration has important roles during 
embryonic development, where repulsion by morphogens like fibroblast growth factor (FGF) 
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8 and Wnt3a induce mesendodermal sheet migration away from the primitive streak during 
gastrulation95. However, whether the integration of signals controlling collective repulsion is 
similar to those in single cells96,97 remains to be established.
Figure 3. Chemical and electrical collective guidance.
Individual modules are displayed in which live-tissue context might occur concurrently. A) Chemo-tactic 
collective guidance. Chemoattractive cytokines are released by stromal cells and stimulate leader cells 
via paracrine signaling (upper panel) or leader cells stimulate themselves via autocrine signaling (self-
generated gradient; lower panel).B) Collective guidance directed by an electric field. While sensing the 
electric field via ion channels, cells move toward the cathode (-) (upper panel) or the anode (+) (lower 
panel), which is dependent on the cell type and ion channels involved.
Electrical guidance 
Electrotaxis (also known as galvanotaxis) is defined as directional migration of cells relative to 
a direct-current electric field with, depending on the cell type, orientation towards the cathode 
or the anode14,98–101 (Fig. 3B and Table 1). As potential steering mechanisms, the electric 
field can open voltage-gated Ca2+ or Na+ ion channels, followed by intracellular influx of ions 
and downstream signaling through activation of ion transport proteins (e.g. Na/K-ATPase 
and sodium-hydrogen exchanger 3 (NHE3)) and cytoskeletal polarization99,102. In addition, 
migration-inducing cell surface receptors, including epidermal growth factor receptor (EGFR), 
acetylcholine receptor (AchR) and integrins were reported to respond to electric fields and 
locally activate PI3K/Akt and MAP/ERK signaling99,101. In epithelial sheets, electrotaxis appears 
to engage both leader and follower cells to generate oriented traction forces parallel with the 
electric field and adaptive reorientation with altered field polarity100,103. 
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Electrotaxis has various effects including stimulation of the migration of many cell types such 
as fibroblasts, epithelial and endothelial cells, neurons, and immune cells as well as cancer 
cells14. Collective electrotaxis supports self-regeneration and wound healing. Disrupted 
epithelial cell sheets induce an endogenous gradient of weak electrical current that enhances 
migration into the open space for wound closure101. Besides the moving epithelium itself, 
endothelial and neuronal cells are also engaged to secure complete tissue regeneration101,102. 
These tissue-intrinsic effects can be clinically exploited and enhanced by external electrical 
stimulation, which accelerates the healing process 102,104. 
In summary, collective movement is guided by numerous cell group-generated and external 
mechanical, chemical and electrical guidance cues. As a consequence, moving cell groups 
must interpret and hierarchically integrate such diverse signals for steering collective polarity, 
path finding, and decision making.
Figure 4. Collective processing of multiple guidance signals and response. 
A) Cell-intrinsic interactions and directed extracellular cues act simultaneously on the cell group. B) 
Integration and prioritization of synergistic and opposing signals allows for prioritization and decision 
making. C) As an outcome, altered polarity, cell-cell cooperation, and additional para-meters including 
growth and differentiation determine persistent or altered direction or migration arrest. 
Collective guidance in complex environments – multiscale integration
In tissues, physical and chemical guidance mechanisms act in parallel; therefore, migrating 
collectives need to integrate concurrent, potentially cooperative, or opposing inputs to make 
go or no-go decisions and adjust the direction of migration (Fig. 4A,B). In addition, integration 
of the input may impact cell-cell interaction strength and intercellular mechanocoupling 
and either support multicellular cohesion or permit dispersal and transition to single-cell 
migration105. Therefore, cell groups process and prioritize guidance cues for coordinated 
movements and cell-fate decisions (Fig. 4C).
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In primordial or interim tissues, often comprising soft, amorphous ECM (e.g. the developing 
embryo, post-traumatic provisional fibrin network), chemical guidance by chemokines and 
growth factors dominates in attracting blood vessels and epithelial structures as part of tissue 
morphogenesis or repair9. Examples include the branching morphogenesis of the trachea 
induced by FGF, the lateral line forming the balance organ in Zebrafish in response to SDF-
1, and vascular sprouting into a wound by vascular-endothelial growth factors (VEGFs) and 
FGF90,105,106. In these cases, chemoattraction initiates and guides collective movement, and 
ECM remodeling is a secondary element contributing to (re)shaping the tissue; for example by 
generating tube-like tissue tracks and deposition of a basement membrane64,107. 
Joint contributions of both chemical and physical guidance cues converge in a hierarchical 
manner in the collective movement of border cells moving in the ovary of developing 
Drosophila embryos. Initially, a single leader-cell is selected and further attracted by growth 
factors released from the oocyte in a paracrine fashion, which activate platelet-derived 
growth factor (PDGF) - and VEGF-related factor 1 (PVF1), EGFR and downstream Rac1 
signaling followed by leader cell protrusion and guidance of the group24,108–110. Congruently, 
the haptokinetic path of the group is pre-defined in an adhesion receptor-dependent manner 
by a few confined trails of least resistance between the nurse cells of the ovary. Thereby, 
E-cadherin mediates interactions within the border cell group as well as between the border 
cell groups and the stationary nurse cells, which serve as an adhesion substrate and guiding 
scaffold for haptokinetic migration of the group37. Because ablation of EGFR signaling is 
sufficient to compromise guidance by the leader cell and deviate the group from its default 
track111, the growth factor signal is likely to dominate leader cell function to prioritize one of a 
few available routes. 
Hierarchy is further defined by the relative strength of guidance modalities. Migration of an 
epithelial monolayer closing a tissue defect follows the interface between the underlying 
substrate and cell-free space until the gap is closed and contact inhibition of migration 
overrules pro-migratory signaling11,30. However, on additional exposure to an electric field, 
electrotaxis overrides other guidance principles resulting in monolayers moving according to 
the current flow and in the opposite direction to open space or cells piling up at a barrier due 
to lack of contact inhibition of migration 102,103. Similarly, endothelial cells following a haptotactic 
gradient initiate migration into the opposite direction when exposed to countercurrent and 
sufficiently strong fluid flow, whereas haptotaxis dominates at low levels of shear stress78.
In mature tissue comprising ordered collagen architecture bordering functional tissue structures 
such as muscle fibers, blood vessels and nerve tracks, physical guidance cues are likely to 
dominate, with fine-tuning by chemical guidance. Such ordered tissue architecture creates 
pre-existing routes permissive for passenger leukocytes or invading tumor cell groups, which 
perform 2D and 3D contact guidance along small tissue interfaces (“tracks”)47,50,56,112,113. Due 
to lateral space limitations in 3D environments, the topographic confinement of invading cell 
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groups leads to “jamming” - the promotion of cell-cell junction formation and supracellular 
mechanocoupling - and thereby reinforces cell-intrinsic collective polarity and guidance35,114,115.
When particularly high tissue density or rigidity impedes or even ablates collective cell 
movement by physical constraints, initial leader cell protrusions may initiate proteolytic tissue 
remodeling, which enables and reinforces migration along the initial direction as well as 
branching of existing strands49,116. Thereby, intrinsic leader cell polarity and primary tissue 
remodeling cooperate to modify tissue and generate 3D haptokinetic collective guidance 
along the newly formed migration track49,117. Such 3D tracks may undergo further widening 
by lateral remodeling caused by follower cells, which reinforces a once established collective 
route107,114,116. Additionally, release or activation of chemotactic or haptotactic guidance signals 
by proteolytic cleavage of ECM and other proteins may act as a secondary cue118,119.
The pathways downstream of the chemical or mechanical inputs discussed here share many 
common signaling intermediates. For example PI3K, FAK, Src, MAPKs, Rho GTPases and 
myosin II, which are prime candidates as major hubs for signal integration99,101,120–122, may 
all contribute to sensing, transmitting, or dampening external guidance signals. However, 
how such guidance signals feed into the overall signal transduction networks and achieve 
collective cell-kinetic output remains largely unresolved.
Concluding remarks
The interdependence of self-organization within the cell groups and their communication 
with surrounding chemical, mechanical, electrical, and probably further tissue cues represent 
fascinating and challenging examples for multicellular signal processing and decision making 
in each individual cell as well as the group. To accommodate this complexity, multiparameter 
analysis at the intersection of physics and life sciences will be required. Technological trends 
to reach in-context analysis of highest-possible number of molecular and physical parameters 
through integration of multiparameter imaging require mechanical probing and the retrieval 
of molecular signatures from the same environmentally controlled sample123. This includes 
bioinformatic multiscale and meta-analysis of cell-derived datasets followed by integration of 
mathematical modeling to interpret and predict hierarchies of cues for collective guidance in 
complex environments124.
Cell biological challenges to resolve both individual and collective cellular information 
processing and intercellular communication from the same sample, in vitro or in vivo, require 
single-cell reporter readout of signaling and mechanical states (“live-cell biochemistry”) and 
optogenetics to delineate functional heterogeneity and integration24. 
Beyond the analysis of collective migration, an integrated view on collective guidance signals 
and their cross-talk/overlap with other cell functions, including stemness and differentiation, 
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growth and survival, and their implications for diagnostics and therapy will have to be 
established. This will include quantitative cell-resolved morphometry of tissue sections in 
tissue samples instead of arbitrary scoring and single-cell genomic and proteomic profiling 
of developing and diseased tissue. Principles delineated here may be being exploited in 
clinical routine; examples are diagnostic physical/molecular tissue probing in cancer125, the 
integration of pro-migratory synthetic scaffold tracks for facilitated regeneration (e.g. to heal 
neuronal injury), and electrical stimulation to support closure of chronic wounds or ulcers102,104. 
Thus, understanding the hierarchies of collective guidance may foster concepts in both basic 
biology and application to steer or prevent collective cell migration for the purpose of applied 
tissue regeneration or intervention in progressing tumors.
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Cancer invasion is a multi-step process which coordinates interactions between 
tumor cells with mechanotransduction towards the surrounding matrix, resulting 
in distinct cancer invasion strategies. Defined by context, mesenchymal tumors, 
including melanoma and soft tissue sarcoma, develop either single-cell and collective 
invasion modes, however, the mechanical and molecular programs underlying such 
plasticity of mesenchymal invasion programs remain unclear. To test how tissue 
anatomy determines invasion mode, spheroids of MV3 melanoma and HT-1080 
fibrosarcoma cells were embedded into 3D collagen matrices of varying density and 
stiffness and analyzed for migration type and efficacy with matrix metalloproteinase 
(MMP)-dependent collagen degradation enabled or pharmacologically inhibited. With 
increasing collagen density and dependent on proteolytic collagen breakdown and 
track clearance, but independent of matrix stiffness, cells switched from single-cell 
to collective invasion modes. Conversion to collective invasion included gain of cell-
to-cell junctions, supracellular polarization and joint guidance along migration tracks. 
Thus, the density of the extracellular matrix (ECM) determines the invasion mode of 
mesenchymal tumor cells. Whereas fibrillar, high porosity ECM enables single-cell 
dissemination, dense matrix induces cell-cell interaction, leader-follower cell behavior 
and collective migration as an obligate protease-dependent process. These findings 
establish plasticity of cancer invasion programs in response to ECM porosity and 
confinement, thereby recapitulating invasion patterns of mesenchymal tumors in vivo. 
The conversion to collective invasion with increasing ECM confinement supports the 
concept of cell jamming as guiding principle for melanoma and sarcoma cells into 
dense tissue. 
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Introduction 
Cancer invasion and dissemination into tissue is a multi-step process which balances 
mechanotransduction towards the ECM with cell-cell interactions between tumor cells. 
Tumor cell movement may result from distinct migration strategies determined by both, 
molecular properties of the tumor cells as well as mechanical and signaling input from the 
tumor microenvironment. Mesenchymal single-cell migration results from stringent adhesion 
sites linked to high actomyosin-mediated traction force and the capability to proteolytically 
degrade or remodel ECM1,2. Conversely, amoeboid single-cell migration is mediated by 
weak cell adhesion to ECM coupled to protrusive leading edge kinetics, including filopodia 
or blebs, and absence of structural ECM remodeling3. Distinct from single-cell movement, 
collective cell migration depends upon intact cell-cell junctions providing mechanical and 
signaling connection between tumor cells for supracellular polarization and coordination4–6. 
In collagen-rich 3D ECM, collective cell migration requires an integrin-based force generation 
and proteolytic cleavage of ECM to generate migration tracks that accommodate the moving 
cell group1,7,8. These cell migration programs are adaptive and interconvertible in response to 
cell-intrinsic and stroma-derived inputs2. 
As central mechanism for the conversion from multicellular to single-cell pattern, epithelial-
mesenchymal transition (EMT) leads to the downregulation of stringent E-cadherin-based 
cell-cell junctions which releases individually migrating cells from multicellular epithelia9–11. 
Consistently, mesenchymal tumor cells migrate individually after experimental cell dissociation 
and exposure to 2D and 3D in vitro substrates, similar to migrating fibroblasts12,13. However, 
mesenchymal cells can also develop N-cadherin-based collective migration patterns in 3D 
models of multicellular invasion in vitro and mouse models of interstitial invasion1,7,9,14–19. 
Whereas molecular mechanisms of cell-cell junction regulation and cell patterning are well 
established, tissue determinants for single-cell versus collective migration modes remain 
unclear. 
Depending on the type of tissue microenvironment, invading tumor cells are confronted 
with different extracellular structures and molecular patterns which jointly determine the 
biomechanics of cell-matrix interaction and migration efficacy. Physical, extracellular 
modulators of cell migration include: confinement, based on pore-size through which the 
cell migrates; geometry along which the cell-body aligns, determined by ECM alignment and 
dimensionality (2D vs. 3D); and stiffness which, depending on the composition, flexibility, 
density and cross-link status of ECM components, can vary greatly between tissue types and 
healthy or malignant tissue20–22. 
Collagen I, the main component of ECM in interstitial tissues, determines the spatial 
organization and stability of connective tissues. Natural patterns of collagen topography include 
low-density zones consisting of thick and thin collagen bundles forming a porous meshwork 
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of random or aligned organization, or high-density zones, composed of tightly arranged and 
often aligned collagen bundles with micron-scale pore size. While loose connective tissue is 
usually located adjacent to epithelial layers, including the dermis or gut submucosa, densely 
packed collagen bundles dominate the desmoplastic peritumor stroma17,20,23,24. To recapitulate 
such heterogeneity of ECM topography and density, multi-scale approaches were developed 
to predict how moving cells integrate varying tissue organization by adjusting migration mode 
and efficacy25.
Several types of adaptation were identified in moving cells in response to ECM heterogeneity. 
Contact guidance enables cells to take the path of least resistance when confronted with 
discontinuous environments, which supports preferential migration along ECM interfaces or 
aligned structures17,25–30. As fundamental biomechanical determinant, deformation of the cell 
body and nucleus maintains individual cell movement through narrow pores of mechanically 
challenging environments31,32. To overcome tissue constraints, cell deformation is further 
complemented by pericellular cleavage of ECM proteins through cell-derived MMPs, which 
increases space for facilitated single-cell and collective cell migration1,8,20,33–35. In addition, 
pericellular functionalization of ECM is achieved by paracrine deposition of ECM components 
which may increase ligand density and stiffness and thereby modulate mechanocoupling 
during migration2,21,25,36–38. These cellular responses cooperate and support a repertoire of 
adaptation responses to cope with heterogeneous tissue organization during migration.
Depending on the experimental model, mesenchymal cells, including fibroblasts, neural crest 
cells, sarcoma and melanoma cells, migrate either individually or as collective cell groups1,7,12,18, 
however the environmental conditions enabling such diversity of migration mode are poorly 
understood. Using a systematic approach to modulate ECM density, stiffness and availability 
of MMP-dependent pericellular proteolysis, we here address how mechanical and molecular 
requirements govern the balance between single-cell and collective invasion of mesenchymal 
melanoma and sarcoma cells. The data show mesenchymal patterning and migration mode as 
a function of matrix porosity and support proteolytic track clearance followed by cell jamming 
as key steps to collective mesenchymal migration in confining environments. 
Material and Methods 
Cell culture 
Human wild-type HT-1080 sarcoma (ACC315; DSMZ Braunschweig)39 and human wild-type 
MV3 melanoma (provided by G. van Muijen, Dept. of Pathology, RadboudUMC Nijmegen, The 
Netherlands)40 cells were cultured (37°C at 5% CO2 humidified atmosphere) in Dulbecco’s 
modified Eagle’s medium (DMEM; Invitrogen) supplemented with 10% FCS (Sigma-Aldrich), 
penicillin (100 U/ml) and streptomycin (100 µg/ml; both PAA), L-glutamine (2 mM) and sodium 
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pyruvate (1 mM; both Invitrogen). MMP function was inhibited by the broad-spectrum inhibitor 
GM6001 (ilomastat; EMD Millipore) at non-toxic concentration (20 µM)13. 
3D spheroid culture
Cells from subconfluent culture were detached with EDTA (1 mM) and trypsin (0.075%; 
Invitrogen), and multicellular spheroids were generated using the hanging-drop method41. In 
brief, cells were suspended in medium supplemented with methylcellulose (20%; Sigma) and 
incubated as droplets (25 µl) containing 7000 (MV3) or 4000 (HT-1080) cells for 24 h to ensure 
multicellular aggregation.
For 3D culture in collagen, spheroids were washed (PBS) and mixed with collagen 
solution consisting of non-pepsinized rat-tail collagen (BD Biosciences/Corning) at 
different concentrations (2.5 mg/mL to 8.0 mg/mL). Collagen-spheroid mixtures were either 
incorporated into a custom chamber or pipetted as a drop-matrix and polymerized at 37°C31. 
To generate collagen lattices with both high ligand and porosity, collagen polymerization in 
a custom chamber was performed at low temperature (21°C) which delayed polymerization 
and increased both fiber caliber and pore dimensions, as described23,31. (For reconstituting 
high-density matrices, the commercially available collagen stock solution was concentrated 
to 12.0 mg/mL using a Speed Vac Concentrator (Savant) prior to reconstitution to final 
concentration of 6.0 or 8.0 mg/mL.).
Spheroid-containing collagen lattices were maintained at 37°C for 24 h (HT-1080 cells) or 48 h 
(MV3 cells).
Time-lapse microscopy and cell tracking
Emigration from 3D spheroid cultures in 3D fibrillar collagen was monitored at 37°C using 
digital time-lapse, bright-field microscopy (20x / 0.30 NA air objective; Leica) connected to 
CCD cameras (Sentech) and Vistek software for up to 72 h at 4 min frame interval. 
Cell tracking and quantification of the migration index was performed manually, using tracking 
plugin, area selection- and measurement tools in Fiji/Image J software (v1.48)42.
Confocal fluorescence microscopy and quantification of matrix porosity and 3D invasion
Spheroids in 3D collagen matrices were fixed (4% Phosphate-buffered PFA), washed (PBS) 
and stained using the following reagents: mouse anti-ALCAM mAb (AZN-L50; IgG2A; 
Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences (RIMLS), 
The Netherlands43); polyclonal rabbit anti-COL23/4C Ab (collagenI cleavage site) (Immuno-
globe); secondary Alexa-Fluor-488-conjugated goat anti-rabbit or anti-mouse IgG (Invitrogen); 
Alexa-Fluor-488- or Alexa-Fluor-568-conjugated phalloidin (Invitrogen); DAPI (Roche). For 
COL23/4C staining, samples were pre-incubated with murine serum IgG (Sigma) to reduce 
non-specific background adsorption, followed by addition of primary antibody prior to fixation.
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For multicolor detection of fluorescent spheroids inside collagen lattices, long working 
distance confocal microscopy was performed (Olympus FV1000 scanner; 20x / 0.50 NA water 
immersion objective). Z-stacks were obtained at 5 µm slice intervals. Migration analysis was 
performed on DAPI- and phalloidin-stained spheroids using high-content epifluorescence 
microscopy combined with automated multi-position image acquisition and stitching (Leica 
DMI6000B; 20x / 0.50 NA air objective; 25 µm slice interval). Maximum intensity z-projections 
were used to quantify the number of emigrated single cells, multicellular strands, area and 
length of strands and the angles between strand axis and mitotic planes using Fiji/Image J 
software (v1.48)42 (Supplementary Fig. 1).
Pore size measurements of cell-free fibrillar collagen was performed in custom chambers 
also used for 3D spheroid invasion cultures. The reflectance signal from collagen fibers was 
obtained by confocal scanning (Olympus FV1000; 40x / 0.80 NA water immersion objective) 
as xy scans with 1 µm slice intervals and 30 µm z-depth from a central region of approximately 
200 µm distance from the cover glass. Pore cross sections were measured from individual xz 
slices, as described31. 
Collagen stiffness measurement by atomic force microscopy (AFM)
Cell-free collagen matrices (~5 µl) were reconstituted in a WillCo-dish with PDMS insert, 
overlaid with PBS and probed in native state by AFM using a cantilever with an attached 
polystyrene microsphere (10 µm diameter) on a Catalyst BioScope (Bruker) coupled to a 
confocal microscope (TCS SP5 II; Leica)31. Bead attachment, calibration, measurements and 
data analysis (conversion of force-distance curves into force-indentation curves) (F-δ)) were 
performed as described44. Subsequently F-δ curves were fitted over the 0-0.6 nN range after 
baseline correction using in-house written Igor Pro 6 (WaveMetrics) algorithms kindly provided 
and written by Jonne Helenius (BSSE, ETH Zürich, Basel, Switzerland) and Joost te Riet 
(Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences (RIMLS), 
The Netherlands) to calculate the stiffness with the Hertz model for spheres in contact with a 
flat surface45:
        
Statistics
Statistical analysis was performed by the two-tailed unpaired Mann-Whitney test using 
GraphPad Prism 5 software. 
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Figure 1. Matrix-density dependent switch from individual to collective cell migration in MV3 and 
HT-1080 cells. 
A) Xy and xz confocal reflectance scans of rat-tail collagen matrices of different concentration and 
polymerization temperature and B) quantification of pore cross-sections (example pores outlined in xz-
scan). P < 0.0001 from 3-4 independent experiments with measurements from ~12 different locations/gel. 
Red horizontal line, median. C) Emigration from spheroids 24h (HT-1080) and 48h (MV3) after embedding 
in collagen matrices of different density, detected as maximum intensity projection from confocal 3D 
stacks. Dashed rectangles, region of detail images. Black arrowheads, roundish, amoeboid cells. White 
arrowheads, elongated, mesenchymal shapes. D) Migration pattern as a function of median pore area. 
Frequency of single-cell or collective invasion from 30 to 70 spheroids/condition (3-5 independent 
experiments), shown as medians and 5th / 95th percentiles (whiskers) derived from Supplementary Fig. 
2B. Approximate cell number per strand at the end-point was 15 (MV3) and 16 (HT-1080). R2 values for 
regression lines are indicated in the graph. Scale bars, 10 µm (A); 50 µm (B).
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Results 
To identify matrix requirements and molecular determinants underlying collective invasion 
in mesenchymal tumor cells, we here used 3D multicellular spheroid cultures of MV3 
melanoma and HT-1080 sarcoma cells in mechanically defined 3D collagen environments of 
varying density. We monitored invasion mode and efficacy as well as MMP-dependent ECM 
remodeling.
3D low- to high-density fibrillar collagen scaffolds were reconstituted from rat-tail type I collagen 
lattices and analyzed for porosity by 3D confocal backscatter reconstruction combined with 
image analysis of pore dimensions between fibers. With increasing collagen concentration 
matrix porosity was incrementally reduced, resulting in a median pore range between 24 µm2 
for low-density (2.5 mg/mL) and 3.5 µm2 for high-density conditions (8.0 mg/mL) (Fig. 1A,B). 
This pore range is suited to accommodate efficient single-cell migration of individualized 
MV346 and HT-108031 cells in the absence of molecular interference.
To test for impact of collagen density on migration mode, multicellular spheroids of MV3 and 
HT-1080 cells were embedded inside 3D collagen matrices with varying density and monitored 
for the efficacy and type of cell invasion. Using both, bright-field time-lapse microscopy 
(Supplementary Fig. 1A) and 3D reconstructions of fixed and stained spheroid cultures (Fig. 
1C, Supplementary Fig. 1B,C), the migration mode was quantified as the frequency of single-
cell versus collective invasion pattern. Both cell types showed a significant discrimination of 
ECM density by invading as individual cells or loose chains without retaining cell-cell junctions 
in loose (2.5 to 4.0 mg/mL) and predominantly collective strands in dense fibrillar collagen (6.0 
to 8.0 mg/mL) (Fig. 1C, Supplementary Fig. 2A). Concurrently, increasing collagen density 
impeded (collective) invasion, detected as decreased number of invading cells and reduced 
length or area of invasion strands (Supplementary Fig.2B,C), while inducing a gradual 
conversion from single-cell to collective invasion as a linear function with near-exclusive 
collective invasion reached at pore cross sections of ~4 µm2 (Fig. 1D).
To address whether the physical matrix porosity, rather than altered content of collagen ligand 
and/or fibril thickness, controls ECM-imposed plasticity of invasion mode, 3D matrices of 
low porosity were generated by using high collagen concentration (8.0 mg/mL) with delayed 
polymerization speed at low temperature31. Compared with collagen matrices polymerized at 
37°C, this altered polymerization regime led to lattices with nine-fold larger pores and increased 
fiber caliber (Fig. 1A,B). Concomitant to increased porosity, collective invasion reverted to the 
single-cell pattern in both cell types, reaching near-complete individual dispersion similar to 
low-density collagen matrices. (Fig. 1 C,D, Supplementary Fig. 1A and 2). An unexpected 
second-order morphological switch could be detected when comparing both high-porosity 
conditions: Whereas spindle-shaped, mesenchymal invasion with clearly visible actin-fibers 
was predominant in low-density microfibrillar conditions (2.5 mg/mL), single cells moving into 
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macrofibrillar porous matrix (8.0 mg/mL, 21°C) showed near-exclusive rounded morphologies 
without profound actin-fibers, indicative of amoeboid migration (Fig. 1C)2,3. Thus, irrespective 
of collagen ligand density, the space between fibrils controls whether mesenchymally migrating 
single cells resort to the collective invasion pattern.
While single-cell migration, including multicellular streaming, lacks long-lasting adhesive 
junctions between moving cells, collective migration depends upon cell-cell interactions and 
supracellular communication, resulting in coordinated path structure and front-rear polarity2,5,9. 
Time-lapse analysis of cell position and path organization of collective strands invading high-
density 3D collagen matrices showed a defined leader-follower behavior with a single tip-
cell leading the strand as well as near-complete alignment of the migration tracks of cells 
composing the strand. Conversely, cells moving individually in low-density scaffolds lacked a 
dedicated follower behavior resulting in individualized tracks that did not, or rarely, overlapped 
with neighbor paths. (Fig. 2A,B). Thus, spatial confinement imposes “leader-follower” patterns 
and shared migration tracks. 
To test whether ECM-induced alignment of migration tracks coincides with intact cell-cell 
junctions, invading spheroid cultures were stained for Activated Leukocyte Cell Adhesion 
Molecule (ALCAM/CD166), which provides homophilic cell-cell interactions and is highly 
expressed in MV3 and HT-1080 cells (data not shown). As expected, cell-cell junctions in 
the spheroid-body showed a linear colocalization of ALCAM and F-actin (Fig. 2C, region 1). 
Likewise, multicellular invasion strands retained linear ALCAM in colocalization with F-actin 
along cell-cell interactions for both, MV3 and HT-1080 cells, consistent with adhesive and 
functional collectivity (Fig. 2C, region 2). 
Functional cell-cell cooperativity is further supported by a striking alignment of mitotic 
plane perpendicular (= angle of ~90°) to the length-axis of invasion (Fig. 2D). Thus, spatial 
confinement imposes central features of collective cell migration in mesenchymal tumor cells, 
including joint trails, linear cell-to-cell junctions with a cortical actin layer and collective front-
rear polarization. 
When monitored side-by-side and irrespective on cell-cell cooperativity, the net speed of 
invasion in both, MV3 and HT-1080 cells, was delayed with increased collagen density during 
both, early-onset and late invasion (Fig. 3A, Supplementary Fig. 1A). 
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Figure 2. Multicellular path coordination, cell interactivity and polarity in MV3 and H-T1080 cells 
with ECM confinement.
A) Early-onset collective MV3 cell strands guided by individual leader cells. Frames taken from a time-
lapse movie with individual invasion zones outlined in color. B) Positional alignment of cell tracks in fibrillar 
collagen of high (8.0 mg/mL) but not low density (2.5 mg/mL). 2D paths were taken from the center of 
individual cells and represented in orthotopic position. For quantification, cells were defined as following 
the same track if tracks showed a ± 10 µm overlay for at least 50% of the track length. C) F-actin and 
ALCAM-positive cell-cell contacts during collective invasion into dense collagen matrix. White arrowhead, 
linear ALCAM distribution along cell-cell junctions. Black arrowheads, relative ALCAM deficiency in the 
periphery of leader and follower cells. D) Orientation of mitotic planes in collective invasion strands. Angles 
were measured between longitudinal strand axis and mitotic plane axis as obtained from 3D confocal 
reconstructions (left panels) and displayed (right panel) (~110 mitotic figures from ~40 independent 
spheroids). Scale bars: 50 µm (A,B); 25 µm (C,D). Red horizontal line: median.
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Collagenolysis mediated by MMPs is a prerequisite for de-novo track generation and collective 
invasion of tumor cells1,26 or invasion-inducing fibroblasts8, suggesting space restriction 
as a support principle for collective cell-cell cooperation. Consistent with MMP-dependent 
proteolytic collagen degradation and track generation, collective cell movement into high-, 
but not low-density collagen matrix was ablated by broad-spectrum MMP inhibitor GM6001 
(Fig. 3B,C, Supplementary Fig. 3A,B). With MMPs inhibited, single-cell dissemination in 
low-density collagen was, however, associated with a more elongated and spindle-shaped 
morphology, indicating enhanced cell deformation as protease-independent rescue strategy 
to navigate through partly confining ECM (median pore size ~24 µm2) (Fig. 3B,C). Despite 
the lack of MMP activity, time-lapse movies and F-actin staining revealed that cells in dense 
collagen were “trying hard” to exit the spheroid body. Especially for HT-1080 cells long, F-actin 
positive and DAPI negative, anuclear cell protrusions extended from the spheroid and, after 
disruption, moved into the collagen (Fig. 3B, Supplementary Fig. 3C). Such moving leading 
edges ripping apart from the main cell body followed by autonomous movement indicate high 
mechanical tension along the cell body, as described for single cells arrested in dense ECM31. 
Thus, proteolytic collagen breakdown is indispensable for collective invasion enforced by 
high-density ECM.
To directly show collagen cleavage and proteolytic track formation collagen degradation 
neoepitope (Col2¾C) was assessed for control and GM6001-treated samples. Pericellular 
collagen degradation was present along the periphery of both, single cells and collective 
strands with MMP activity unperturbed, and absent in the presence of GM6001 (Fig. 3D). Thus, 
cell extensions and migrating F-actin containing anuclear cell fragments were independent of 
collagen breakdown but, because of arrested position of the main cell body and nucleus, 
insufficient to establish multicellular invasion strands as consequence of space constraints 
(Fig. 3B, insets). 
In addition to porosity, altered collagen matrix density impacts mechanical properties of 
the migration substrate. To test whether ECM stiffness independently controls invasion 
patterns36,47, the elastic modulus of collagen scaffold types associated with single-cell or 
collective migration were probed by AFM (Fig. 4A). Constant force input was provided and 
downward movement of the cantilever together with the collagen surface was registered (Fig. 
4B). ECM conditions associated with single-cell dissemination showed either high (8.0 mg/
mL, 21°C) or low (2.5 mg/mL, 37°C) rigidity, whereas scaffold conditions favoring collective 
invasion (8.0 mg/mL, 37°C) showed an intermediate stiffness level (Fig. 4C). Thus, the single-
cell to collective invasion switch was a function of ECM porosity (compare Fig. 1D) but not 
rigidity (Fig. 4C). This identifies matrix density as dominant modulator of migration plasticity. 
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Figure 3. Emigration delay of MV3 and HT-1080 cells and proteolytic path clearance in dense ECM.
A) Speed of emigration from spheroids embedded in collagen matrices of different density. The migration 
index was calculated from frames taken at different time points from time-lapse movies as the area covered 
with migrating cells minus initial spheroid area at 0 h (blue area). The 100% value corresponded to the 
maximum region covered by migrating cells at the end-point. B) Pattern and C) quantification of invasion 
efficiency of MV3 and HT-1080 cells from spheroids treated with DMSO or MMP inhibitor GM6001. Black 
arrowheads, mesenchymal protrusions. White arrowheads, thin, filament-like protrusions. ***, P < 0.0001 
and P = 0.0002 for HT-1080 single cells 2.5 mg/ml DMSO vs. GM6001 and P = 0.0007 for HT-1080 and 
MVS strands 8.0 mg/ml DMSO vs. GM6001; ~30spheroids/condition (3-4 independent experiments). D) 
Pericellular collagen degradation along invasion strands in dense collagen matrix. Differences in absolute 
signal intensity in MV3 cells are caused by lower MMP-14 expression in MV3 compared to HT-1080 cells 
(data not shown). Scale bars, 50 µm; 10 µm (insets B,D). Red horizontal line, median.
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Figure 4. Lack of correlation between invasion pattern and matrix stiffness.
A) Principle of measuring collagen stiffness by atomic force microscopy (AFM). The cantilever was 
functionalized with a 10 µm bead to probe a 3D fibrillar collagen sample in PBS. B) Registration of 
Z-displacement while probing the surface of the collagen lattice by applying force with the bead-
functionalized cantilever. The graph shows representative force curves of different collagen samples fitted 
with the Hertz deformation model. Dotted, vertical lines: deformation depth at 0.6 nN applied force. C) 
Stiffness for collagen matrices of different concentration and polymerization conditions. ***, P < 0.0001; 
measurements at 10-15 different positions (average of 3 repetitive probing cycles per position) from 3 
independent experiments. Red horizontal line, median. 
Discussion
Proteolytic tracks of least resistance generated by leader cells provide 3D space and an 
aligned interface which accommodate multiple cell bodies and guide collective migration. The 
transition from single-cell to collective invasion of mesenchymal MV3 melanoma and HT-1080 
sarcoma cells in response to strong ECM confinement thus provides wet-lab evidence for cell 
jamming48 as plasticity mechanism supporting collective cell migration in 3D tissue. 
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To probe the mechanisms balancing single-cell versus collective invasion of mesenchymal 
cells, we here used a type I collagen-based 3D model that matches the spectrum of tissue 
porosity and rigidity in vivo. Its pore-size range (0.5 to 170 µm2) represents the estimated space 
between collagen fibers in vivo ranging from 2 to 30 µm diameter which reflects both upper and 
lower limits of interstitial tissue densities and, to the lower end, reaches strong confinement 
near the physical limit of cell migration17,23,31,49. Likewise, the initial diameter of proteolytic 
migration tracks established by leader cells amounts to 10-20 µm which corresponds to the 
space between collagen interfaces in vivo2,17. The stiffness range of in vitro generated collagen 
matrices (24 to 1160 Pa) corresponds to the stiffness of diverse tissues ranging from 20 Pa 
(adipose tissue) to 1000 Pa (interstitial tissue and tumor stroma)22,50–53. Other in vitro models 
provide similar confinement and rigidity, including microchannels of defined width47,54–56 and 
stiffness47, however, due to their synthetic polymer-based organization these models preclude 
cell-derived space adjustments by pericellular degradation or ECM remodeling1,21,25,57. 3D 
collagen matrices thus provide a reasonably physiological model for the biomechanics and 
susceptibility to cell-derived physicochemical modification of in vivo tissues. Beyond the 
biology of fibrillar collagen, additional modulation of cell-cell and cell-matrix interactions likely 
occurs in response to additional structural and molecular complexity not included in this study, 
including signals from collagen subtypes, fibronectin, laminins, and proteoglycans21,58,59. Thus, 
addressing additional microenvironmental modulation of cell patterning will require the use of 
polymorphous multimolecular ECM models that probe additional complexity of cell invasion, 
including cell adaptation and decision making when confronted with tissue heterogeneities.
Whereas collective cell migration is an established feature of normal epithelia and endothelia 
moving as cohesive sheets or tube-like strands across or through interstitial tissue9,60–62, the 
ability of mesenchymal cells to move collectively remains controversial5. The plasticity response 
observed here confirms that constitutively mesenchymal tumor cells may readily switch 
between individual and collective migration strategies, depending on spatial confinement. 
Similar plasticity is observed in neural crest cells during development which, after EMT, adapt 
a variety of migration strategies, including single-cell migration, multicellular streaming and/
or collective migration modes63–67. Likewise, invasive mesenchymal sarcoma or breast cancer 
cells after EMT generate single-cell or collective patterns, depending on the availability of 
ECM-degrading MMPs1. Several features identified here indicate that tissue confinement 
contributes to acquisition of collective cooperativity in mesenchymal cells. These include the 
precise use of joint trails, the maintenance of linear cell-to-cell junctions containing ALCAM 
and a cortical actin layer as well as collective front-rear polarization with leader-follower 
behavior2,5,68. Thus, by dictating a morphological pattern, plasticity of migration directly impacts 
intercellular communication and coordination. Beyond the here identified switch from single-
cell to collective migration in mesenchymal cells, a transition from elongated, spindle-shaped 
to roundish, amoeboid morphologies was noted for migration conditions of highest porosity. 
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3D ECM ligand density and porosity variation thus likely impose such single-cell plasticity 
response by regulating cell adhesion strength and/or the dependence of cell translocation 
from protease engagement and proteolytic tissue remodeling25,32. Thereby, mesenchymal-
to-amoeboid interconversion may represent a further response program to tissue-imposed 
confinement.
Multi-scale in silico computational modeling combining actomyosin dynamics and cell-matrix 
adhesion in the context of discontinuous or confined 3D matrix geometries retrieved no 
indication for the conversion from single-cell to collective migration of mesenchymal tumor 
cells69. A mechanically different monolayer-based in silico model combining cell density, 
amount of cell-cell adhesion and cell motility suggests the transition from individual-cell to 
sheet-like, collective movement as a function termed cell jamming phase diagram48. In this 
model, cell monolayers lack the stringent space confinement present in ECM-based 3D 
environments, however with increasing density (“jamming”) cells gain cell-cell coordination 
during migration, thus representing a 2D variant of the here described matrix-density induced 
switch from single-cell to collective migration. In 3D environments, cell jamming occurs when 
space is limited and cells become increasingly confined, either in preexisting tissue tracks 
observed in vivo16,17 or proteolytic de novo tracks generated by leader cells1,8, which both 
provide space that approximates the width of single cells or small cell groups23,26. Because in 
high-density collagen lattices the pore cross-sections of the substrate and likely the boundaries 
of proteolytic tracks range below the physical limit of cell deformation (below 5-10 µm2)31, its 
inner lumen enables the jamming of follower cells which rather follow the track lining than 
breaking out laterally and establish new tracks. 
The consequences of cell jamming on molecular cell functions, including cell-to-cell 
signaling and the molecular migration machinery, remain to be addressed. Mesenchymal 
tumor cells retain rather weak constitutive cell-cell adhesion, as indicated by spontaneous 
single cell dispersion in unconfined matrix conditions. However, cell jamming may impose 
contact-mediated secondary cell-to-cell signaling, altered protein-expression, -function and 
-localization, and eventually reinforce cell-cell junctions. In other mesenchymal cell models, cell-
cell adhesion depends upon N-cadherin or adhesion receptors of the immunoglobulin family, 
including L1-CAM, NCAM, ALCAM, which may cooperate for multicellular interactivity and 
function7,9,19,70,71. Alternatively, in the absence of cell-cell adhesion engagement, confinement-
imposed jamming may result in physical convolution of cell bodies which, despite high cell-cell 
proximity, maintain independent cytoskeletal activity and migrate as individual cells similar 
to mulitcellular streaming2,5. In other, microchannel-based models of cell migration, confined 
space causes a switch in molecular migration mechanisms, from actin-based kinetics to 
microtubule- or water-flux based, hydrostatic mechanisms of cell propulsion and transport72,73. 
Consequently, together with altered biomechanics, the impact of cell jamming on active 
versus passive cell-cell cooperation and, possibly, functionally inert, “agnostic” next-neighbor 
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behaviors, will help to define subtypes of multicellular migration and associated cell-function 
states during migration in complex tissue. 
These findings support the notion that mesenchymal cells with constitutively loose cell-cell 
adhesions63,74,75 respond to ECM density by adjusting their cell-cell interactions, aggregation 
and protease dependence, and thereby transit from single-cell to collective invasion 
strategies, and vice versa. This plasticity response, albeit imposed by a physical mechanism 
that forces moving cells into and along confined tissue tracks, likely impacts the signals 
received from local cues, including organization of cell-matrix and cell-cell junctions. Future 
work will show whether the ECM-density induced collective pattern further induces cell-cell 
coupling by connexins, and altered signaling states, e,g. epithelium-like cell-cell junctions and 
apicobasal polarity reminiscent of mesenchymal-epithelial transition (MET)9,10,75,76 and clarify 
the relevance of cell jamming in physiological and pathological contexts.
Acknowledgements
We gratefully acknowledge Joost te Riet (Department of Tumor Immunology, RIMLS, 
The Netherlands) for providing anti-ALCAM antibody. Work of AH was supported by the 
PhD fellowship program of the RadboudUMC (Nijmegen, The Netherlands). We further 
acknowledge support be the NWO-Vidi (917.10.364) to KW and by the European Research 
Council (617430-DEEPINSIGHT), NWO-Vici (918.11.626) and the Cancer Genomics Center 
(cancergenomics.nl) to PF. AFM work was supported by NWO Medium Sized Investment 
(NWO-ZonMW 91110007). 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Cell Jamming: Collective Invasion of Mesenchymal Tumor Cells Imposed by Tissue Confinement  |  67
3
Supplementary Figure 1.
A) Extent of emigration from spheroids 24h (HT-1080) and 48h (MV3) after embedding in collagen matrices 
of different concentration and polymerization conditions. Bright-field images denote the tumor-collagen 
border at 0h (black line) and at the end-point (white dashed line). B) Quantification of the frequency of 
cells migrating individually (numbers) or collectively (blue dots within one strand). Yellow outline, area 
covered by a single strand. Red arrows, strand length. The sum of single cells and cells present in strands 
was used as total number of invading cells. C) Invasion pattern visualized in the context of the collagen 
reflection signal. Lower panels, 5x zoom highlighting cells and organization of the fibrillar network from 
regions indicated in the upper panel. Scale bars, 50 µm. 
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Supplementary Figure 2.
A-C) Quantification of single-cell and collective invasion using DAPI and phalloidin signal as described 
in Supplementary Fig. 1B (30-70 spheroids/condition from 3-5 independent experiments). *** P < 0.0001 
and P = 0.0008 (HT-1080 strands 2.5 mg/mL vs. 8.0 mg/mL (21°C)); * P ≤ 0.0432. Red horizontal lines, 
median.
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Supplementary Figure 3.
A) Extent of emigration from spheroids 24h (HT-1080) and 48h (MV3) after embedding in collagen matrices 
of different concentration in the presence of DMSO or MMP inhibitor GM6001. Bright-field images denote 
the tumor-collagen border at 0 h (black line) and at the end-point (white dashed line). B) Invasion pattern 
visualized in the context of the collagen reflection signal. Lower panels, 5x zoom highlighting cells and 
organization of the fibrillar network from regions indicated in the upper panel. C) Example of two anuclear 
actin-rich cell fragments (indicated by white arroheads) that moved for at least 48h in the absence of MMP 
activity in a dense matrix. Scale bars, 50 µm.
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Cancer cell invasion followed by intravasation are rate-limiting steps contributing to 
systemic dissemination and distant metastasis. Adhesion receptors of the integrin 
family have been implicated in mediating cancer invasion and metastasis based on 
their critical function in mechanotransduction and migration. Accordingly, integrins 
are being considered as targets for anti-cancer therapy to inhibit tumor dissemination 
and progression. To assess the role of integrins in cancer metastasis, we monitored 
the growth and local tissue invasion of mesenchymal HT-1080 sarcoma and MV3 
melanoma cells by intravital microscopy in orthotopic xenografts and followed their 
efficacy of systemic dissemination and distant metastasis. Integrins were targeted by 
stable shRNA-mediated knockdown of β1 and β3 integrins combined with adhesion-
perturbing human-selective anti-β1/αV integrin antibody which reached >99% reduction 
of integrin availability without compensatory upregulation of other integrins or 
perturbing viability in vitro. In both models, integrin targeting caused a severe growth 
deficit leading to marginalization of local tumors. However migration, local tissue 
infiltration and emergence of circulating tumor cells were unperturbed and, when 
normalized to tumor burden, lung colonization and micrometastasis were enhanced. 
Invading cells in vivo showed switch behavior from predominantly collective to single-
cell invasion, with diminished elongation and slightly reduced speed and persistence, 
and this plasticity response was confirmed in vitro using a 3D collagen interface assay. 
These data suggest that β1 and β3 integrins are indispensable for tumor growth and 
macrometastasis, but rather restrain cancer cell plasticity, local invasion and distant 
organ colonization. In conclusion, the metastatic cascade in vivo may be supported 
by low-adhesion, friction-based mechanisms suggesting that therapeutic targeting of 
integrins may bear the risk of enhancing metastatic dissemination. 
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Introduction 
Systemic cancer metastasis results from a multi-step process which depends upon the 
interdependence of tumor cell migration, survival and growth. Tumor cells first detach and 
emigrate from the primary tumor lesion, infiltrate the surrounding tissue locally, intravasate into 
blood vessels, survive as circulating tumor cells in the vasculature, extravasate in secondary 
organs where, after a period of variable latency, they initiate metastatic outgrowth1,2. Whereas 
locally confined tumor growth usually results in a good prognosis, metastatic progression is 
the leading cause of cancer fatality3. Therefore, an ideal cancer therapy would target the entire 
metastatic cascade, including regression of the primary lesion but also inhibition and prevention 
of cancer cell dissemination. This however requires deep molecular and mechanistic insight 
into all steps underlying metastasis formation, which is currently still lacking1,4. 
For primary tumor growth and metastatic progression cancer cells rely on physical and 
chemical interaction with the surrounding environment, a prerequisite for the delivery of pro-
survival signals and movement of cancer cells away from the main lesion1,5,6. Central mediators 
of this tumor-stroma interplay are integrins: comprising an α and a β chain they assemble 
into heterodimeric transmembrane adhesion receptors and interact with components of the 
extracellular matrix (ECM)7. Composition of the integrin heterodimer drives ligand specificity, 
where β1 and αV intgerin subfamilies serve as versatile receptors as they both interact with 
fibronectin and vitronectin and β1 integrin additionally with collagen and laminin, all abundant 
constituents of the ECM7,8. 
The short cytoplasmic tail of integrin molecules lacks enzymatic functions but through 
interactions with intracellular adaptors and signaling complexes integrins exert multiple 
functions. Talin-mediated coupling of integrins to the actin cytoskeleton stabilizes cell-ECM 
junctions which is necessary for mechanotransduction during adhesion-mediated migration9. 
Integrin-mediated activation of focal adhesion kinase (FAK) and various downstream signaling 
cascades, including phosphatidylinositide 3-kinase (PI3K)-Akt and mitogen-activated protein 
kinase (MAPK) stimulate cell survival, proliferation and counteract apoptosis10–12 whereas 
activation of Rho-family GTPases promotes motility by protrusion formation and development 
of front-rear polarity13. Beyond this, lateral associations between integrins and growth factor 
receptors potentiate activity and downstream signaling of these receptor tyrosine kinases, 
again feeding into pro-survival pathways14. Thus, integrin-mediated cell-matrix junctions 
serve an important anchoring function and work as a hub for stimulating motility and survival, 
preventing anchorage-dependent cells from undergoing detachment-induced apoptosis, 
called anoikis10,15.
Concordant with pro-survival and pro-invasive functions it has been shown that integrins play 
an important role in cancer growth and metastatic dissemination14,16, making them also an 
important target in cancer therapy17. Studies comparing integrin expression in normal and 
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malignant tissue revealed, that in cancer cells integrin expression often becomes deregulated 
and that expression of certain integrins correlates with metastatic disease such as 
upregulation of αVβ3 integrin in melanoma18–20. Similar correlations have been shown for β1 
integrin, however here the interacting α chain co-determines effects: whereas α5β1 and α4β1 
integrin expression have been associated with cancer progression in melanoma and ovarian 
carcinoma, α2β1 integrin was shown to be downregulated in breast cancer with reversal of 
malignant phenotypes upon re-expression12,21,22. Furthermore, also tumor-associated blood 
vessels or stromal fibroblasts show distinct expression of αVβ3 integrin and β1-containing 
integrin heterodimers, associated with ubiquitous integrin expression on blood cells and 
platelets12,23–28. Thus both, cancer cells themselves and associated tissue components exhibit 
distinct integrin expression, which has been shown to contribute to various steps of the 
metastatic cascade. 
In the primary lesion integrin signaling stimulates cancer cell proliferation and neo-
angiogenesis, which taken together underlie exponential tumor growth29,30. Upon initiation 
of invasion, integrin-mediated ECM adhesion, mechanocoupling and stimulation of cellular 
motility enable cancer cells to invade surrounding tissue either collectively or as individual, 
mesenchymal cells13,31–33. However, also cells lacking ECM adhesion are able to move via 
so-called amoeboid migration modes, although thus far these have been hardly observed 
during cancer cell invasion34. Beyond stimulation of migration and survival, integrin activation 
also mediates upregulation of matrix metalloproteinases (MMPs), necessary to degrade 
the basement membrane which facilitates transendothelial migration and thus entry of 
cancer cells into the vasculature2,35,36. The following haematogenous phase is most critical 
for disseminated cancer cells as the blood compartment lacks an ECM, the main substrate 
for integrin engagement and subsequent survival stimuli1,14. Therefore cancer cells undergo 
selectin- and integrin-mediated interactions with leukocytes and platelets, delivering survival 
stimuli to evade anoikis in the blood stream27,37,38. To overcome the endothelial barrier, cancer 
cells develop protrusions which has been shown to be dependent on β1 integrin expression 
and is further stimulated by the intgerin-based interactions with platelets14,39–41. Granulae 
released by platelets contain, among others, adhesive ligands and factors that decrease 
integrity of the endothelium, which further enhances transendothelial migration41. Generally, 
the process of extravastion constitutes the rate limiting step in the metastastic cascade as 
only cells that succeed in exiting the blood stream have a chance to colonize a distant organ3. 
The microenvironment and ECM composition of metastatic sites is usually quite distinct from 
the primary lesion and thus cancer cells are challenged to cope with this foreign stroma. 
In order to do so, primary tumors have the ability to create pre-metastatic niches at distant 
sites to facilitate homing of disseminated cancer cells42,43. Nevertheless, the integrin repertoire 
expressed by disseminated cancer cells and according ligand selectivity dictates whether they 
are able to “anchor” in the new environment and subsequently receive pro-proliferation signals 
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for metastatic outgrowth14. However, initial incompatibility between ECM ligands and integrin 
expression profile on cancer cells does not mean that cells undergo immediate anoikis but 
they are able to remain quiescent till changes in the microenvironment provide stimuli upon 
which cancer cells re-enter the cell cycle1,44.
Thus, overall there are several lines of evidence assuming an important role of integrins in 
cancer cell dissemination, including their function as important mechanotransducing system 
during invasion and source of growth and survival signals2. But, the relative contribution of both 
functions to metastatic outcome and relevance for integrin-targeted therapy remains unclear 
thus far. Using intravital analysis covering all steps of the metastatic cascade, we therefore 
investigated the role of integrins for distinct steps of metastatic cancer cell dissemination in a 
soft tissue sarcoma and melanoma model. 
Materials and Methods
Cells and cell culture
Human HT-1080 sarcoma45 and MV3 melanoma cells46 were cultured in DMEM (Invitrogen) 
supplemented with 10% fetal calf serum (Sigma Aldrich), penicillin and streptomycin (both 
100 μg/mL; PAA) at 37°C in a humidified 5% CO2 atmosphere. Cell line identity was verified 
by SNP_ID Assay (Sequenom, MassArray System, Characterized Cell Line Core Facility, MD 
Anderson Cancer Center, Houston, TX, USA) and mycoplasma contamination was routinely 
excluded using the MycoAlert Mycoplasma Detection Kit (Lonza). Dual-color variants of HT-
1080 and MV3 cells, expressing cytoplasmic DsRed2 and nuclear histone 2B (H2B)-EGFP47 
were cultured in medium additionally containing Hygromycin B (Invitrogen, 0.2 mg/mL) and 
G418 sulfate (Calbiochem, 0.2 mg/mL).
Generation of stable integrin knockdown cell lines by lentiviral shRNA
ShRNA sequences targeting ITGB1 (β1 integrin; AGCCACAGACATTTACATTAAA) and 
ITGB3 (β3 integrin; AAGTCACTTTCTTCTTCTTAAA) for gene silencing by RNA interference 
were cloned into the lentiviral vector pLBM containing a puromycin cassette and two 
shRNA integration sites (p-puro2). Lentiviral particles were produced and concentrated by 
ultracentrifugation, as described48. HT-1080 and MV3 dual-color cells were infected with 
empty p-puro2 pLBM viruses (empty vector (EV) controls), or with ITGB1/ITGB3 targeting 
p-puro2 pLBM viruses (β1/β3 integrin RNAi cells). For maintaining stable dual-color HT-1080 
and MV3 control and knockdown cells medium was supplemented with puromycin (Sigma 
Aldrich, 5 μg/mL). Stability of knockdown was confirmed by Western Blot after 4-week culture 
and prior to implantation into mice.
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To determine integrin expression profiles in HT-1080 and MV3 cells before and after integrin 
interference using flow cytometry, shRNA sequences targeting ITGB1 and were cloned into 
the pLBM vector containing either a puromycin (p-puro) or a neomycin (p-neo) cassette. After 
virus particle production, wildtype, non-dual-color HT-1080 and MV3 cells were consecutively 
infected with empty p-puro and p-neo pLBM viruses (p/n vector controls), or with ITGB1 
(on p-puro) and ITGB3 targeting (on p-neo) pLBM viruses. Stably transduced cells were 
selected with puromycin (Sigma Aldrich, 5 μg/mL) and G418 sulfate (400 mg/mL). Stability of 
knockdown without antibiotics selection was confirmed after 4-week culture in antibiotic-free 
medium.
Animal experiments and experimental anti-integrin therapy
Animal procedures were approved by the Ethical Committee on Animal Experiments of the 
Radboud University, Nijmegen (The Netherlands) (RU-DEC 2013-074) and by the Institutional 
Animal Care and Use Committee (IACUC) of The University of Texas, M.D. Anderson Cancer 
Center (Texas, USA) (ACUF 07-11-07631, -07632). Animal experiments were performed in 
the Central Animal Laboratory of the Radboud University Nijmegen in accordance with the 
Dutch Animal Experimentation Act and the European FELASA protocol and at the University 
of Texas, M. D. Anderson Cancer Center (Texas, USA), Department of Genitourinary Medical 
Oncology Research, Division of Cancer Medicine in accordance with institutional guidelines. 
To perturb integrin-mediated adhesion, monoclonal mouse anti-human β1 integrin antibody 
(clone 4B4, IgG1, Beckman Coulter, 6603113) and αV integrin antibody (clone 17E6, IgG1, 
Merck Serono, kindly provided by Simon Goodman, Department of Cellular Pharmacology - 
Oncology Platform, Merck KGaA, Darmstadt, Germany) were injected i.p. in mice bearing β1 
and β3 integrin RNAi xenografts immediately after tumor implantation (day 0) and at day 3, 
7, 11, 16 and 22 (before tumor removal) (Supplementary Fig. 3A). With a dosing of 5 mg/kg 
body weight (BW) a calculated antibody concentration of ~8 μg/mL in body fluids (60% of body 
weight)49 could be pursued which ranged >2x above the minimum concentration required for 
99% integrin epitope saturation in vitro (Supplementary Fig. 2D). Based on an IgG1 half-life of 
6-8 days50 a calculated antibody concentration of >3 μg/mL in a body fluids could be achieved 
for at least 6 days by a single injection and maintained by injection intervals of 3-6 days, 
sufficient to achieve >99% epitope saturation on HT1080 and MV3 cells (Supplementary 
Fig. 2D). Mice with EV control xenografts received mouse IgG1κ isotype (clone MOPC-21, 
Sigma Aldrich, M7894) at a dose of 10 mg/kg BW. Prior to application in vivo, NaN3-containing 
antibody stocks (mAb 4B4, IgG1) were dialyzed against 0.9% NaCl solution (Braun). By using 
αV instead of β3 integrin blocking antibody we maintained proper αIIbβ3 integrin expression 
on platelets51 and thereby prevented potential adverse effects of the in vivo integrin blocking 
treatment.
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Intravital microscopy and image analysis
Polyethylene dorsal skin imaging windows were transplanted onto 10- to 14-week-old male 
athymic Balb/c nude mice (CANN.CG-FOXN1NU/CRL, Charles River), as described52. One 
day post-surgery tumor cells (~5x105 cells in 4 µl PBS) were implanted into the dermis by 
image-guided microinjection. 1x106 cells of each implantation round were not injected but 
snap-frozen in liquid nitrogen or on dry-ice for subsequent protein lysate preparation to confirm 
integrin expression or presence of integrin knockdown.
For intravital microscopy, mice were anesthetized with isofluorane and stably mounted onto a 
temperature-controlled platform (37°C). Progression of dual-color tumors was monitored using 
longitudinal intravital multiphoton microscopy (MPM, LaVision BioTech)53,54. Epifluorescence 
overviews of xenografts and surrounding vascular network were obtained with a 4x objective 
(NA 0.3, Olympus) at day 1, 3, 8, 10, 15, 17 and 22 for HT-1080 xenografts and day 1, 4, 8, 
11, 15, 18 and 22 for MV3 xenografts (Supplementary Fig. 3A). At day 7 (HT-1080 tumors) 
or day 8 (MV3 tumors) subcellular multiphoton time-lapse microscopy was performed of up 
to 4 invasion zones per tumor (Supplementary Fig. 3A), which were beforehand annotated in 
overview images. The emission ranges were 400/40 (blue), 535/50 (green), 605/70 (red), and 
710/75 (far-red). Perfused blood vessels were visualized by i.v. injection of AlexaFluor-750-
conjugated dextran (70 kD, Invitrogen, 1 mg/mouse). Sequential 4D image series (xyz & time) 
were recorded with a 20x objective (NA 0.95, Olympus) for up to 300 μm penetration depth 
at 7 μm step interval and 7 min time-interval for ~4 h. While obtaining image sequences mice 
were kept hydrated through s.c. injections of 0.9% NaCl solution (Braun). 
Tumor volumes were derived from epifluorescence overview images by measuring length 
and width of the tumor core for each xenograft lesion along reference points (blood vessels, 
tumor shape) that were determined on the overview image acquired at day 1. Only coherent 
(parts of) lesions were measured while the presence of single-cell remnants was recorded 
without measurements. Eventually tumor volumes were calculated as (tumor width)2 x (tumor 
length) x π / 6 / 2. To determine the residual mass of tumor sub-regions (core vs. invasion 
zone) for β1 and β3 integrin interference xenografts, areas of sub-regions were measured 
using the freehand-selection tool in FIJI55. For HT-1080 tumors images obtained at day 3 and 
10 were used to calculate the relative mass per sub-region of day 10 compared to day 3. For 
MV3 xenografts respective time-points were day 4 and 11. Area under the curve (AUC) of 
individual growth curves, needed to correct the number of metastatic lesions for tumor size, 
was analyzed using GraphPad Prism 5 software (per mouse AUCs of individual lesions were 
added up).
To analyze invasion in control and β1 and β3 integrin interference xenografts, 4D image 
sequences were corrected for tissue drift using the Correct 3D Drift plugin in FIJI55,56 Specifically, 
the blood vessel (Alexa 750 Dextran) channel was used for registration. For cell tracking, a 
maximum projection spanning 3-10 z-slices (7 µm per slice, 21-70 µm thickness) was made 
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of the nuclear channel (H2B-EGFP). Nuclei were tracked manually using the MTrackJ plugin 
in FIJI55,57 and the nuclear/cell velocity was calculated based on nuclear displacement and 
acquisition rate. Migration modes were classified as collective, groups, and single cells 
based on the following criteria: strands are a continuous (from core/field) file of cells with 
a thickness of ≥ 1 cell, groups are cells in contact with more than 2 cells and 2 cells thick, 
single are cells not in contact with any neighboring cells and/or are displaying independent 
migration behavior. For migration mode classification, each tracked nuclei was located within 
the full 4D image sequence and spatial and temporally assessed for cell-cell association, 
dimensionality and motility and matched to the most consistent migration mode classification. 
Cellular elongation was measured in only single cells or leader cells with defined cytoplasmic 
DsRed2 fluorescent signal. The elongation factor was calculated to be the ratio of the longest 
chord defined by the cell cytoplasm and the longest chord approximately perpendicular to and 
still intersecting the cell nucleus (Supplementary Fig. 4B). Directionality of invasion was taken 
to be the ratio of the total displacement and the distance between the start and end nuclear 
position (Supplementary Fig. 4C).
Quantification of circulating tumor cells (CTCs)
To check for the presence of dual-color fluorescent CTCs, per xenograft model and group 
(control or β1 and β3 integrin interference) a fraction of mice was sacrificed at day 11 with 
prior total blood sampling through cardiac puncture58. In brief, mice were deeply anesthetized 
through a sublethal dose of isofluorane and subsequently fixed laying on the back onto a 
plastic tube with a slit, allowing to place the imaging window inside the tube. Cardiac puncture 
was performed using a 22G needle and 1 mL syringe, followed by immediate transfer of blood 
samples into Lithium Heparin microcuvettes (Sarstedt). Per mouse 300-800 µL blood were 
drawn. After removal of clots, blood samples were diluted with heparin sodium salt buffer 
(Sigma, H-3393, 2 units/mL) to a final concentration of 20 units per mL blood. To collect CTCs 
and leukocytes, blood-heparin solution was filtered through a microsieve with 5 µm pore size 
(Aquamarijn and Vycap), using a filtration system (Vycap) and applying 15-30 mBar pressure. 
In case the microsieve got clogged by blot clots, remaining solution was transferred to a 
second sieve. 
Cells collected on the microsieve were washed 2x with phosphate-buffered saline (PBS), fixed 
with 2% Paraformaldehyde (PFA) for 10 min at room temperature (RT) and washed again 3x 
with PBS. To visualize leukocytes and counterstain all nuclei of cells captured on the sieve, 
cells were incubated with PBS supplemented with 10% normal goat serum (NGS, GIBCO Life 
Technologies, 30min RT), followed by primary antibody incubation (30 min RT) in PBS 10% 
NGS using rat anti-mouse CD45 antibody (clone 30-F11, BioLegend) at a final concentration 
of 2.5 µg/mL. After washing 3x with PBS, secondary antibody goat anti-rat Alexa Fluor 647 
(Invitrogen, 4 µg/mL) and DAPI (Roche, 1 µg/mL) were diluted in PBS 10% NGS, added to 
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the cells for incubation (30 min RT), succeeded by 3x washing with PBS and sealing the sieve 
and enclosed cells with FluoromountG (Southern Biotech) and a coverslip. 
The entire surface of each microsieve was imaged using high-content epifluoresecence 
microscopy (DAPI, FITC, TRITC, Cy5 filter) combined with automated multi-position image 
acquisition and stitching (Leica DMI6000B, 10x HCX FL PLAN/0.25 NA air objective). 
Autofocus image plane was set based on the DAPI signal. Subsequently, every image was 
checked manually for the presence of potential CTSs, which were characterized by (partially) 
overlapping EGFP and DsRed2 signal. Nuclear area of potential CTCs was measured using 
FIJI55, followed by exclusion of all cells with nuclei <300 µm2. Remaining CTC candidates 
were further checked for overlapping DAPI and H2B-derived EGFP signal and absence of 
CD45 staining (Supplementary Fig. 6B). Cells fulfilling all criteria were counted as CTCs and 
categorized into single-cell CTCs or CTC clusters, the latter meaning two or more CTCs 
appearing connected to each other. 
Analysis of spontaneous metastasis
Removal of the imaging window including xenografts or cellular remnants 22 days after tumor 
implantation was required due to animal welfare regulations and enabled us to separate the 
processes of cancer cell dissemination and metastatic outgrowth, thus metastasis outcome 
got not biased by continuous replenishment of disseminating cells. Instead it represents the 
fraction of cancer cells that successfully entered blood vessels when the primary lesion was 
present and gives a readout whether these disseminated cells were able to grow out or not 
after colonizing distant organs (Supplementary Fig. 3A).
Dorsal imaging windows were removed following a final overview image of the xenograft 
lesion. To check for a correlation between duration of tumor presence and metastasis 
outcome (Supplementary Fig. 7D), skin windows imposing almost an experimental humane 
endpoint (e.g. inflammation, necrosis, sideward flipping of the imaging window) prior to day 
22 still were removed if the mouse was in an overall healthy condition. To remove the imaging 
window mice received ketamine/xylacine anesthesia and dorsal skin, including the imaging 
window, was disinfected with iodine solution (Meda Pharma (Betadine)), followed by cutting 
away the imaging window and excessive skin which formed due to stretching of the dorsal 
skin by the imaging window. The emerging wound was disinfected with a sterile gauze swab 
and iodine solution and subsequently sewed with a running percutaneous suture using 
absorbable filaments (Covidien (Caprosyn)), providing secure wound approximation for ~10 
days. As analgesic treatment mice received buprenorphine hydrochloride (Schering-Plough 
(Temgesic), ~0.15 mg/kg BW i.m). Before waking up from anaesthesia, each mouse was 
subjected to whole-body fluorescence imaging (FluorVivo100, INDEC BioSystems, dorsal 
and ventral) to check for the presence of metastasis-derived fluorescence signal, especially in 
the thoracic area (Supplementary Fig. 7A). 
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After removal of the dorsal imaging window mice were followed up for 8 weeks with daily health 
monitoring and weight measurements minimum twice per week. Mice that were screened 
positive during whole-body fluorescence measurements after removing the imaging window, 
or mice showing symptoms like continuous weight loss or dyspnoea, were additionally imaged 
once per week to monitor potential metastasis progression. If severity of symptoms fulfilled 
humane end-point criteria, mice were sacrificed before completing the 8 week follow-up phase.
Prior to euthanasia and metastasis screen, all mice were again subjected to whole-body 
fluorescence imaging. Immediately after sacrifice, lymph nodes (superficial cervical, 
brachial, inguinal), lung, liver and brain were isolated and submerged in PBS to keep the 
tissue hydrated. Organs were screened for the presence of superficial metastases using 
fluorescence stereomicroscopy (Leica MZFLIII, EL6000external light source, GFP Plus and 
DsRed filter sets). While we frequently observed cancer cells in the lungs, superficial and easily 
countable lesions in other organs were rarely detected. Therefore our eventual metastasis 
outcome focused on disseminated tumor cells in the lung. After counting metastatic lesions 
down to single-cell level, organs were embedded in O.C.T. compound (Sakura), deeply 
frozen using dry-ice or through swaying in liquid nitrogen and stored at -80°C. To validate that 
green fluorescence signal of lung metastases was derived from H2B-EGFP positive tumor 
cells, lungs were cut into 50-100 µm thick cryosections mounted on superfrost plus object 
slides. After fixation with 2% PFA (15 min, RT), lung tissue slices were rinsed with PBS and 
incubated in PBS containing 0.1% Triton X-100 (Sigma Aldrich) for permeabilization (20 min, 
RT), followed by incubation with DAPI (1 µg/mL) diluted in PBS 2% NGS, 0.1% cold water 
fish skin gelatin (CWFG, Sigma Aldrich) for 10 min at RT, washing with PBS and mounting in 
Fluoromount G. GFP positive tissue slices were subsequently imaged by confocal microscopy 
(Olympus FV1000) to verify colocalization of H2B-EGFP and DAPI signal. Selected lesions 
were scanned as 3D stacks using a 20x / 0.50 NA or 40x / 0.80 NA water immersion objective 
and 1 µm step size. Filters to additionally capture DsRed2 derived signal were activated, 
however signal was either blurred or lost due to freezing and fixation procedures. 
In vitro interface migration assay
Multicellular spheroids (5000 cells per spheroid) were prepared from subconfluent cultures 
after detachment with EDTA (Invitrogen, 2 mM,) by 48h hanging-drop incubation59 in the 
presence of 40% methylcellulose (Sigma) and bovine collagen-I (Advanced Biomatrix, 9.3 mg/
mL final concentration). 
Between two 6 mg/mL high-concentration collagen I layers we obtained the best defined 
interface and created a rather restrictive environment constraining the major part of migration 
along the interface to mimic the in vivo situation (Supplementary Fig. 5B,C). To prepare cell-
free collagen-collagen interface gels, two 6 mg/mL rat-tail collagen-I (Corning) gels of each 50 
mL were polymerized in in7x7x2 mm silicone isolators (Electron Microscopy Sciences), placed 
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inside 24-well plates. The bottom layer was polymerized for 30 min at 37°C after which the 
upper layer was pipetted directly on top and polymerized similarly. For migration experiments, 
one spheroid was placed on the bottom gel after polymerization, prior to adding the upper 
layer of collagen. 0.75 mL culture medium containing 5 mg/mL puromycin was added per well 
after polymerization on top of the gel. Culture medium was supplemented with anti-b1 integrin 
monoclonal antibody (mAb) 4B4 and anti-aV integrin mAb 17E6 (both 10 mg/ml) for β1/β3 
knock-down cells and IgG1κ isotype from murine myeloma (20 mg/mL) for EV control cells. 
Cells were allowed to migrate for 48 h followed by fixation with 4% PFA (1 h, RT). 
PFA-fixed samples were washed twice with PBS followed by staining with mouse anti-ALCAM 
mAb (AZN-L50; IgG2A; kindly provided by Joost te Riet, Department of Tumor Immunology, 
Radboudumc Nijmegen, The Netherlands)60, after over-day blocking in 0.1% bovine serum 
albumin (BSA, Aurion) at 4°C. Primary antibody was diluted in PBS 0.1% BSA and incubated 
overnight (o/n) at 4°C whilst gently agitating. Subsequently, samples were washed with 
PBS followed by o/n incubation with goat anti-mouse Alexa Fluor 405 and Phalloidin Alexa 
633 (both Invitrogen, 4 µg/mL) in PBS 0.1% BSA (4°C) and washing with PBS. Eventually, 
stained collagen lattices were sealed into a PBS, 0.1% BSA, 0.05% sodim azide (Sigma 
Aldrich) containing self-made chamber on an object slide covered with a coverslip. Imaging 
was performed using a high-content epifluoresecence microscope (DAPI, FITC, Cy5 filter) 
combined with automated multi-position image acquisition and stitching (Leica DMI6000B, 
10x HCX FL PLAN/0.25 NA air objective), generating z-stacks with 10 µm step-size. To obtain 
high-quality images, selected samples were subsequently re-imaged using confocal scanning 
microscopy (Olympus FV1000, 20×/0.5 NA and 40×/0.80 NA water immersion objectives, 5 
and 1.38 mm step size respectively).
Analysis of migration modes was performed on a per spheroid basis, including only cells that 
were migrating into the collagen-collagen interface. To determine total area of the invasion zone 
as well as the fraction of cells migrating in a particular mode, outlines of 2D cohesive sheets 
connected to the spheroid, detached cells and cell clusters (>2 cells) were traced, assessing 
both brightfield and phalloidin signal for determining cellular detachment. Subsequently areas 
of each migratory fraction were measured and plotted as percentage of the total area of the 
invasion zone. Cellular elongation was determined from detached single cells by dividing the 
length of the longest possible straight line through the cell that intersects the nucleus by the 
longest possible line perpendicular to it (Supplementary Fig. 4B). 
For time-lapse microscopy, samples were prepared with bicarbonate-free DMEM containing 
HEPES (Invitrogen, 20 mM). The 24-well plate containing the samples was placed in a heated 
chamber (Okolab; 37°C) with humidified gas supply, which was mounted on a motorized stage 
on an inverted microscope (Nikon Diaphot 300; 10× / 0.25 NA dry objective) equipped with 
a CCD Camera (Hamamatsu C8484-05G). Brightfield images were acquired every 10 min 
using Okolab time-lapse software for up to 48 h. Cell migration velocity and persistence were 
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analyzed by manual tracking using the MTrackJ plugin for FIJI55,57. Persistence was calculated 
by dividing the distance from the first to the last measured point by the length of the track 
(Supplementary Fig. 4C).
Statistics
Statistical analysis was performed using GraphPad Prism 5 software. For data quantifying 
tumor growth or β1/β3 integrin knockdown two-tailed t-tests were performed, paired for 
intratumor comparison of tumor core and invasion zone, unpaired for all other cases. Migration 
analyses, amount of CTCs per mouse and metastasis outcome were analyzed using the two-
tailed unpaired Mann–Whitney test. To evaluate differences between mice bearing CTCs and 
mice that were CTC negative, a Mantel-Cox Log-rank test performed. To adjust for multiple 
comparisons, p-value cutoffs were subjected to Bonferroni correction.
Results
To address the role of integrins for tumor progression and metastasis formation in HT-1080 
sarcoma and MV3 melanoma xenografts we applied a preventive integrin interference 
approach prior to and during tumor implantation, aiming to minimize the availability of all 
integrin subtypes expressed by the cells. Both cell lines expressed β1 integrins at high 
and αV and β3 integrins at moderate to low levels, but lacked all other β integrin subsets 
(Supplementary Fig. 1). This integrin expression profile was consistent with mesenchymal 
cells, which lack integrins restricted to leukocytes (β2) or basement membrane interaction 
(β4-β8)61,62. Simultaneous downregulation of β1 and β3 integrins using shRNA resulted in 
respective 75-85% and 90-99% reduction of protein surface expression, without compensatory 
upregulation of other β chains (Supplementary Fig. 1, 2A,B). After integrin downregulation 
cells showed reduced mitotic activity but retained low frequency of apoptosis, indicating 
largely unperturbed survival without increased risk to select for anchorage-independent, 
anoikis-resistant clones63 (Supplementary Fig. 2C). To improve targeting, adhesion of residual 
β1 and αVβ3 integrin epitopes was perturbed in vitro and in vivo by applying anti-β1 and -αV 
integrin antibodies (4B4 and 17E6, respectively) in HT-1080 and MV3 cells and xenografts 
expressing β1/β3 shRNA. Using 24h-exposure with both antibodies at a concentration of 3 
µg/mL, as realistically achieved in body fluids in vivo with the applied dosing and application 
regime, surface β1 and β3 integrins were diminished to isotype control levels on HT-1080 and 
MV3 wild-type cells (Supplementary Fig. 2D). Consistently, HT-1080 β1/β3 integrin shRNAi 
xenografts growing in nude mice treated with mAb 4B4 and 17E6 showed efficient reversion 
of increased phospho-FAK signal to levels equal to the stromal background (Supplementary 
Fig. 2E). 
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Figure 1. Tumor regression upon β1/αVβ3 integrin interference.
A) Time-dependent whole tumor morphology of HT-1080 and MV3 empty vector (EV) control xenografts 
treated with isotype and xenografts after shRNA-mediated RNAi for β1 and β3 integrin additionally treated 
with adhesion perturbing antibodies 4B4 (β1) and 17E6 (αVβ3). For MV3 tumors, last pictures of the series 
show the control lesion at day 22 and the integrin interference lesion at day 11. Beyond day 11 the β1/β3 
shRNAi tumor had undergone complete regression. Scale bar, 200 µm. B) Relative tumor progression of 
individual control and β1/β3 integrin RNAi lesions at day 10 (HT-1080) or day 11 (MV3) compared to day 
1, displayed as waterfall plots. Data include 25 (HT-1080, 13 mice) and 38 (MV3, 19 mice) control tumors 
and 26 (HT-1080, 13 mice) and 38 (MV3, 18 mice) integrin interference lesions. Statistics, unpaired t-test 
comparing tumor volumes of control or interference lesions at day 10/11 (see also Supplementary Fig. 
3B). C) Median residual mass of core and invasion (Inv.) zone after β1/β3 integrin interference at day 10 
compared to day 3 (HT-1080) or day 11 compared to day 4 (MV) from 5 (HT-1080) or 7 (MV3) independent 
tumors. Statistics, paired t-test. 
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To monitor how preventive integrin targeting affects spontaneous metastasis, HT-1080 and 
MV3 xenografts expressing nuclear H2B-EGFP and cytoplasmic DsRed2 were implanted 
intradermally and their growth and invasion were monitored using intravital microscopy. In 
addition, cells reaching the circulation were counted as CTCs after 11 days and metastatic 
outcome was quantified 11 weeks post-implantation (Supplementary Fig. 3A). In vivo, HT-
1080 sarcoma and MV3 melanoma tumors expressing vector control, treated additionally with 
isotype antibody developed distinct growth behaviors: HT-1080 lesions grew exponentially 
whereas MV3 tumors were slowly progressing (Fig. 1A, Supplementary Fig. 3B). Despite this 
difference, HT-1080 and MV3 tumors were equally sensitive to integrin interference, reaching 
partial or complete regression within 3 weeks of observation (Fig. 1A,B, Supplementary Fig. 
3B), confirming an essential role for integrins in mediating growth and survival of the primary 
tumor lesion.
When monitored by intravital MPM, HT-1080 and MV3 control tumors developed predominantly 
strand-like collective invasion with intact cell-cell junctions as described52 (Fig. 1A, 2A,B, 
Supplementary Fig. 4A). Such collective migration patterns have been shown to depend 
on integrin-mediated cell-matrix adhesion, where especially the leader cells generate actin 
and integrin-mediated traction forces to propel the cell group forward and loss of integrin 
function goes along with a switch to amoeboid single-cell migration or abolished cellular 
migration33,64,65. Surprisingly, after multi-integrin targeting in HT-1080 and MV3 xenografts, 
collective invasion patterns persisted, however were accompanied by increased detachment 
of multicellular clusters and single cells (Fig. 2A,B). Decreased cellular elongation, especially 
in MV3 cells, further indicated a switch towards more amoeboid-like migration (Supplementary 
Fig. 4B). Independent of the migration mode, movement efficacy at single cell level was 
largely unperturbed after integrin targeting, showing only slightly reduced velocity and 
directionality (Fig. 2C, Supplementary Fig. 4C). Notably, compared to the tumor core, in both 
tumor types invasion zones of integrin-targeted xenografts were clearly more persistent and 
lagging behind in the regression process (Fig. 1A,C). Thus, in contrast to the tumor core, cells 
invading the deep dermis exhibited improved survival capacity upon blocking integrin function, 
accompanied by persisting integrin-independent invasion and enhanced migrational plasticity. 
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Figure 2. Persisting collective invasion and increased single-cell detachment after β1/αVβ3 
integrin interference.
A) Invasion zones of HT-1080 or MV3 control or β1/β3 integrin interference xenografts. Tumor cells stably 
express nuclear H2B-EGFP and cytoplasmic DsRed2. Alexa Fluor 750-conjugated Dextran contrasts 
perfused blood vessels. Second harmonic generation (SHG) visualizes muscle and collagen fibers. Blue 
lines: migration tracks. Red dotted outlines: collective strands. Other dotted outlines: single cells and 
detached cell groups. Dashed lines: position strand tip or cell/cell group at start time-lapse sequence. 
* apoptotic cells. Scale bar, 50 µm. (B,C) Analysis of migration mode and velocity. B) Migration-mode 
based categorization and distribution of invading tumor cells displayed as mean fraction ± SEM. C) 
Median velocity derived from tracking 248 (HT-1080 EV), 112 (HT-1080 β1/β3 integrin RNAi) or ~480 
(both MV3 conditions) individual cells. Migration mode and velocity data were analyzed from 2 (HT-1080) 
and 3 (MV3) mice for control conditions and 4 (HT-1080) and 3 (MV3) mice for interference conditions with 
4-6 imaging positions per mouse. Statistics, Mann-Whitney test.
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These findings were not consistent with the significant integrin dependence of HT-1080 and 
MV3 cells migrating into 3D fibrillar collagen matrices, which is strongly compromised by 
addition of anti-β1 integrin mAb 4B432,66. We thus sought to reconcile this apparent in vitro/
in vivo inconsistency by analyzing the different environmental conditions. The deep mouse 
dermis is heterogeneously organized with interfaces provided by preexisting tissue structures 
including myofibers or blood vessels, interspersed with collagen fibers and other ECM 
components, altogether forming a track-like system guiding moving cells67,68. Conversely, the 
in vitro collagen I matrix is a dense network of randomly aligned fibers requiring proteolytic 
cleavage to form tracks of least resistance and enable cellular movement69,70. Following the 
concepts on adhesion-independent migration (i.e. “chimneying”) in 3D channel-like, confined 
environments71–74, we hypothesized that guidance paths relative to space constraints dictate 
the differential requirement for integrin function and refined the 3D spheroid invasion model 
by introducing an interface between two high-density collagen matrices (6 mg/mL), serving 
as path of least resistance for invading cells (Supplementary Fig. 5A-B). When compared to 
engineered collagen-based models, using stamps to generate a “clean” interface75,76, through 
two-step polymerization we secured a loose network of perpendicular collagen fibrils bridging 
the interface between both collagen compartments (Supplementary Fig. 5B), thus mimicking 
in vivo interfaces bordered by loose fibrillar structures67,68. 
Cells from HT-1080 and MV3 control spheroids embedded into this modified collagen I model 
invaded the interface collectively as cohesive 2D sheet with intact cell-cell junctions maintained 
(Fig. 3A,B, Supplementary Fig. 5C,D). After integrin interference, migration was clearly 
reduced but persistent with decreased velocity and collective sheets showing disintegration 
into smaller cell groups and single cells, which additionally displayed slightly less elongation 
compared to control cells (Fig. 3B,C, Supplementary Fig. 5E). Furthermore, especially in MV3 
cells integrin interference impaired directional movement (Supplementary Fig. 5F). Overall, 
this unperturbed invasion and increased diversity of migration patterns obtained in vitro after 
integrin targeting recapitulated major patterns also observed in vivo, emphasizing the need of 
interfaces and track-like structures to enable integrin-independent movement. 
To address whether multi-integrin interference affects intravasation and the occurrence of 
CTCs, blood samples from mice were analyzed ~2 weeks after tumor implantation using 
sensitive filter-based isolation procedure (Supplementary Fig. 6). The time of CTC analysis 
coincided with the phase of subtotal or complete regression in the majority of lesions after 
integrin targeting (compare Fig.1B and Supplementary Fig. 3A). In tumor-bearing control 
mice, 30-60% of the mice were CTC negative, whereas in the remaining mice either single-
cell CTCs or in 10-20% of the mice CTC cluster and single-cell CTCs were detected (Fig. 4A-
C). Notably, after integrin interference for both models fractions of CTC positive and negative 
mice as well as mice with single-cell CTCs and CTC clusters hardly changed (Fig. 4A,B). 
Additionally, normalized CTC counts revealed a moderate increase in CTC concentration after 
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integrin function blocking, although not significant (Fig. 4C). Thus, the occurrence of both 
disseminating individual cells and CTC clusters was undiminished after integrin targeting, 
indicating that integrins are not required for intravasation and systemic dissemination. 
To investigate whether integrins are required for distant metastasis, xenografts were allowed 
to progress for 3 weeks, then removed and after follow up of additional 8 weeks, typical target 
organs for metastasizing soft tissue sarcoma and melanoma including lung, liver, brain and 
draining lymphnodes77–79 were subjected to fluorescence detection, with eventual metastasis 
outcome focusing on disseminated tumor cells in the lung (Fig.5A,B, Supplementary Fig. 7A). 
To account for all colonizing events, including macroscopically visible lesions, multicellular 
micrometastases and single cells, metastases were subsequently validated by DAPI 
counterstaining as being real cells rather than autofluorescent debris (Fig. 5A,B). To rule out 
that intradermal tumor cell injection caused accidental injury of blood vessels and passive 
entry of cancer cells into the blood stream followed by experimentally-induced metastasis, 
mice with detectable bleeding during tumor implantation were excluded from the analysis. 
To still rule out artificial dissemination in mice without detectable vascular damage during 
implantation, for a subset of mice the imaging window and tumor were removed 6h after tumor 
implantation, resulting in a negative metastasis outcome after 11 weeks (Supplementary 
Fig. 7D). Likewise, no early-onset of metastasis was detected, but rather the occurrence of 
metastatic lesions was strongly dependent on time after implantation (Supplementary Fig. 
7D). These data rule out the likelihood that metastases were incurred by the implantation 
procedure but occurred through spontaneous dissemination.
For both, control and β1/β3 integrin targeted tumors in the HT-1080 and MV3 model, overall 
incidence of lung metastases was comparable (Fig. 5C). In absolute counts, both tumor 
models showed reduced numbers of multicellular micrometastases after integrin targeting, 
whereby HT-1080 control xenografts also developed macrometastases which were lacking 
upon integrin interference and were generally absent in the MV3 model (Supplementary Fig. 
7B). The amount of single-cell lesions was similar for control and integrin-targeting conditions 
in the HT-1080 and MV3 model (Supplementary Fig. 7B). To exclude that this metastasis 
outcome was biased by escape behaviors, i.e. instability or loss of the β1/β3 integrin RNAi, 
we used β1 integrin mRNA expression as indicator to test reliability of the β1/β3 intgerin 
knockdown, which was possible because both β1 and β3 integrin shRNAs are expressed 
from the same vector. RNA was isolated from lung pieces containing fluorescent metastatic 
lesions derived from control or intgerin knockdown tumors obtained 11 weeks after tumor 
implantation, followed by cDNA generation and qPCR using human-specific β1 integrin and 
GFP specific primer to exclusively amplify tumor-cell derived cDNA, confirming maintenance 
of β1 integrin knockdown levels similar to in vitro cultured cells under antibiotics selection 
(Supplementary Fig. 7E). 
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Figure 3. Interface-guided migration enables integrin-independent cellular movement in vitro.
A) Interface-guided emigration from HT-1080 and MV3 control and β1/β3 integrin interference spheroids 
48 h after embedding between two collagen matrices, displayed as maximum intensity projection from 
confocal 3D stacks. Dashed rectangles, region of detail images. 1, detached single cells (a, elongated, 
mesenchymal; b, roundish, amoeboid). 2, collective 2D sheets or cell groups. Arrowheads, cell-cell 
junctions. Scale bar, 50 µm (overview and zoom image). (B,C) Analysis of migration mode and velocity. 
B) Migration-mode based categorization and distribution of emigrating cells displayed as mean fraction 
± SEM. C) Median velocity derived from tracking 91 (HT-1080 EV), 100 (HT-1080 β1/β3 integrin RNAi), 
110 (MV3 EV) and 87 (MV3 β1/β3 integrin RNAi) individual cells. Migration mode and velocity data were 
analyzed from 3 independent experiments with 2-3 spheroids per experiment. Statistics, Mann-Whitney 
test.
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Figure 4. Unperturbed haematogenous dissemination of single cells and multicellular clusters 
upon β1/αVβ3 integrin interference.
A) Single-cell CTC and CTC cluster captured from blood samples on a microsieve. Tumor cells were 
identified based on (partial) colocalization of nuclear H2B-EGFP (overlapping with DAPI signal) and 
cytoplasmic DsRed2 signal. CD45 staining visualizes immune cells. Scale bar, 10 µm. B) Fractions of 
mice for HT-1080 and MV3 control and β1/β3 integrin interference xenografts, being either CTC negative 
or CTC positive with either exclusively single-cell CTCs or a combination of single-cell CTCs and CTC 
clusters. Blood samples were taken from 9 (HT-1080 EV), 7 (HT-1080 β1/β3 integrin RNAi), or 8 (both 
MV3 conditions) mice. Statistics, Log-Rank test. C) Normalized median amount of CTCs obtained per 
mouse. Total CTC numbers per mouse were counted with cases highlighted where multicellular clusters 
contributed to total CTC amount. Statistics, Mann-Whitney test.
Because growing control lesions comprised a 30-fold (HT-1080) and 20-fold (MV3) larger 
volume compared to regressing β1/β3 integrin RNAi lesions at day 10/11, individualized 
normalization of the amount of metastatic lesions relative to the time-integrated tumor mass 
was performed for each mouse (Supplementary Fig. 7C), to standardize metastatic outcome 
to tumor burden. Compared to absolute counts, this resulted in a significantly increased 
number of single cell and overall metastases for β1/β3 integrin interference xenografts of both 
models (Fig. 5D). For HT-1080 tumors even the normalized amount of micrometastases was 
enhanced after integrin targeting whereas for MV3 xenografts the number of micrometastases 
approximated for both conditions (Fig. 5D). Thus, after combined targeting of β1/β3 integrins 
by RNAi and adhesion-interfering antibodies, HT-1080 and MV3 xenografts developed an 
increased probability to colonize the lungs as single cells or small clusters which however 
lacked early onset outgrowth.
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Figure 5. Enhanced metastatic seeding of cells after β1/αVβ3 integrin interference.
A) Categorization of metastatic lesions in the lung. Macroscopic lesions were visible by eye, micro 
metastasis could be detected in fluorescence overview images of whole lungs and constituted a 
homogeneous mass in contrast to countable single-cell lesions. Dashed circles, region of detail images.*, 
part of the highly autofluorescent esophagus. BF, brightfield image. FL, fluorescence signal. Scale bar, 
1 mm (overview images and zoom macro metastasis), 100 µm (zoom micro metastasis), 10 µm (zoom 
single-cell metastasis). B) Metastatic lesions of different categories identified based on H2B-EGFP-
derived green fluorescence colocalizing with nuclear DAPI signal displayed as maximum intensity 
projection from confocal 3D stacks of 50-100 µm tissue slices. Scale bars, 100 µm (macro metastasis), 
10 µm (micro and single-cell metastasis). C) Fractions of mice for HT-1080 and MV3 control and β1/β3 
integrin interference xenografts where lung metastases were detected. In total 13 (HT-1080 control and 
β1/β3 integrin RNAi), 19 (MV3 control) and 18 (MV3 β1/β3 integrin RNAi) mice were analyzed of which 
indicated percentages were metastasis positive. D) Median amount of lung metastases normalized for 
size of the primary lesion over time, determined as area under the curve (AUC). See also Supplementary 
Fig. 7 for absolute number of metastatic lesion and details on AUC analysis. Statistics, Mann-Whitney 
test. *, significant p value after Bonferroni correction (Bonferroni-corrected threshold was 0.017). 
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Discussion
The results of this work, investigating the relevance of integrins for all steps of the metastatic 
cascade in vivo by intravital imaging, confirmed that integrins function as important mediators 
of growth and survival signaling, showing that integrin targeting leads to a growth deficit in 
the primary tumor and diminished outgrowth after lung colonization with a dormancy-like 
phenotype80. However, unexpectedly and hardly anticipated by published in vitro results, 
our results also revealed that integrins are largely dispensable for local tissue invasion, 
intravasation and metastatic arrival at distant sites; instead integrin interference increased 
plasticity and efficiency of invasion and even enhanced metastatic dissemination when tumor 
load was taken into account. Thus, except for outgrowth of primary and metastatic lesions we 
could not identify any step in the metastatic cascade of mesenchymal sarcoma and melanoma 
xenografts to be significantly dependent on integrin function. This contradicts the common 
conclusion that integrins are indispensable for invasion and metastasis formation, mainly 
based on (i) in vitro models such as migration analysis on 2D ECM-coated surfaces or in 3D 
matrix models, transwell migration assays and microfluidics-based microvascular networks 
after integrin knockdown/blockade or overexpression40,81–84, (ii) preclinical studies which either 
analyzed experimentally-induced metastasis or solely investigated growth of the primary 
and/or metastatic lesion82,85–88 or (iii) studies showing correlations between (high) integrin 
expression and cancer progression18,19,21,89. Accordingly, our results emphasize the need for in 
vivo studies which longitudinally analyze the entire metastatic cascade in orthotopic models, 
including tumor sub-regions, while separating between survival and migration function of 
integrins.
During cell migration, integrins mediate attachment to the ECM and serve as linker between 
extracellular substrates and the actin cytoskeleton, necessary to generate traction forces to 
propel the cell body forward90. Despite this essential function of integrins in cell migration, we 
here show, that integrin-independent migration mechanisms contribute to cancer invasion 
and metastasis. Environments requiring adhesion-dependent migration include 2D substrates 
and dense, discontinuous 3D matrices without any pre-defined interface, where adhesion 
interference blocks migration and causes cells to round up32,66,73,74. Conversely, highly porous 
3D matrices and confined 2.5D and 3D channel-like structures promote adhesion-independent 
migration, inducing cells to employ alternative mechanisms to build up traction forces34,71–74. 
The environmental conditions of disseminating cancer cells in the deep dermis include 
predefined tracks between tissue structures like endothelial cells or myofibers and offer such 
confined, channel-like structures67. They allow cells to adapt adhesion-independent migration 
modes such chimneying or friction-based migration where cells either exert pushing forces 
against the surrounding substrate or generate contractile flows of the actomyosin cortex to 
produce forward movement34,91,92. 
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But, latest when reaching the basement membrane and crossing the endothelial barrier, 
disseminating cancer cells are thought to be forced to employ adhesion-dependent 
mechanisms combined with proteolytic ECM cleavage as transendothelial migration during 
in-and extravasation rather resembles migration in a discontinuous 3D matrix, similar to 
recirculating leukocytes which depend upon β1 and β2 integrins93–95. Accordingly, also for 
disseminating cancer cells integrins are the most prominent candidate to mediate attachment 
and facilitate proteolytic cleavage during intravasation2,35,36. However, our findings showing 
even increased CTC concentrations after integrin interference strongly contradict these 
assumptions but rather suggest alternative mechanisms to support transendothelial migration 
and crossing of the basement membrane. Essentially, both, the endothelial layer and space 
between individual endothelial cells and small capillaries which cause tumor cells to arrest, 
constitute a confined space comparable to the preexisting tissue tracks1,3, which would allow 
employment of above-mentioned adhesion-independent migration mechanisms. Alternative, 
integrin-independent adhesion mechanisms which might facilitate dissemination include cell-
cell adhesion-mediated interactions between cancer and stromal cells, such as N-cadherin- or 
selectin-based junctions that were shown to develop between cancer and endothelial cells 
or fibroblasts96–99. Although not shown yet experimentally for the process of intravasation but 
only as invasion-promoting mechanism, essentially also cancer-associated fibroblasts might 
contribute to basement membrane cleavage and blood vessel entry of cancer cells lacking 
integrin expression100. Furthermore, adhesion receptors of the discoidin domain receptor 
(DDR) family of transmembrane tyrosine kinases or CD44 are able to mediate alternative 
ECM interactions101–104, with DDR signaling also inducing MMP upregulation to facilitate matrix 
cleavage103,104. 
Given these varying environmental topographies along the metastatic cascade, including 
both tissue invasion and passage through vessel walls, differential prerequisites for adhesion-
dependent and independent migration in in vivo-inspired re-design of in vitro models used 
to probe defined aspects of metastatic cell migration, need to be considered. Using side-by-
side analyses, we here modeled mechanisms observed in vivo by adjusting the randomly 
polymerized 3D collagen matrix towards an interface-based model which provides a confined, 
channel-like structure and consequently enabled in-vivo-like migration after stringent 
interference with integrin functions. Our combined in vitro and in vivo data thus indicate that 
all key steps of the metastatic cascade enable low integrin-based adhesion requirements to 
be efficiently accomplished.
Beyond fully unperturbed migration, lowering integrin availability in sarcoma and melanoma 
cells further induces plasticity of migration, switching from exclusively collective to collective 
and single-cell invasion with decreased cellular elongation after integrin interference. 
Known mechanisms of migrational plasticity include epithelial to mesenchymal or collective-
amoeboid transition (EMT and CAT), both mainly described for epithelial models105–108. EMT 
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is a molecular process resulting in down-regulation of cell-cell adhesion molecules with 
subsequent release of single cells106,107. During CAT, additional weakening or loss of cell-
matrix interactions results in transition towards amoeboid crawling105,109. For mesenchymal cell 
types thus far matrix density has been identified as major regulator of migration plasticity, with 
loose matrix conditions favoring single-cell migration whereas confinement promotes a switch 
towards collective migration (chapter 3). Integrin-availability, as identified here, confirms a 
role for integrins in controlling migrational plasticity in mesenchymal cell types by directly 
or indirectly controlling cell adhesion. As consequence of integrin interference increased 
detachment of multicellular clusters and single cells is promoted in vitro33 and shown here in 
vivo. Mechanistically, thus far no direct contribution of integrins to cell-cell junctions has been 
shown, however, several indirect mechanisms have been described. Via intercellular deposits 
of ECM components such as fibronection or laminin and integrin-mediated attachment to these 
matrix fibers, cells become indirectly linked to each other 110–112. Furthermore, by undergoing 
so-called “adhesive crosstalk” with cadherins, integrins regulate cell-cell adhesion, whereby 
integrin-derived signals upregulate cadherins and subsequently (re)enforce cadherin-based 
cell-cell junctions113–115. Accordingly, similar to EMT, integrin interference might downregulate 
cadherins, destabilize cadherin-based junctions and stimulate a switch from collective to 
individual cell migration. By reducing cell-matrix adhesion and limiting cell spreading, reduced 
integrin availability then further promotes a rounded cell shape and amoeboid migration modes 
similar to CAT. Thus, through altering cell-cell and cell-matrix adhesion strength, lowering 
integrin levels releases tumor cells from multicellular units which constitutes a functionally 
critical plasticity step of migration in mesenchymal tumor cells in vivo.
Apart from integrin-independent migration, integrin interference initially did not affect survival 
of disseminating cells, whereas the tumor core and metastatic lesions instantly suffered from a 
survival deficit, which was consistent between both tumor types and across individual lesions. 
On the one hand these results confirm a critical function of integrins in cancer cell growth, 
however, initial anoikis resistance in the invasion zone suggests additional mechanisms 
which sustain survival despite integrin deficit. In contrast to the tumor core, which resembles a 
spheroid-like structure of densely packed tumor cells and blood vessels, hardly interspersed by 
ECM components52, disseminating cancer cells reside in a ligand-rich environment containing 
various ECM components and numerous stromal cell-types, including fibroblasts, endothelial 
cells, myofibers, nerve cells and macrophages6. Either directly, through cadherin-based cell-
cell junctions between stromal and cancer cells, or indirectly, via secretion of growth factors 
binding to receptor systems present on cancer cells, these microenvironmental components 
are able to activate pro-survival and anti-apoptotic pathways, including PI3K-Akt and MAPK 
signaling, similar to integrins, thereby promoting anoikis resistance96,116–120. Likewise, alternative 
cell-matrix adhesion systems such as DDRs induce downstream signaling events including 
PI3K-Akt and MAPK and thus might contribute to cell growth and survival104. Beyond these 
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microenvironmental factors, cadherin-based homotypic cell-cell junctions between cancer cells 
themselves during collective migration display an important source to stimulate survival96,117. 
Upon integrin-interference, loss of integrin-based cadherin upregulation and release of single 
cells, former junction-mediated cell survival might be compensated by release of cytoplasmic 
adhesion adaptor proteins including beta-catenin and p120 catenin121, which independently 
of cell junctions have been implicated in anoikis inhibition122–125. Thus, while infiltrating tissue, 
tumor cells may acquire largely integrin-independent survival strategies, mediated by both, 
external, environmental factors and cell-intrinsic mechanisms. It further suggests that, in case 
of abundant stroma- or cell-cell junction-derived survival stimuli, tumor lesions or sub-regions 
may not generally depend upon integrin-mediated survival stimuli, which becomes supported 
by heterogeneous patterns of integrin expression in tumor samples126–128. 
Overall our data show that a low integrin status agrees with efficient adhesion-independent 
invasion, increased migration plasticity and microenvironmentally-induced anoikis evasion, 
altogether promoting dissemination and resulting relative to tumor size in increased metastasis 
formation, however with a survival deficit of metastatic lesions as rate-limiting step. Growth 
and survival functions of integrins might stimulate rapid outgrowth of primary and metastatic 
lesions but become dispensable once tumor cells disseminate. Despite instant regression 
of the primary tumor and delayed regression of the invasion zone metastatic dissemination 
was not abrogated, ending up with metastatic disease but lacking primary tumor. Transferred 
to clinical observations, cancer of unknown primary site (CUP) is a common phenomenon 
observed in 3-5% of advanced cancers129. The etiology of CUPs may be diverse, thus 
investigation of mechanisms causing the primary lesion to spontaneously regress will be 
required and should include analysis of the integrin status. 
Likewise, analysis of CTCs is currently becoming a valuable prognostic tool in the clinics130, 
but thus far integrin expression in CTCs has been hardly investigated and does not show 
concordant correlations between integrin status of CTCs and metastasis outcome yet131,132. 
In our experiments, increased dissemination capacity after integrin downregulation became 
evident by both, increased relative CTC counts and enhanced single-cell metastasis relative 
to the tumor size. To reliably characterize correlations between integrin status and efficiency 
of metastatic seeding, similar parameters should be included in studies analyzing the integrin 
status of patient-derived CTCs in various cancer types, rather than focusing only on the 
sole presence of CTCs and clinically relevant, macroscopic, metastatic lesions. Eventually, 
extensive CTC profiling will help to reveal precise integrin-dependent and independent 
mechanisms that mediate metastatic dissemination and in particular transendothelial migration 
and survival in the blood stream. 
Despite increased relative CTC concentrations after integrin interference, for both the sarcoma 
and melanoma model we detected single-cell and clustered CTCs of which proportions were 
remarkably not affected by the enhanced migration plasticity and cellular individualization 
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observed upon integrin interference. Although not determined here which invasion mode 
and CTC type mainly contributed to metastasis formation, recent findings suggest collective 
invasion and multicellular CTCs to be more efficient in seeding metastatic lesions133,134. 
Therefore we assume that also in our models, the collective fraction majorly contributes to 
dissemination beyond intravasation, however experimental validation using experimental 
models as described is pending. 
In summary, future preclinical studies on mechanisms of metastatic progression should 
analyze the entire metastatic cascade, rather than focusing on sub-stages like invasion, 
CTCs or metastatic lesions, including also single-cell analyses. To gain clinical insight into 
the status of integrin expression during metastasis formation, clinical studies should analyze 
integrin expression in tumor sub-regions and CTCs to identify potential niches and steps to 
metastasis with low integrin or integrin-ligand availability. Therapeutic approaches including 
blockade of integrin function should be seen with caution as it might have fatal outcome 
in patients, inducing cell release from the regressing local site and eventually macroscopic 
metastasis upon completion of integrin-targeted therapy. Instead, as delineated in Chapter 
5 of this thesis, such mono-therapy approaches should be combined with a second lethal 
component to decrease the apoptosis threshold in integrin-low subsets and overcome initial 
anoikis resistance. 
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Supplementary Materials and Methods
Flow cytometry
The surface expression of adhesion molecules on HT-1080 and MV3 wild-type, vector control 
(p-puro or p-puro/p-neo) and stable knockdown (β1/β3RNAi) cells were obtained using cells 
from 3D matrix conditions after 24h-culture in 3D collagen lattices. Suspended cells were 
obtained by digestion with collagenase I (Sigma Aldrich, 1000 U/mL, 30 min, 37°C), pelleted 
and stained for 30 min on ice with the following monoclonal antibodies or isotypic control 
antibody: mouse anti-α1 integrin (clone TS2/7, Abcam), mouse anti-α2 (CD49b, clone AK-7), 
mouse anti-α3 integrin (CD49c, clone C3II.1, both BD Biosciences), mouse anti-α5 integrin 
(clone SAM-1, Millipore), rat anti-α6 integrin (CD49f, clone GoH3, BD Biosciences), mouse 
anti-αV (CD51, clone AMF7, Beckman Coulter), mouse anti-β1 (CD29, clone 4B4), mouse 
anti-β2 (CD18, clone 7E4), mouse anti-β3 integrin (CD61, clone SZ21, all Beckman Coulter), 
rat anti-β4 (CD104, clone 439-9B, BD Biosciences), mouse anti-β5 integrin (clone KN52, 
eBioscience), mouse anti-β6 (clone 437211, R&D), rat anti-β7 integrin (clone FIB504, BD 
Biosciences), mouse anti-β8 integrin (clone 416922, R&D); isotypic mouse IgG1κ (clone 
MOPC-21) and IgG2bκ (clone 27-35), rat IgG2aκ (clone R35-95) and IgG2bκ (clone A95-1) 
(all BD Biosciences). When primary antibody was unconjugated, secondary mouse IgG (H+L) 
antibodies conjugated to Alexa Fluor 488 (Invitrogen) were used for detection. Viability of cells 
was determined using propidium iodide exclusion.
To measure efficiency of integrin-blocking antibodies anti-β1 integrin 4B4 and anti-αV integrin 
17E6, adherent HT-1080 and MV3 wild-type were cultured in the presence of either mouse 
IgG1κ isotype (6, 10 and 20 µg/mL) or 4B4/17E6 (2x 3, 5 and 10µg/mL) for ~18h. Prior to flow-
cytometry measurements, cells were detached with 1mM EDTA (Thermo Fisher Scientific) 
and resuspended in culture medium supplemented with either 4B4/17E6 or isotype followed 
by incubation at 37°C for ~5h to compensate for potential loss of integrin blocking upon EDTA-
mediated cell-detachment. Residual β1 and β3 integrin epitopes were subsequently stained 
using FITC-conjugated mouse anti-β1 mAb clone 4B4-FITC (Beckman Coulter, 6603109, 
10 μg/mL) and rat anti-β3 integrin (kindly provided by Bernhard Nieswandt, Department of 
Experimental Biomedicine – Vascular Medicins, Rudolf Virchow Center Würzburg, Germany, 
10 µg/mL) in combination with goat-anti-rat Alexa Fluor 647 (Invitrogen, 10 µg/mL). For 
isotype staining either mouse IgG1 negative control (Neormarker, NC-748-PABX, 10µg/mL) 
combined with goat-anti-rat Alexa Fluor 488 (Invitrogen, 10 µg/mL) or rat IgG (Thermo Fisher 
Scientifc, 02-9602, 10 µg/mL) were used. Cells were kept on ice during the staining procedure 
with 30 min incubation time each for primary and secondary antibodies. Viability of cells was 
determined using propidium iodide exclusion.
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RNA isolation, cDNA generation and quantitative real-time PCR (qPCR)
RNA isolation from dual color HT-1080 and MV3 EV and β1/β3 integrin RNAi cells was 
performed using the RNeasy Miro kit (Qiagen) following the protocol “Purification of total RNA 
from animal and human cells (version 12/2007)”. Per cell line 250.000 cells were lysed using 
RLT buffer supplemented with β-mercaptoethanol and subsequently homogenized using a 
blunt 20G needle and syringe. DNase I digested RNA was eluted in a volume of 14 µL nuclease-
free water. To extract RNA from metastatic lesions in the lung, samples frozen in O.C.T. 
compound were carefully thawed on ice in cold PBS. Tissue pieces containing fluorescent 
lesions were identified through fluorescence stereomicroscopy and then submerged in 
RNAlater stabilization reagent (Qiagen). Prior to RNA isolation, RNA stabilization reagent 
was removed by squeezing tissue pieces between sterile filter paper (Whatman) followed by 
mincing them into smaller pieces which were put into a 2 cm3 mortar. After adding 1 mL Trizol 
(Merck Millipore), tissue was homogenized with a pestle till no tissue pieces were left. The 
homogenate was transferred to a 1.5 mL tube, incubated at RT for ~5 min and then stored at 
-80°C for ~7 h to increase RNA yield. After thawing, per sample 200 µL Chloroform (Merck 
Millipore) were added. For phase separation, Trizol and Chloroform were mixed by inverting 
reaction tubes and centrifuged at 12,000 g for 15 min at 4°C after incubating samples at 
RT for 2-3 min. For RNA precipitation ~400 mL aqueous phase were transferred to 500 µL 
Isopropanol (Merck-Millipore), mixed by inverting reaction tubes, incubated at RT for 10 min 
and then at -80°C for 1 h. Thawed samples were centrifuged at maximum speed for 30 min 
at 4°C. Subsequently, RNA pellets were washed twice with 500 µL 80% Ethanol followed by 
centrifugation at maximum speed for 15 min at 4°C and air-drying the RNA pellet after the 
final washing step. For DNAse I treatment, RNA pellets were resuspended in 80 µL DNAse 
I solution and transferred onto a RNeasy spin column (Qiagen), which was incubated at RT 
for 15 min. The following steps were performed as described in the RNeasy Micro Handbook 
(version 12/2007) protocol ‘Purification of total RNA from animal and human tissues’ steps 
9-12. After placing the spin column into a new 1.5 ml collection tube, RNA was eluted using 10 
µL DNase/RNase-free water. Following application of nuclease-free water onto the filter of the 
column, collection tubes containing the column were incubated at 37°C for 1 min. After 1 min 
centrifugation at full speed for elution, RNA samples were immediately put on ice. Following 
the same procedure, RNA elution from the same spin column was repeated using a new 
collection tube, yielding in total ~16 µL RNA per sample. 
After RNA concentration measurements (NanoDrop 1000, Thermo Fisher Scientific), for cell 
line samples 1 µg RNA and for metastasis samples 10µg RNA were used to generate cDNA 
using the iScript cDNA synthesis kit (BioRad), including per sample one reaction without 
reverse transcriptase. To check cDNA purity, per reaction 1 µL cDNA was added to a PCR 
amplifying human beta actin (forward (fw) primer GCGGGAAATCGTGCGTGACATT, reverse 
(rev) primer GATGGAGTTBGAAGGTAGTTTCGTG) resulting in specific bands (230 bp) for 
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cDNA samples. Absence of any PCR product for reactions without reverse transcriptase 
indicated that RNA and cDNA were free of genomic DNA contamination. 
qPCR was performed using iQ SYBR green Supermix (BioRad) and the following primer pairs: 
human specific β1 (fw: GAAGGGTTGCCCTCCAGA, rev: GCTTGAGCTTCTCTGCTGTT) 
and β3 integrin (fw: CCGTGACGAGATTGAGTCA, rev: AGGATGGACTTTCCACTAGAA) 
(specific amplification of only human β1 and β3 integrin was experimentally validated), GFP 
(fw: AAGCTGACCCTGAAGTTCATCTGC, rev: CTTGTAGTTGCCGTCGTCCTTGAA), human 
GAPDH (fw: TGATGACATCAAGAAGGTGGTGAA, rev: TCCTTGGAGGCCATGTGGGCCAT 
(only for cell line samples)) and human beta actin. For cell line samples, 1 µL cDNA was 
used for per reaction, whereas for metastasis samples 10 µL cDNA were added to pick up 
signal derived from human tumor cell metastatic lesions in a mouse tissue background. qPCR 
reactions were ran in a CFX96 Touch Real-Time PCR detection system (BioRad) with 40 
cycles for cell line samples and 80 cycles for metastasis samples including generation of melt 
curves. For cell line derived cDNA, 2^ΔΔCt for β1 and β3 integrin normalized to GAPDH signal 
was calculated, while for metastasis samples GFP signal was used to normalize specifically 
for tumor-cell derived RNA. Overall, amounts of human tumor-cell derived RNA in metastasis 
samples were too low to measure β3 integrin expression, though as β1 and β3 integrin were 
targeted simultaneously by one vector, persistence of β1 integrin in metastatic lesion indirectly 
validates stability of β3 integrin knockdown. 
Protein gelelectrophoresis and Western Blot
β1 integrin knockdown efficiency in dual-color HT-1080 and MV3 cells was detected by 
protein gel electrophoresis and Western blot analysis using complete cell lysates generated 
in TENT lysisbuffer135. β1 integrin was detected with rabbit anti-β1 integrin (Millipore, #04-1109 
or AB4952) and GAPDH, as loading control, with rabbit anti-GAPDH (Sigma, #G9545). All 
protein samples were separated under reducing conditions on 8% SDS-PAGE and transferred 
onto a PVDF-FL (Immobilon) membrane, blocked with 5% milk– Tris-buffered saline 0.5% 
Tween (TBST, 1h, RT) incubated with primary antibody (~18 h, 4°C), washed with TBST, and 
incubated with fluorescence-labeled goat anti-rabbit antibody (Li-Cor, 1 h, RT). Protein bands 
were detected using an Odyssey CLX imaging system (Li-Cor). 
Analysis of mitotic and apoptotic frequencies
To control for functional consequences after integrin knockdown in vitro, mitotic and 
apoptotic frequencies were determined from the H2B-EGFP label of dual-color HT-1080 cells 
incorporated in 3D collagen lattices for 48 h. Snapshots of cells (brightfield and FITC) were 
taken using a Zeiss Axiophot2 Fluorescence microscope with Axiocam MRm CCD camera 
(20×/0.30 NA air objective). Subsequently cell numbers and fractions of mitotic and apoptotic 
cells were determined manually using the "multi-point selection" tool in FIJI55.
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Immunohistological staining of tumor samples
Phospho-FAK signals were detected in tumors 5 days post-implantation into the imaging 
window. Tumor-containing tissue samples were cryopreserved as described above and 
processed as 10 µm thick cryosections mounted on superfrost plus object slides. After drying 
for ~18 h tissue slices were stored (-80°C) and prior to staining fixed (2% parafomaldehyde 
diluted in PHEM buffer, 15 min, RT), rinsed with phosphate-buffered saline (PBS) and 
incubated in PBS containing 0.1% Triton X-100 (Sigma Aldrich) for permeabilization (20 min, 
RT). To minimize background, samples were incubated in PBS supplemented with 5% NGS 
and 0.1% cold water fish skin gelatin (Sigma Aldrich; 30 min, RT), followed by staining with 
rabbit anti-phospho-Fak (pTyr397, Abcam, ab4803, 1:50) primary antibody, diluted in PBS 
supplemented with 2% NGS and 0.1% CWFG. Tissue slices were incubated with primary 
antibody solution (1 h, RT followed by ~18 h, 4°C), washed 8x 15 min (PBS), incubated with 
goat anti-rabbit IgG (H+L) Alexa Fluor 647 (Invitrogen, A-21245, 4 µg/mL) and DAPI (1 µg/
mL), both diluted in PBS/NGS (2%)/CWFG (0.1%), washed (4x 15min, PBS) and mounted in 
Fluoromount G. 
For the visualization of cell-cell junctions via ALCAM staining, untreated control tumor-bearing 
mice carrying the skin window were sacrificed on day 5 (HT-1080) or day 8 (MV3) after 
tumor implantation. Tumor-containing dorsal skin samples were cryopreserved with marked 
orientation of invasion strands and having the invasion status documented by intravital 
epifluorescence microscopy. Frozen tissue samples were cut into 50 µm thick cryosections 
(HM500OM Cryostat Microtome, Microm) which were immediately fixed in neutral buffered 
formalin (4%, formulation according to Lillie), incubated for ~18 h at room temperature and 
stored in phosphate buffer (0.1M, pH 7.4, 4°C). For staining, free aldehyde groups and 
unspecific epitopes were blocked using 0.15% glycine in Tris-buffered saline (30 min, RT), 
followed by incubation with TBS supplemented with 1% bovine serum albumin (Sigma Aldrich) 
and 15% normal goat serum (GIBCO Life Technologies, 30-60min, RT). After washing (TBS), 
endogenous mouse IgG in the tissue was blocked with unlabeled anti-mouse IgG Fab' 
fragments (Jackson ImmunoResearch, 15-007-003, ~18 h, 4°C) followed by washing (TBS). 
Mouse anti-ALCAM mAb (AZN-L50; IgG2A; kindly provided by Joost te Riet, Department of 
Tumor Immunology, Radboudumc Nijmegen, The Netherlands)60 was biotinylated using biotin-
SP (long-spacer) conjugated anti-mouse IgG Fab fragment (Jackson ImmunoResearch, 115-
067-003, 1:2, 20 min, RT), followed by incubation in mouse serum (Biowest, 10 µl/1 µg Fab' 
biotin, 10 min, RT). Anti-ALCAM/biotin-Fab' complexes were diluted (1:15) in TBS/BSA (1%) 
and added to the tissue slices for incubation (~18 h, 4°C). After washing (TBS) tissue slices 
were overlaid with streptavidin-coupled Alexa 647 (Jackson ImmunoResearch, 016-600-084, 
2 µg/mL) and DAPI (Roche, 1 µg/mL), in TBS/BSA (1%, 20 min, RT), washed (TBS) and 
mounted in Fluoromount G (Southern Biotech) on object slides for confocal microscopy. 
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Tissue samples stained for phosphor-Fak and ALCAM were analyzed by confocal microscopy 
(Olympus FV1000) as 3D stacks. Stainings of phosphor-FAK were scanned with a 40x / 0.80 
NA water immersion objective and 3 µm step size to represent the whole 10 µm tissue slice 
using identical instrument settings for control and integrin interference conditions. ALCAM 
stainings were recorded using either a 20x / 0.50 NA water or 60x / 1.35 NA oil immersion 
objective with 3 or 1 µm step size respectively. 
Visualization of collagen-collagen interface migration
To visualize the collagen-collagen interface by scanning electron microscopy (SEM), cell-
free samples were fixed for 1 h at RT with 2% glutaraldehyde (Merck) in 0.1 M cacodylate 
buffer, followed by two washes in the same buffer. 1% osmium tetroxide (EMS) in 0.1 M 
cacodylate buffer was used as a secondary fixative with incubation for 1 h at RT. Cross 
sections of collagen-collagen interface gels were made by manually slicing the gel with a 
scalpel. Samples were then processed for SEM by dehydration through a graded series of 
ethanol followed by critical point drying using CO2 and then sputtered with gold and imaged 
by SEM (JSM-6340F; JEOL).
To image tumor cell invasion from the spheroid along the collagen-collagen interface, cells 
were allowed to migrate for 48 h followed by fixation with 4% PFA and phalloidin staining as 
described above. Prior to embedding, cross sections of collagen samples were generated 
manually by an orthogonal cut through the collagen. Cross sections were imaged by confocal 
microscopy as described above, using a 20×/0.5 NA water immersion objective with 4µm 
z-steps, including record of the collagen reflectance signal. 
Spiked CTC analysis
To determine the nuclear size cutoff to distinguish blood cells from CTCs, blood obtained from 
mice not having received any tumor cell injection was mixed with cell suspension of HT-1080 
and MV3 dual color cells (10-60 tumor cells per 100-200 µL blood). Blood-cell solution was 
processed as above to capture both, blood and tumor cells on a microsieve followed by DAPI 
staining and imaging. Nuclear areas were measured using FIJI55. 
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Supplementary Figure 1. Integrin expression profiles in HT-1080 and MV3 cells before and after 
β1/β3 integrin knockdown.
(A,B) Surface expression pattern of integrin β chains and αV integrin on HT-1080 (A) and MV3 (B) control 
cells (blue line) and after β1/β3 integrin shRNAi (red line) determined by flow cytometry. Black line, isotype 
control. Values, mean fluorescence (minus isotype values).
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Supplementary Figure 2. RNAi and antibody-based integrin targeting in HT-1080 and MV3 cells.
A) Relative β1 and β3 integrin expression in control cells and after β1/β3 integrin interference determined 
from cDNA by qPCR, displayed as mean ± SD (n=2-3). Statistics, unpaired t-test. B) β1 integrin protein 
levels in control cells and after β1/β3 integrin interference determined by whole-cell lysis and Western 
Blot. β1 integrin signal was normalized to GAPDH signal to calculate relative β1 integrin levels after β1 
and β3 integrin RNAi displayed as mean ± SD (n=5 (HT-1080) or 7 (MV3)). Statistics, unpaired t-test. C) 
Mitotic and apoptotic frequencies of HT-1080 β1/β3 integrin RNAi cells compared to vector control cells 
after incorporated in 3D collagen lattices for 48h displayed as mean ± SD (3 visual fields of 500 cells 
were analyzed). Statistics, Mann Whitney test. D) Reduction of free, non-blocked β1 and β3 integrin 
adhesion epitopes after incubation with integrin-blocking antibodies 4B4 (unconjugated) and 17E6 or 
mouse isotype, detected by FITC-conjugated mAb 4B4 and rat anti-β3 integrin using flow cytometry. 
Blue line, integrin levels after isotype treatment. Red line, integrin levels after 4B4/17E6 treatment. Grey 
curve, isotype staining. Values, mean fluorescence (minus isotype values). E) Reduced phosphoFAK 
signal in HT-1080 β1/β3RNAi compared to HT-1080 control xenograft sections. Histograms show the 
mean pixel fluorescence (MF) intensity of AlexaFluor647-phosphoFAK calculated from tumor areas only 
(yellow dotted lines) normalized to stroma-derived signal (blue dotted lines). Dashed rectangle, region of 
detail image.
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Supplementary Figure 3. Xenograft models and experimental approach to analyze role of integrins 
in the metastatic cascade.
A) Experimental set-up: Cancer cells were given three weeks to initiate dissemination and enter the 
vasculature, then the imaging window including the tumor lesion was removed and mice were kept for 
a maximum of 8 more weeks till metastasis development was analyzed. To check for the presence of 
circulating tumor cells (CTCs), at least 6 mice were subjected to total blood sampling after ~2 weeks 
of tumor development. DSFC, dorsal skin-fold chamber containing imaging window. HEP, humane end 
point. B) Tumor development of HT-1080 and MV3 control and β1/β3 integrin RNAi xenografts displayed 
as median, 25th/75th (box) and minimum/maximum (whiskers), corresponding to Fig. 1B. Blue and red 
dotted line, tumor growth curves based on median values. Statistics, unpaired t-test. 
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Supplementary Figure 4. Validation of cell-cell junctions in collective invasion and effects of β1/
αVβ3 integrin targeting on invasion in vivo.
A) Distribution of ALCAM along cell-cell junctions (arrowheads) in invading tumor strands (Inv.) of HT-
1080 and MV3 control cells. Maximum intensity projections (overview) and individual sections (insets) 
from confocal 3D stacks. Background fluorescence originates from myofibers (M). Dashed rectangle, 
region of detail image. Scale bars, 50 µm (overview) and 10 µm (insets). (B,C) Median cellular elongation 
(B) and median directionality (C) of invading HT-1080 and MV3 control and β1/β3 integrin shRNAi cells. 
Cell shape was determined as ratio of cellular width and length. To analyze directionality of invasion, ratio 
of shortest and actual distance was identified. Statistics, Mann-Whitney test.
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Supplementary Figure 5. Characterization of in vitro interface migration and effects of β1/αVβ3 
integrin targeting.
A) Principle of interface-guided invasion (Inv.) between two high-density collagen (C) layers. Beyond 
migration along the interface (arrow) as track of least resistance, proteolytically-active cells will also, 
though to a lesser extent, migrate directly through the collagen matrix. S, spheroid. B) Visualization of 
the collagen-collagen interface (arrow) in cross-sections of the collagen-collagen layer through confocal 
reflection microscopy (top) or SEM (bottom). Zoomed SEM image shows single collagen fibers interspersing 
the interface. Scale bars, 10 µm (reflection and SEM overview), 1 µm zoom SEM. C) HT-1080 and MV3 
dual-color control cells primarily migrating along the collagen-collagen interface (arrow) accompanied by 
scattered single-cell migration inside the collagen matrix, displayed as maximum intensity projection from 
confocal 3D stacks. Collagen matrix visualized by reflection imaging. Scale bar, 100 µm. D) Distribution 
of ALCAM along cell-cell junctions (arrowheads) in collective 2D sheets and strands of HT-1080 and MV3 
control cells migrating along the collagen-collagen interface, displayed as maximum intensity projection 
from confocal 3D stacks. Scale bar, 50 µm. (E,F) Median cellular elongation (E) and median directionality 
(F) of HT-1080 and MV3 control and β1/β3 integrin RNAi cells migrating in the collagen-collagen interface 
model. See also Supplementary Fig. 4 B,C. Statistics, Mann-Whitney test.
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Supplementary Figure 6. Capture and detection of CTCs.
A) Nuclear size measurements of dual-color HT-1080 and MV3 control cells collected together with 
mouse blood cells on a microsieve. A cutoff of 300 µm2 was determined to distinguish human tumor cells 
and mouse blood cells Red line, median. B) Work-flow for identification of dual-color labeled CTCs in 
mouse blood. CTCs were identified based on their fluorescent markers (H2B-EGFP (green signal) and 
DsRed2 (red signal)) combined with a nuclear area ≥300µm2, positive DAPI and negative CD45 staining. 
Arrows point towards potential CTCs matching criteria of the analysis work-flow.
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Supplementary Figure 7. Quantification and analysis of metastatic lesions.
A) Development of fluorescent lung macrometastasis (arrow) visualized by whole-body fluorescence 
imaging. Day 22+0 corresponds with removal of the imaging window and tumor lesion. Mouse suffered 
from clinical symptoms and was terminated before reaching end of the 8-week follow-up phase. Calibration 
bar, minimum and maximum grey value. B) Median amount of lung metastases detected per category and 
mouse for HT-1080 and MV3 control and β1/β3 integrin shRNAi xenografts. Statistics, Mann-Whitney test. 
*, significant p value after Bonferroni correction (Bonferroni-corrected threshold was 0.017). C) Growth 
curves of individual HT-1080 control and β1/β3 RNAi tumors to exemplify determination of the area under 
the curve (AUC), which was needed to correct numbers of metastatic lesions for tumor size. Dashed 
areas represent average AUC for HT-1080 xeongrafts of both conditions. D) Number of metastatic lesions 
detected per mouse approximately correlate with tumor presence which excludes experimentally-induced 
metastasis formation due to tumor cell injection (left panel). Additionally, in mice where tumors were 
removed 6 h after injection (right panel) no metastatic lesions were detected after 11 weeks (per group 3 
mice were included). Scale bar, 100 µm. E) Maintenance of β1 RNAi in HT-1080 and MV3 metastases. 
Left panel: metastatic lesions isolated from one mouse lung of either the HT-1080 and MV3 control or 
β1/β3 integrin RNAi group to validate presence of β1 RNAi. Scale bars, 100 µm. Right panel: relative 
β1 integrin expression of β1/β3 integrin RNAi metastasis samples or in vitro cultured cells normalized 
to levels obtained for control metastases, analyzed from cDNA by qPCR and displayed as mean ± SD. 
Statistics, unpaired t-test.
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Cancer fatalities are caused by two often concurrent events, metastatic dissemination 
of neoplastic cells and resistance to therapy. To visualize these processes and dissect 
their interdependence in vivo, we have used longitudinal intravital microscopy on 
sarcoma and melanoma xenografts and demonstrate that these mesenchymal tumors 
invade collectively. Radiotherapy induced apoptosis and regression preferentially 
in the tumor core, whereas the collective invasion niche showed accelerated DNA 
damage repair and survived. Thus, collective invasion mediates radioresistance. 
Invading sarcoma and melanoma cells engage β1 and β3 integrins, and integrins 
support metastatic progression and resistance signaling, yet therapeutic targeting of 
individual integrins has met limited clinical success. Consistently, β1 or αVβ3 integrin 
monotargeting achieved incomplete radiosensitization, whereas dual-interference 
with β1/αVβ3 integrins ablated invasion-associated radioresistance, spontaneous 
metastasis and secured tumor eradication long-term. Collectively invading cancer 
cells thus withstand radiation therapy and DNA damage by β1/αVβ3 integrin crosstalk 
which can be overcome by dual-integrin targeted therapy. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Collective Cancer Invasion – An Integrin-dependent Radioresistant Niche  |  121
5
Introduction
Metastatic progression of cancer depends upon neoplastic cells migrating from the primary 
tumor into the surrounding tissue1. To initiate and maintain invasion, cancer cells receive 
tumor stroma-derived signals which enhance both their invasion and survival potential2–4. 
Stroma-derived tumor cell invasion and survival programs are mediated by hypoxia-related 
and/or metabolic stress and signaling from adhesion to extracellular matrix and growth 
factor receptors3,5,6; these environmentally controlled signals often cooperate and generate 
functionally complex networks supporting cancer progression2,7.
Cancer invasion occurs through individual or collective cell migration1,8. Moving single cells 
detach from the primary site and deliver high numbers of circulating tumor cells which 
retain only limited probability to survive the metastatic cascade9,10. Alternatively, collective 
metastasis empowers grouped and cooperating cells to invade, circulate and efficiently 
colonize distant organs10,11. While the particular ability of collective cancer cell behaviors for 
metastatic progression is becoming appreciated, their significance for the response to anti-
cancer therapy remains unclear. 
During invasion, tumor cells engage a range of mechano-chemical systems, and integrin-
based adhesion systems have been identified as central mediators of cell interaction with the 
surrounding matrix to enhance collective invasion12, antagonize apoptosis (anoikis) by providing 
anchorage13 and mediate radiation resistance, among many other functions14–16. Accordingly, 
integrins or their downstream signaling networks are considered as important targets for 
overcoming cancer resistance3,14–17. Single-agent targeting of integrins, however, has failed to 
reach clinical endpoints in delaying advanced cancer disease even in continuous or antibody-
based delivery schemes alone or in combination with cytotoxic therapy17,18 or, consistent with 
partial inefficacy, to eradicate established lesions in preclinical tumor models which express 
multiple and likely redundant integrin systems14,16. Integrins possess overlapping ligand-
dependent and -independent functions, coordinate multiple and plastic signaling cascades 
dependent on cell type and context, and support distinct important tumor-promoting functions, 
including survival, proliferation and DNA damage repair19–22. While several integrin-dependent 
signaling hubs and functions are suited for therapeutic intervention23, their crosstalk in solid 
tumors may also limit the efficacy of single-agent based integrin targeting. 
To address these potential caveats limiting therapeutic efficacy, we here aimed to identify 
the lesional sub-regions responsible for integrin-dependent tumor cell survival upon radiation 
therapy, and probe whether multiple integrin systems confound stringent integrin-based 
targeting. By combining preclinical intravital microscopy with in situ cytometry and long-term 
survival analysis, we identify the collective invasion niche as primary zone for an efficient 
DNA damage response and integrin-dependent radiation resistance and the requirement of 
dual-β1/αVβ3 integrin targeting to achieve efficient sensitization and elimination of cancer 
disease. 
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Materials and Methods 
Cells and cell culture 
Human HT-1080 sarcoma24 and MV3 melanoma cells25 were cultured in DMEM (PAN 
Biotech GmbH or Invitrogen) supplemented with 10% fetal calf serum (Aurion or Sigma 
Aldrich), penicillin and streptomycin (both 100 μg/mL; PAN Biotech GmbH or PAA) at 37°C 
in a humidified 5% CO2 atmosphere. Identity of the cells was verified by SNP_ID Assay 
(Sequenom, MassArray System, Characterized Cell Line Core Facility, MD Anderson Cancer 
Center, Houston, TX, USA) and lack of contamination with mycoplasma was routinely verified 
using the MycoAlert Mycoplasma Detection Kit (Lonza). Dual-color variants of HT-1080 and 
MV3 cells, expressing cytoplasmic DsRed2 and nuclear histone 2B (H2B)-EGFP26 were 
cultured in medium additionally containing Hygromycin B (Invitrogen, 0.2 mg/mL) and G418 
sulfate (Calbiochem, 0.2 mg/mL).
Generation of stable knockdown cell lines by lentiviral shRNA
ShRNA sequences targeting ITGB1 (β1 integrin; AGCCACAGACATTTACATTAAA) and 
ITGB3 (β3 integrin; AAGTCACTTTCTTCTTCTTAAA) for gene silencing by RNA interference 
were cloned into the lentiviral vector pLBM either containing a puromycin (p-puro) or a 
neomycin (p-neo) cassette, and lentiviral particles were produced and concentrated by 
ultracentrifugation, as described27. HT-1080 dual-color cells were infected with p-puro or 
p-neo viruses (vector controls), or with ITGB1 (on p-puro) or ITGB3 targeting (on p-neo) pLBM 
viruses. For generation of double knockdown cells, HT-1080 p-puro or HT-1080 β1RNAi cells 
were additionally infected with ITGB3 targeting or p-neo viruses, respectively. For maintaining 
stable HT-1080 knockdown cells medium was supplemented with puromycin (Sigma Aldrich, 5 
μg/mL) for single transfectants (single vector control, β1RNAi) or puromycin and G418 sulfate 
(400 mg/mL) for dual-transfectants (dual vector control, β1/β3RNAi). Stability of knockdown 
without antibiotics selection was confirmed after 4-week culture in antibiotic-free medium and 
prior to implantation into mice.
Skin window model, intravital microscopy and image analysis
Dorsal skin imaging windows were transplanted onto 10- to 14-week-old male athymic 
Balb/c nude mice (CANN.CG-FOXN1NU/CRL, Charles River), as described28. One day post-
surgery tumor cells (~5x105 cells in 4 µl PBS) were implanted into the dermis by image-
guided microinjection. Tumor progression and therapy response were typically monitored for 
up to 14 days using a titanium window. In selected experiments, monitoring for 26 days was 
achieved using a polyethylene window. Tumors used for histological analysis of the DNA 
damage response were harvested 4 or 5 days after implantation, representing the time 
point of radiation therapy initiation. Dual-vector control xenografts showed no significant 
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differences in growth and invasion parameters compared with wild-type tumors and thus were 
used interchangeably as controls. For intravital microscopy, live mice were anesthetized with 
isofluorane and stably mounted onto a temperature-controlled platform (37°C). Progression 
of dual-color tumors was monitored using longitudinal multiphoton microscopy (LaVision 
BioTech)29,30. By taking overview images of the entire tumor and surrounding vascular 
network prior to subcellular multiphoton microscopy, regions of interest for detailed image 
acquisition could be repetitively annotated and traced over multiple days and measurements. 
The emission ranges were 400/40 (blue), 535/50 (green), 605/70 (red), and 710/75 (far-red). 
Epifluorescence overviews of xenografts were obtained with a 4x objective (NA 0.3) and 
subcellular-resolved multiphoton microscopy with a 20x objective (NA 0.95, both Olympus). 
Sequential 3D stacks were obtained for up to 300 μm penetration depth at 5 μm step interval. 
Perfused blood vessels were visualized by i.v. injection of AlexaFluor-660-conjugated dextran 
(70 kD, Invitrogen, 1 mg/mouse). 
Images obtained during intravital microscopy were 3D reconstructed, stitched and analyzed 
using ImageJ 1.40g (W. Rasband, NIH), ImSpector 3.4 (LaVision BioTec GmbH), Photoshop 
CS 8.0.1 (Adobe Systems Inc.), and Volocity 4.0.1 (Improvision). Unless indicated otherwise, 
multiphoton micrographs represent z-projections of 120 to 250 μm imaging depth. Migration 
velocities were obtained by computer-assisted cell tracking of invasion strand tips (Autocell 
software, Universities of Bremen and Würzburg). Tumor volume from epifluorescence overview 
images was calculated as (tumor width)2 x (tumor length) x π / 6 / 2. Mitotic and apoptotic 
fractions were determined from the morphology of tumor cell nuclei identified by H2B-EGFP 
from 5-30 multiple visual fields (dependent on analyzable cell amounts) representing ~100 
cells each from 3 to 5 independent tumors. The orientation of mitotic planes was expressed 
as angle relative to the length axis of the invasion strand, measured in invading cells and the 
adjacent core of the lesion. The extent of residual invasion after treatments was measured 
as the area covered by invading cells at day 13 normalized to day 6 of the same lesion using 
stitched high-resolution overviews from 3D projections obtained by multiphoton microscopy 
(Supplementary Fig.2G). 
Long-term monitoring of intradermal tumors
Intradermal xenograft lesions without imaging window were injected along the dorsal mid-line 
(~1x104 cells in 20µl PBS, 30G needle, two tumors per mouse) sparing rostral and caudal 
zones. Correct intradermal positioning of growing tumors was verified by high frequency 
ultrasound (DermaScan, Cortex Technology). Tumor development and therapy response 
were monitored by whole-body fluorescence imaging (FluorVivo100, INDEC BioSystems) 
and caliper measurements of macroscopic nodules. Treatment of tumors was initiated at 
day 6 (HT-1080) or day 13 (MV3) (Supplementary Fig. 8A), to secure a macroscopically 
visible tumor stage and equal size distribution between different groups. Inclusion criteria for 
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treatment were at least one macroscopic, fluorescence-positive and exponentially growing 
tumor lesion per mouse not exceeding a volume of 35 mm3 (HT-1080) or 40 mm3 (MV3). Prior 
to and during therapy, tumor development was monitored every second day. After therapy 
was completed monitoring frequency was adjusted to the progression rate ranging from 3x 
/ week (growing tumor) to 2x / month (complete regression) for up to 180 days. Humane 
end-point criteria were a tumor size of 2 cm3, ulceration, weight loss or poor overall condition 
due to internal metastasis. Each sacrificed animal was screened for the presence of tumor 
remnants in the dorsal dermis, lymph nodes (superficial cervical, brachial, inguinal), lung, 
liver and brain using fluorescence stereomicroscopy (Leica MZFLIII, EL6000external light 
source, GFP Plus and DsRed filter sets). Tumor material and organs were embedded in 
O.C.T. compound (Sakura), deeply frozen using dry-ice or through swaying in liquid nitrogen, 
stored at -80°C and analyzed for the presence or absence of tumor cells or invasion status 
from 10 to 50 µm thick cryosections (M500 or HM500OM Cryostat Microtome, Microm) by 
epifluorescence microscopy (Leica DMRA fluorescence microscope, Leica DFC340 FX 
CCD camera, Cytofluor software; 2.5x to 40x objectives). A fixed monolayer of HT-1080 or 
MV3 dual-color cells from in vitro culture served as positive control to discriminate specific 
fluorescence from autofluorescence. 
Antibody treatment
Adhesion-perturbing mouse anti-human β1 (clone 4B4, IgG1, Beckman Coulter, 6603113) 
and αV integrin (clone 17E6, IgG1, Merck Serono, kindly provided by Simon Goodman, 
Department of Cellular Pharmacology - Oncology Platform, Merck KGaA, Darmstadt, 
Germany) monoclonal antibody (mAb) or mouse IgG1κ isotype (clone MOPC-21, Sigma 
Aldrich, M7894) were injected i.p. at 5 mg/kg or 10 mg/kg body weight, respectively, to reach 
a calculated antibody concentration of ~8 μg/mL in body fluids (60% of body weight) 31 which 
ranges >2x above the minimum concentration required for 99% integrin epitope saturation in 
vitro (Supplementary Fig. 5D and data not shown). Based on an IgG1 half-life of 6-8 days32 
a calculated antibody concentration of >3 μg/mL in a body fluids is achieved for at least 6 
days by a single injection, sufficient to achieve >99% epitope saturation on HT1080 cells 
(Supplementary Fig.5D). To additionally secure sufficient availability during the therapy phase 
antibody was administered every 2-3 days starting with a boost (2 injections at 2 subsequent 
days). For application in vivo, NaN3-containing antibody stocks (mAb 4B4, IgG1) were 
dialyzed against 0.9% NaCl. In mice carrying the imaging window antibody was administered 
at days 3, 4, 7 and 10 as therapeutic intervention in established tumors after the onset of 
invasion (Supplementary Fig. 7A). Mice carrying established tumors without imaging window 
received antibody on days 6 (before irradiation), 7, 9, 11 and 13 (HT-1080) or days 13 (before 
irradiation), 14, 16, 18 and 20 (MV3) after tumor implantation (Supplementary Fig. 8A). 
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Irradiation procedures
Tumors in mice carrying the imaging window were irradiated either locally with a focused beam 
of 2 cm in diameter using a RT 50 (X-ray) source (Philips Medical Systems) at a dose-rate 
of 4.9 Gy/min or with a wide-field beam using an X-ray tube (X-RAD 320ix, Precision X-Ray) 
with 0.75 mm tin, 0.25 mm copper and 1.5 mm aluminum filter for beam conditioning, 30 cm 
source-skin distance (SSD), 320 KV output voltage with 12.5 mA for a dose rate of 3.6 Gy/min. 
To shield the mouse body but expose the tumor and peritumor tissue to the wide-field radiation 
beam, the mouse was placed inside a 6 mm lead-coated tube, while the tumor in the skin-fold 
window was exposed through a slit. To irradiate tumors in imaging window-free mice using 
the non-focused beam, the mouse was positioned inside the shielding tube and the skin-fold 
containing the tumor was gently extended through the slit, fixed by surgical tape and exposed 
to the radiation field. By varying the duration of exposure, radiation doses ranging from 2 to 
10 Gy per session were applied. For tumors growing in the imaging window, a fractionation 
scheme with cumulative doses of 40 Gy for HT-1080 tumors (daily fractionation from day 4 
to 8) or 50 Gy for MV3 tumors (day 4, 5, 7, 8, 11) was used, to reach detectable response 
curves within a 2-week period for intravital microscopy. Tumors used for the analysis of DNA 
damage markers received a single dose of either 8 Gy (HT-1080) or 10 Gy (MV3) at day 
4. Intradermal tumors in imaging window-free mice used for long-term follow-up obtained a 
fractionated scheme with adjusted individual doses of 2 Gy from day 6 to 10 (HT-1080) or 3 Gy 
at day 13, 14, 16, 17 and 20 (MV3) after tumor implantation, amounting to cumulative 10 Gy 
(HT-1080) or 15 Gy (MV3) (Supplementary Fig. 8A). This mid-dose scheme was established 
by dose-escalation and long-term monitoring to yield relapse frequencies between 60 and 
80% for detecting the long-term effects of radiosensitization by integrin-targeted combination 
therapy (data not shown).
Immunohistological stainings
For the visualization of cell-cell junctions via ALCAM staining, untreated tumor-bearing mice 
carrying the skin window were sacrificed on day 5 (HT-1080) or day 8 (MV3) after tumor 
implantation. Tumor-containing dorsal skin samples were cryopreserved as described above, 
with marked orientation of invasion strands and invasion status documented by intravital 
epifluorescence microscopy. Frozen tissue samples were cut into 50 µm thick cryosections 
(HM500OM Cryostat Microtome, Microm) which were immediately fixed in neutral buffered 
formalin (4%, formulation according to Lillie), incubated for ~18 h at room temperature (RT) 
and stored in phosphate buffer (0.1M, pH 7.4, 4°C). For staining, free aldehyde groups and 
unspecific epitopes were blocked using 0.15% glycine in Tris-buffered saline (TBS, 30 min, 
RT), followed by incubation with TBS supplemented with 1% bovine serum albumin (BSA, 
Sigma Aldrich) and 15% normal goat serum (NGS, GIBCO Life Technologies, 30-60min, RT). 
After washing (TBS), endogenous mouse IgG in the tissue was blocked with unlabeled anti-
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mouse IgG Fab' fragments (Jackson ImmunoResearch, 15-007-003, ~18 h, 4°C) followed 
by washing (TBS). Mouse anti-ALCAM mAb (AZN-L50; IgG2A; kindly provided by Joost te 
Riet, Department of Tumor Immunology, Radboudumc Nijmegen, The Netherlands)33 was 
biotinylated using biotin-SP (long-spacer) conjugated anti-mouse IgG Fab fragment (Jackson 
ImmunoResearch, 115-067-003, 1:2, 20 min, RT), followed by incubation in mouse serum 
(Biowest, 10 µl/1 µg Fab' biotin, 10 min, RT). Anti-ALCAM/biotin-Fab' complexes were diluted 
(1:15) in TBS/BSA (1%) and added to the tissue slices for incubation (~18 h, 4°C). After 
washing (TBS) tissue slices were overlaid with streptavidin-coupled Alexa 647 (Jackson 
ImmunoResearch, 016-600-084, 2 µg/mL) and DAPI (Roche, 1 µg/mL), in TBS/BSA (1%, 20 
min, RT), washed (TBS) and mounted in Fluoromount G (Southern Biotech) on object slides 
for confocal microscopy. 
For analysis of DNA damage response (DDR) markers, non-irradiated or irradiated tumors 
(day 4 or 5) grown in the imaging window were obtained before or 30-60 min and 23-24 h 
after irradiation. Tumor-containing skin samples were cryopreserved with marked invasion 
status as described above. Frozen tissue samples were cut into 10 µm cryosections (HM500 
Cryostat Microtome, Microm), mounted on superfrost plus object slides and screened to 
determine tumor sub-region as core or invasion zone. After drying for ~18 h tissue slices 
were stored (-80°C) and prior to staining fixed (2% parafomaldehyde diluted in PHEM buffer, 
15 min, RT), rinsed with phosphate-buffered saline (PBS) and incubated in PBS containing 
0.1% Triton X-100 (Sigma Aldrich) for permeabilization (20 min, RT). To minimize background, 
samples were incubated in PBS supplemented with 5% NGS and 0.1% cold water fish skin 
gelatin (CWFG, Sigma Aldrich; 30 min, RT), followed by staining with the following primary 
antibodies: rabbit anti-γH2AX (pSer139, Novus Biologicals, NB-100-384, 1:10,000), rabbit 
anti-phosphoChk2 (pThr68, Abcam, ab85743, 1:1,000) or rabbit anti-phospho(Ser/Thr)-ATM/
ATR-substrates (4F7, Cell Signaling, 2909, 1:1,000), all diluted in PBS supplemented with 
2% NGS and 0.1% CWFG. Tissue slices were incubated with primary antibody solution (1 h, 
RT followed by ~18 h, 4°C), washed (PBS), incubated with goat anti-rabbit IgG (H+L) Alexa 
Fluor 647 (Invitrogen, A-21245, 4 µg/mL) and DAPI (1 µg/mL), both diluted in PBS/NGS (2%)/
CWFG (0.1%), washed and mounted in Fluoromount G. For reliable intratumor comparison of 
sub-regions all slices per tumor sample and staining were processed and recorded in parallel. 
Hypoxia and phospho-p44/42-MAPK signals were detected in tumors 7 days post-implantation 
from window-bearing mice. As hypoxia probe, pimonidazole (Hypoxyprobe-1 Kit, Hypoxyprobe 
Inc.) was applied i.p. (60 mg/kg body weight) and tissue was harvested 60 min thereafter. 
Tumor-containing samples were cryopreserved with marked invasion status and processed 
as 10 µm thick cryosections. Fixation, staining and mounting were performed as described for 
immunohistological analysis of DDR markers using primary rat anti-CD31 (clone MEC13.3, 
BD Biosciences, blood vessel staining), mouse anti-pimonidazole adducts (Hypoxyprobe-1 
Kit, staining hypoxic cells) and rabbit anti-phospho-p44/42-MAPK antibody (Thr202/Tyr204, 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Collective Cancer Invasion – An Integrin-dependent Radioresistant Niche  |  127
5
Cell Signaling, 9101, 1:50, phospho-Erk1/2 signal) and secondary goat anti-rat, anti-rabbit or 
anti-mouse IgG (H+L) Alexa Fluor 488 or 647 (Invitrogen) antibodies. 
Image acquisition and analysis
Tissue samples stained for ALCAM and DDR markers were analyzed by confocal microscopy 
(Olympus FV1000) as 3D stacks. ALCAM stainings were recorded using either a 20x / 0.50 
NA water or 60x / 1.35 NA oil immersion objective with 3 or 1 µm step size respectively. 
Stainings of DDR markers were scanned with a 40x / 0.80 NA water immersion objective and 
3 µm step size to represent the whole 10 µm tissue slice using identical instrument settings for 
each tumor sample and staining. Hypoxia and phosphoErk staining were scanned as z-stacks 
(2 μm step depth) on a LSM 510 META confocal microscope (Zeiss). 
Using Fiji/Image J software (v1.48)34, DDR staining in tumor sub-regions was analyzed from 
average intensity projections of ~10µm 3D stacks, followed by image segmentation using the 
H2B-EGFP signal to identify and mark the edges of tumor nuclei (Supplementary Fig. 3C). 
Compared to maximum intensity projections, the mean intensity projection resulted in cleaner 
image segmentation with less regions of interest (ROIs) ≤ 1 µm2 incurred from irrelevant 
particles and background noise signal (data not shown). The mean gray value representing an 
individual DDR signal was quantified for large nuclear segments (≥38 µm2) representing intact, 
non-apoptotic nuclei, and the values were corrected for the background signal measured in 
non-nuclear regions (Supplementary Fig. 3C,D). Because image acquisition was optimized to 
identify intratumor heterogeneity, direct comparison of data points from different time-points 
was obsolete.
Statistics
For comparative analysis of DDR markers in tumor sub-regions, data were log-transformed 
and a longitudinal analysis in the form of a mixed model ANOVA was performed using the lmer 
function of the R package lme435. Per DDR marker and time point (before/after IR) differences 
between the variables “tumor sample” and “sub-region” (i.e. core versus invasion zone) 
were analyzed. Due to the high number of data points and high inter-tumor variability, each 
comparison between tumor sub-regions resulted in statistically significant differences, even 
when independent replicates of the same condition were compared based on quantitatively 
minor sample-to-sample variation with typically inconsistent trends (Supplementary Fig. 3G, 
left panel). To separate biologically relevant effects from background variability, comparisons 
showing inconsistent data trends were considered non-significant, whereas analyses with 
consistent trends (i.e. similar slope and direction of mean of log values between tumor sub-
regions) (Supplementary Fig. 3G, right panel) were considered biologically significant with 
p-values displayed.
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Survival of tumor-bearing mice during long-term follow-up was analyzed using the Mantel-
Cox Log-rank test. For all other statistical analyses the two-tailed Mann-Whitney U-Test 
for independent and Student’s T-test for paired samples were used. To adjust for multiple 
comparisons, Bonferroni correction was performed. Unless mentioned otherwise, GraphPad 
Prism 5 or 6 software was used.
Study approval
All animal procedures were approved by the German regional government (Regierung von 
Unterfranken) (TVA_AZ 54-2531.01-47_06), the Ethical Committee on Animal Experiments 
of the Radboud University, Nijmegen (The Netherlands) (RU-DEC 2011-124, 2011-230, 
2013-008, 2013-125), both in accordance with the respective German and Dutch Animal 
Experimentation Acts and the European FELASA protocol, and by the Institutional Animal 
Care and Use Committee (IACUC) of The University of Texas, M.D. Anderson Cancer Center 
(Texas, USA) (ACUF 07-11-07631, -07632), performed according to the institutional guidelines 
for animal care and handling. 
Results
To identify tumor sub-regions of therapy resistance as well as whether invasion and survival 
programs coincide, we monitored fluorescent orthotopic HT-1080 sarcoma and MV3 melanoma 
xenografts in the mouse dermis using longitudinal intravital microscopy28. Originating from 
the growing tumor, both sarcoma and melanoma lesions developed deep dermis invasion 
(mean velocity 100 µm/day) (Supplementary Fig. 1A-C), with >98% of the cells moving 
collectively, either as continuous strands connected to the tumor core or detached clusters 
(Fig. 1A-C). Intact junctions and collective polarity were verified from (i) linear enrichment 
of the homophilic adhesion receptor ALCAM (CD166) between invading HT-1080 and MV3 
cells (Fig. 1D), (ii) collective front-rear polarity with mitotic planes aligned perpendicular to 
the invasion direction (Supplementary Fig. 1D) and (iii) multicellular orientation along tissue 
landmarks, including collagen bundles, myofibers (Fig. 1D) and perfused blood vessels (Fig. 
1B)36. These collective patterns obtained in the mouse model recapitulated the typical strands 
and nest-like organization of invasion zones in clinical sarcoma and melanoma specimens 
(Supplementary Fig. 1E,F)37,38. 
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5Figure 1. Collective invasion as primary invasion pattern in sarcoma and melanoma xenografts. 
A) Schematic view defining tumor core and collective invasion zone (CI) of tumors growing in the deep 
dermis of the mouse monitored intravitally through an imaging window. B) Collective invasion strands of 
human HT-1080 sarcoma (left; day 7) and MV3 melanoma xenografts (right; day 8). Tumor cells stably 
express nuclear H2B-EGFP and cytoplasmic DsRed2. Alexa Fluor 660-conjugated Dextran contrasts 
perfused blood vessels. Second harmonic generation (SHG) visualizes muscle and collagen fibers. 
Arrowheads, alignment of invasion strands with perfused blood vessels. Scale bar, 100 µm. C) Prevalence 
of invasion types, including individual cells, detached clusters or collective strands connected to the core 
(day 5-7). Data represent the means and standard deviation from 5 (HT-1080) and 3 tumors (MV3). D) 
Distribution of ALCAM along cell-cell junctions (arrowheads) in invading tumor strands. Maximum intensity 
projections (overview) and individual sections (insets) from confocal 3D stacks. Diffuse background 
fluorescence originates from fat (F) and myofibers (M). Scale bars, 100 µm (overview) and 10 µm (insets). 
Rather than approaching the therapy response of the tumor as a homogeneous entity14,16, 
we next addressed whether tumor sub-regions, including the collective invasion niche, retain 
differential sensitivity to genotoxic therapy. In disseminated clinical sarcoma and melanoma 
DNA damaging radiotherapy is highly effective, with patient subsets nonetheless developing 
detrimental resistance39,40. To reach homogeneous and sustained exposure across all tumor 
regions, isometric whole-field irradiation (IR) and fractionation were applied in invading 
tumors after the angiogenic switch (Supplementary Fig. 2A-C). Irradiation thus avoids varying 
compound delivery to tumor sub-regions caused by heterogeneous vascular perfusion 
or pressure distribution which may confound systemic chemotherapy41. Fractionated IR 
induced mitotic arrest within hours in both the tumor core and the invasion zone followed by 
apoptosis induction (Fig. 2A,B, Supplementary Fig. 2D,E) and substantial tumor regression 
a few days later (Fig. 2C,D, Supplementary Fig. 2F). Despite an overall reliable response, 
apoptosis induction identified by three-dimensional intravital reconstruction and single-cell 
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cytometry identified significant variance of the radiation response between tumor sub-regions. 
Collectively invading cells showed a mild, approximately 2-fold apoptotic increment, whereas 
apoptosis in the tumor core was elevated 4-fold and higher (Fig. 2A-C, Supplementary Fig. 
2E). Consistently, over time the collective invasion niche largely survived whereas the core 
regressed (Fig. 2E). Thus, collective invasion conveys relative radioresistance in an otherwise 
radiosensitive tumor.
Irradiation induces DNA double-strand breaks (DSBs) followed by a DNA damage response 
(DDR) with DNA repair or apoptosis induction as outcomes42,43. To address whether the tumor 
core and the invading niche differ in their DDR, we performed quantitative sub-region analysis 
of central DDR effectors in untreated and irradiated lesions (Fig. 3A, B, Supplementary Fig. 
3A- E). Both HT-1080 and MV3 cells express wildtype p5344,45 and thus are competent to 
undergo cell cycle arrest and DNA repair after DNA damage42. 30-60 min post-IR, the general 
DSB marker γH2AX46 was induced with equal (HT-1080) or mildly increased levels (MV3) in 
the invasion zone relative to the core (Fig. 3C,D, Supplementary Fig. 3F), indicating uniform 
initiation of the DDR in all tumor sub-regions. The low γH2AX baseline in invading cells rules 
out preset DSB elevation induced by mechanical damage of the nucleus during invasion47 
or other microenvironmental assault. Chk2 activation which controls DDR outcome43, was 
similar in all tumor regions 30-60 min after IR but declined in the collective invasion zone 
one day later, while phosphoChk2 levels remained elevated in the tumor core (Fig. 3C,D, 
Supplementary Fig. 3F,G). Consistently after IR the phosphorylation of phosphoATM/ATR 
substrates, which also include Chk243, remained significantly increased in the tumor core but 
decreased in the invasion zone of HT-1080 lesions (Fig. 3D), verifying completion of the DDR 
at multiple levels. By inducing cell cycle arrest Chk2 kinase enables DSB repair or mediates 
apoptosis when damage is irreparable43. Thus, timely phosphoChk2 normalization followed 
by cell survival indicates efficient repair in the collective invasion niche. Conversely, persisting 
Chk2 activation and ongoing apoptosis beyond day 13 in the tumor core reveal sustained but 
eventually ill-fated attempts of DNA repair.
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Figure 2. Collective invasion niche mediates radioresistance. 
A) Differential response to radiation therapy in invasion strands and tumor core. Multiphoton microscopy 
images show the borders between core and collective invasion zone (day 13). Asterisk, regressing tumor 
core. Insets upper panel, infiltrating dextran-positive macrophages. Circles and insets lower panel, 
apoptotic nuclear fragmentation used for quantification. Scale bars, 100 µm. B) Frequency of apoptotic 
nuclei in HT-1080 tumor cores and collective invasion strands. Data represent the medians, 25th/75th 
(box) and 5th/95th percentiles (whiskers) from 5 to 20 fields/tumor from 3-4 independent mice. Statistics, 
Mann-Whitney test. C) Epi-fluorescence overviews of whole-tumor topology in untreated and irradiated 
HT-1080 (5 x 8 Gy) and MV3 (5 x 10 Gy) lesions (day 13). Scale bar, 1 mm. D) HT-1080 tumor growth 
before, during (dashed lines; 5 x 8 Gy) and after irradiation, compared to untreated tumors in independent 
mice (Ext Ctrl) or non-irradiated contralateral tumors in the same mouse (Int Ctrl). Means ± standard 
deviation (3 to 9 independent tumors). P value, significant difference between irradiated and control 
tumors at the end-point (day 13). Statistics, Mann-Whitney test. E) Extent of tumor regression in core 
and invasion zone of irradiated tumors. Data show median residual areas, 25th/75th (box) and 5th/95th 
percentiles (whiskers) of day 13 normalized to day 6 from 4 independent tumors. Statistics, paired t-test. 
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Figure 3. Differential DNA damage response in tumor core and collective invasion niche. 
A) Strategy for differential immunohistological analysis of DNA damage response in tumor core and 
collective invasion (CI) zone. Upper panel, serial sectioning of the entire tumor; lower panels, resulting 
cross-sectioned patterns. B) γH2AX and pChk2 signal in tumor core and collective invasion zone detected 
at early (≤1h) and late (24h) time-point after a single-dose irradiation. Maximum intensity projections from 
confocal 3D stacks. Dashed rectangles indicate representative tumor nuclei for single-channel display of 
γH2AX or pChk2 signal. H2B, H2B-EGFP (tumor nuclei). Scale bars, 50 µm (overview), 25 µm (inset). 
Examples for non-irradiated samples are shown in Supplemental Figure 3e. C) Intensity distribution of 
DDR signals in HT-1080 tumors after a single-dose irradiation. Data show the mean gray value after 
background correction (lines) and signal range (filled areas, lowest to highest values) from 3 independent 
tumors. Dark grey shaded area, difference between core and collective invasion zone. D) Quantification of 
γH2AX, pATM/ATR substrates and pChk2 signal intensity after single-dose irradiation. Data represent the 
median gray value per nucleus after background correction, with 25th/75th (box) and 5th/95th percentiles 
(whiskers) from 3 independent tumors. ~150-600 nuclei per invasion zone and tumor and ~1,000-6,000 
representative nuclei per core and tumor were analyzed. Dashed lines visualize approximate dynamics of 
DNA damage response. Statistics, mixed model ANOVA (see methods section for details). 
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When probed for vascular integrity by intravascular dextran retention (Fig. 1B,E) or for 
tissue oxygenation using pimonidazole staining (Supplementary Fig. 1G), we found that 
invading sarcoma and melanoma cells engaged with morphologically intact, well-perfused 
and metabolically unperturbed dermal stroma. These results exclude hypoxia-mediated 
resistance5. We therefore tested whether integrins, which are expressed and preferentially 
engaged during collective invasion12 and have been implicated in mediating radiation 
resistance14–16, orchestrate cell survival during invasion in vivo. HT-1080 and MV3 cells 
expressed high levels of β1 and moderate levels of β3 integrin, but lacked other β integrin 
sub-types (Supplementary Fig. 4) and thus provide a system for probing the relative function 
of multiple integrins. To test the role of both integrin systems in enhancing survival during 
collective invasion, β1 integrin alone or, to account for potential compensation, both β1 and 
β3 integrins were stably downregulated in HT-1080 cells by RNAi (Supplementary Fig. 5A-
C). To maximize interference strength but minimize cell reprogramming towards anchorage 
independence48, mice carrying shRNA expressing tumors additionally received anti-β1 integrin 
antibody 4B4, and this regimen repressed the β1 adhesion epitope by 99.5% (Supplementary 
Fig. 5D,E). In non-irradiated HT-1080 tumors, single- and dual-integrin interference were both 
sufficient to compromise tumor growth by arresting mitosis and enhancing apoptosis in the 
tumor core (Fig. 4A-C). Mitogen-activated protein kinase (MAPK) signaling which supports 
cell growth and survival downstream of integrins20, was diminished after integrin targeting 
to levels slightly below the stromal background (Supplementary Fig. 5F). Notably after dual-
integrin targeting, similar to the radiation response, the tumor core regressed, whereas the 
collective invasion zone retained ongoing low-level mitotic activity and persisted (Fig. 4A,D,E). 
This indicates that the collective invasion niche withstands anoikis induction after integrin 
deprivation, reminiscent of an overarching anchorage-independent survival advantage13,49.
However, when combined with radiotherapy, β1 integrin targeting induced significant 
disruption and shrinkage of collective invasion strands (Supplementary Fig. 6A,C). This effect 
was further enhanced by dual-targeting of β1 and β3 integrins, reaching effective regression 
of both the tumor core and collective invasion niche (Supplementary Fig. 6). As dual β1/β3 
integrin targeting was superior to β1 integrin mono-targeting in radiosensitization of HT-1080 
tumors, these results suggested that β1 and β3 integrins cooperate to enhance cancer cell 
survival after IR in collectively invading cells. 
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Figure 4. Compromised tumor integrity and persistence of the invasion niche by RNAi- and 
antibody-based targeting of β1/β3 integrins in HT-1080 tumors. 
A) Time course of tumor growth or regression in control tumors transduced with empty vectors (p-puro/p-
neo), β1RNAi or β1/β3RNAi in the absence or presence of IgG1 or anti-β1 integrin mAb 4B4. White 
arrowheads, onset of collective invasion. Numbers (right column), percent mean regression of the 
tumor core (day 13 compared to day 6) from 3 to 4 independent tumors. Scale bars, 1 mm. B) Mitotic 
and apoptotic fractions from the tumor core for different interference schemes displayed as medians, 
25th/75th (box) and 5th/95th percentiles (whiskers) from 20 independent fields from 3 to 4 independent 
tumors. Statistics, Mann-Whitney test. C) Tumor development in response to the indicated interference 
procedures. Data show the means ± standard deviation from 3 to 4 independent tumors, with p-values for 
comparing treated tumors with vector controls (Bonferroni-corrected threshold was p=0.0125). Statistics, 
Mann-Whitney test. D) Preferential survival of invading collective strands after combined β1/β3 integrin 
targeting. Z-projections of the same tumor region. Insets, mitotic figures in collective strands. Scale bar, 
250 µm. E) Median residual volume of tumor core and collective invasion (CI) zones after β1/β3RNAi 
combined with mAb 4B4 (day 13 compared to day 6) from 3 independent tumors. Statistics, paired t-test. 
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To validate these findings using a translational approach for both HT-1080 and MV3 lesions, 
dual-integrin targeting was performed by antibody-based systemic therapy prior to and 
during radiotherapy (Supplementary Fig. 7A). To target β3 integrins, but spare αIIbβ3 integrin 
expressed by platelets50, we used anti-αV integrin antibody 17E6 which interferes with αVβ3 
integrin51. When combined with fractionated IR, antibody-based β1/αV integrin targeting 
induced severe apoptosis followed by regression of the entire lesion in both tumor types (Fig. 
5A,B, Supplementary Fig. 7B,C,E,F). By day 7 post-IR, HT-1080 tumor remnants consisted of 
few individualized non-dividing and slowly regressing cells in perivascular position, of which 
few cells persisted until day 28, when intravital monitoring had to be terminated for reasons 
of animal welfare (Fig. 5A,C, Supplementary Fig. 7B,D,H). Likewise, both tumor core and 
invasion strands of MV3 lesions effectively regressed with mitotically inactive scattered cells as 
remnants (Fig. 5A,C, Supplementary Fig. 7E,G). This notable difference in regression kinetics 
between both tumor models replicates the higher radiation sensitivity of clinical sarcoma 
compared to melanoma39,40. These data indicate that combining antibody-based β1 and αVβ3 
integrin targeting overcomes invasion-associated radiation resistance and effectively shrinks 
the invasion niche.
To verify the curative impact of single- vs. dual-integrin targeting combined with IR, fluorescent 
HT-1080 and MV3 tumors were directly implanted into the dermis of mice, without an imaging 
window using ultrasound-controlled implantation, and followed up for 180 days (Fig. 6A, 
Supplementary Fig. 8A,B). Mice bearing emerging macroscopic tumors were treated with 
antibodies 4B4 and 17E6, individually or combined, and irradiated using an adjusted dosing 
scheme to model relapsing disease (Supplementary Fig. 8A). To account for minimal residual 
and disseminated disease, the tumor implantation site and distant organs were dissected 
at the end-point and scored for the presence of tumor cells (Supplementary Fig. 8C,D,E). 
Tumors in window-free mice developed collective invasion as a primary pattern (Fig. 6B), 
ruling out artifacts caused by the imaging window. Dual-integrin targeting drastically improved 
the efficacy of the radiation response and resulted in relapse-free follow-up in 80% (HT-1080) 
and >90% (MV3) of the mice with elimination of the lesions locally and at metastatic sites, 
whereas individual targeting of either β1 or αV integrins was less efficient (Fig. 6C,D and Table 
1,2). This outcome indicates that dual-integrin targeting is required to maximize the radiation 
sensitivity of experimental sarcoma and melanoma lesions.
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Figure 5. Dual-integrin targeting abrogates radioresistance in the collective invasion niche. 
A) Radiation response of tumor core and collective invasion zone after combined treatment with mAbs 
4B4 and 17E6 compared to IgG1-treated control (day 13). Asterisks, areas of regression. Arrows, 
persisting invasion strands. Alexa Fluor 660-conjugated Dextran, perfused blood vessels. Second 
harmonic generation (SHG) originates from muscle and collagen fibers. Scale bar, 250 µm. B) Frequency 
of apoptotic figures in core and collective invasion (CI) zone after antibody-based integrin targeting and/
or irradiation (day 6). Data show the medians, 25th/75th (box) and 5th/95th percentiles (whiskers) from 4 
to 5 tumors reflecting a total of 9 to 28 different microscopic fields. *, significant p-value after Bonferroni 
correction for multiple comparisons (Bonferroni-corrected threshold was p=0.0125). Statistics, Mann-
Whitney test. C) Extent of tumor regression in core and collective invasion zone of irradiated tumors 
combined with or without integrin targeting. Data show median residual areas, 25th/75th (box) and 
5th/95th percentiles (whiskers) of day 13 normalized to day 6 from 4 independent tumors. Statistics, 
Mann-Whitney test. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Collective Cancer Invasion – An Integrin-dependent Radioresistant Niche  |  137
5Figure 6. Dual-targeted but not individual anti-integrin therapy to enhance radiation response, 
tumor eradication and long-term survival. 
A) Tumor lesion (T) after implantation in imaging window-free mouse. Intradermal localization was 
confirmed by high-frequency ultrasound. B) Collective invasion (CI) pattern in intradermal tumors in 
imaging window-free dermis (maximum intensity projections). Number of multicellular strands per tumor 
was counted from 50 µm thick tumor sections from 9 (HT-1080) and 7 (MV3) tumors. Scale bar, 100 µm. 
C) Tumor-free long-term survival of mice after application of treatment, including fractionated irradiation 
without and with individual and dual-targeted integrin inhibition with antibodies 4B4 and/or 17E6. Mice 
were sacrificed after 180 days or earlier, upon humane endpoint criteria. See Table 1 for details on mouse 
numbers (8-12 mice per group), metastasis formation and tumor remnants. Grey-shaded area, therapy 
phase. *, significant p-value after Bonferroni correction for multiple comparisons (Bonferroni-corrected 
thresholds were p=0.01 (HT-1080) and p=0.008 (MV3)). Statistics, Log-rank survival analysis. 
Table 1. Survival rates and tumor outcome for long-term follow up experiments on integrin-
targeted and IR (combination) therapy in HT-1080 sarcoma xenografts.
Treatment NegativeA Growing 
primary lesionB 
Macroscopic 
tumor relapseC 
Minimal 
residual lesionD 
Metastatic 
diseaseE 
IgG1 0 / 9 0% 9 / 9 0 / 9 0 / 9 0 / 9
4B4 & 17E6 0 / 9 0% 9 / 9 0 / 9 0 / 9 3 / 9
IR + IgG1 3 / 10 30% 6 / 10 1 / 10 0 / 10 7 / 10
IR + 17E6 2 / 9 22% 5 / 9 1 / 9 1 / 9 6 / 9
IR + 4B4 8 / 11 72% 1 / 11 2 / 11 0 / 11 3 / 11
IR + 4B4 & 7E6 8 / 10 80% 0 / 10 1 / 10 0 / 10 1 / 10F
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Table 2. Survival rates and tumor outcome for long-term follow up experiments on integrin-
targeted and IR (combination) therapy in MV3 melanoma xenografts.
Treatment NegativeA Growing 
primary lesionB 
Macroscopic 
tumor relapseC 
Minimal 
residual lesionD 
Metastatic 
diseaseE 
IgG1 0 / 9 0% 9 / 9 0 / 9 0 / 9 0 /9
4B4 & 17E6 0 / 9 0% 9 / 9 0 / 9 0 / 9 0 / 9
IR + IgG1 1 / 12 8% 8 / 12 1 / 12 2 / 12 8 / 12
IR + 17E6 6 / 10 60% 3 / 10 0 / 10 1 / 10 2 / 10
IR + 4B4 3 / 8 38% 1 / 8 1 / 8 2 / 8 3 / 8F
IR + 4B4 & 7E6 10 / 11 91% 0 / 11 0 / 11 1 / 11 0 / 11
ALack of growing primary lesion, relapse, minimal residual lesion or metastasis. 
BPersisting and increasing fluorescence signal at the tumor implantation site reaching endpoint tumor 
burden. 
CRecurring and increasing fluorescence signal at the implantation site after a period of absence of signal 
(transient regression).
DAbsence of detectable tumor or fluorescence signal until the end point, but presence of H2B-EGFP 
positive cells in the dermis. 
EPresence of fluorescent lesions detected by microscopic screening of lungs and lymph nodes.
F 1mouse with complete regression of primary lesion but distant metastasis.
Discussion
Using single-cell and time-resolved preclinical intravital microscopy we here show that, 
beyond other emergent properties of multicellular behaviors including collective chemotactic 
and stiffness sensing52,53 and boosted metastatic seeding10,11, collective invasion empowers 
sarcoma and melanoma cells to better withstand DNA damaging radiotherapy. In contrast 
to metabolically perturbed, hypoxic resistance niches5, the invasion niche is normoxic and 
co-engages β1 and αVβ3 integrins interacting with the ligand-rich microenvironment of the 
deep dermis containing collagens, laminins and fibronectins36,54. Integrin-mediated growth 
and survival signaling comprises a complex network originating from integrin-dependent 
activation of focal adhesion kinase (FAK), Src and other components of the integrin adhesome 
(e.g. integrin-linked kinase (ILK), PINCH1); this membrane-proximal platform synergizes 
with receptor tyrosine kinase activation and other receptor systems including CD63/TIMP1 
interaction to engage MAPK and phosphoinositide 3-kinase (PI3K) signaling and downstream 
effectors, including Myc and NF-κB15,16,19–23. Several integrin-dependent pathways were 
reported to accelerate clearance of DSBs and regulate cell cycle checkpoints, including FAK/c-
Jun N-terminal kinase 1 (JNK1) and PI3K signaling combined with nuclear actin delivery22,55,56 
and hence might account for enhanced DNA damage repair and subsequent resistance in 
the collective invasion niche. By directly targeting integrin receptors upstream of the signaling 
network, even moderate radiation doses (cumulative 10 to 15 Gy) were sufficient to achieve 
eradication of the entire tumor, including the invasion zone as sub-region of highest survival 
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ability, and further to eliminate distant metastasis. Thus, direct interference with β1/αVβ3 
integrin receptors may reach particular stringency in perturbing integrin-dependent signaling 
as most direct and arguably robust strategy to dampen integrin functions, besides interfering 
with signaling intermediates (e.g. FAK, Src, MAPK) which may suffer from compensatory 
network rewiring and resistance development3,17,57. 
In aggregate, we propose that antibody-based clinical integrin receptor targeting in solid 
tumors requires reconsideration, with emphasis on (i) prior profiling of expressed integrin 
subsets to select the most appropriate antibody combination, (ii) pre- or post-operative 
intervention of surgically challenging, non-curable and recurrent invasive lesions, and/or (iii) 
persisting lesions exhibiting clinical radiation resistance. Future work is required to secure the 
tolerability of combined β1 and αV integrin targeting in patients. αVβ3 integrin antagonists 
(Etaracizumab, Cilengitide) are clinically well tolerated17, whereas targeting of β1 integrin, due 
to its ubiquitous expression, may require particular care to minimize leukocyte malfunction or 
wound healing defects58. Intermittently applied, dual- or multi-integrin targeted therapy may 
thus (re)gain clinical relevance to improve efficacy of DNA damaging therapy and eradicate 
niches of tumor resistance.
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Supplementary Material and Methods
Immunohistochemistry
Human tissue was fixed in 4% PBS-buffered formalin, routinely processed and paraffin-
embedded. Mouse dorsal skin was cryopreseved as described in the Material and Methods 
section. 2 to 4 μm thick sections of human tissue and 10 µm thick sections of mouse tissue 
were routinely stained with hematoxylin and eosin and subsequently immuno-histochemically 
stained by HRP reaction using mouse monoclonal anti-human α-smooth muscle actin 
(clone 1A4, DAKO) or rabbit polyclonal anti-GFP (Department of Cell Biology, Radboudumc 
Nijmegen, The Netherlands)59 after antigen retrieval. Imaging was performed using a Leica 
DM6000B microscope.
Protein gelelectrophoresis and Western Blot
β1 integrin knockdown efficiency in HT-1080 cells was detected by protein gel electrophoresis 
and Western blot analysis using complete cell lysates. β1 integrin was detected with mouse 
anti-β1 integrin (clone 18/CD29, BD Biosciences) and α-tubulin, as loading control with mouse 
anti-α-tubulin (clone DM1A; Millipore). All protein samples were separated under reducing 
conditions on 8% SDS-PAGE and transferred onto a nitrocellulose membrane, blocked with 
2% milk–PBST (1h, RT) incubated with primary antibody (~18h, 4°C), washed with PBST, and 
incubated with HRP-conjugated anti-mouse antibody (Jackson Immunoresearch; 1 h, RT). 
Protein bands were detected using Luminol/H2O2. To detect multiple proteins on the same 
membrane, membranes were stripped using Restore Western Blot Stripping buffer (Thermo 
Scientific), blocked again and labeled with primary and secondary antibody.
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Supplementary Figure 1. Kinetics and organization of collective invasion in mouse dermis and 
comparison to human samples. 
(A,B) Time-dependent whole-tumor morphology (A) and tumor volume (B) of HT-1080 and MV3 
xenografts in the skin window. Arrowheads, onset of collective invasion. Scale bar, 1 mm. C) Median 
velocity of collective invasion into the dermis. Data represent distance migrated per day from day 4 to 
day 6 of individual collective strands. Negative values originate from occasional rearward orientation or 
retraction of strand tips. D) Orientation of mitotic planes in the core or collective invasion (CI) strands 
relative to the direction of migration. A median angle of ~90° reflects mitotic planes aligned perpendicular 
to the invasion direction. E) Collective invasion pattern in human adult primary soft tissue sarcoma in sub-
diaphragmal location. Multicellular strands bordered by reactive α-smooth muscle actin (SMA) positive 
stromal cells. Inset, mitotic planes (arrowhead) orientated perpendicularly to the invasion direction. 
Dashed lines, border between invasion zone and stroma. F) Collective invasion pattern in human primary 
melanoma lesion during vertical growth phase with deep dermal invasion. Inset, mitotic plane (arrowhead) 
perpendicular to invasion direction. Dashed lines, border stroma to invasion zone. Asterisks, individual 
tumor cells. G) Absence of hypoxic areas in HT-1080 xenograft after 7 days of growth in the skin window. 
Hypoxic regions detected by pimonidazole staining (red) include the upper epidermis (black arrowheads), 
sebaceous glands (white asterisks) and dermal fat tissue (white arrowheads), but not the tumor core. 
Green asterisks, autofluorescent myofibers. Scale bar, 1 mm. 
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Supplementary Figure 2. Work flow and quantitative analysis of the radiation response of sarcoma 
and melanoma tumor sub-regions monitored by intravital microscopy. 
(A,B) Dimensions and uniform dosing of irradiation across the visible field of the skin window using 
focal-beam irradiation (2 cm beam diameter). (A) Topography of the irradiation field (1) and skin window 
(2). (B) Dosimetry of irradiation measured across the irradiation field (1). Due to the metal frame of 
the imaging window only the window itself (2) is exposed to irradiation. C) Experimental procedure for 
sequential intravital imaging of the tumor response to fractionated irradiation. Fluo, epifluorescence 
overview microscopy. MPM, subcellular-resolved multiphoton microscopy. D) Frequency of mitotic planes 
in HT-1080 tumor core and collective invasion strands, by scoring the H2B-EGFP pattern (1, interphase 
nucleus; 2-4, mitotic nuclei (2, prometaphase, 3; metaphase; 4, anaphase). Data show the median fraction, 
25th/75th (box) and 5th/95th percentiles (whiskers) from 5-20 different microscopic fields representing 3 
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to 4 tumors. E) Frequency of mitotic and apoptotic nuclear pattern in tumor core or collective invasion 
(CI) zone of MV3 tumors (day 6). Data show the median fraction, 25th/75th (box) and 5th/95th percentiles 
(whiskers) from 9-28 different microscopic fields representing 4 to 5 tumors. Statistics, Mann-Whitney 
test. F) Time course of radiation response in representative lesions, compared to non-irradiated control 
tumors (day 13). Arrowheads, invasion zone. Asterisks, regression zone. Scale bar, 1 mm. G) Sequence 
of images to quantify the residual tumor mass in tumor sub-regions (example lesion, regression after 
irradiation combined with anti-b1b3 integrin treatment). The area covered by invading cells measured at 
day 13 was normalized to the area at day 6 and expressed as relative fraction for each tumor. The same 
procedure was used to determine the area of the tumor core. Scale bar, 250 µm. 
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Supplementary Figure 3. Tumor sub-region analysis of the DNA damage response by serial 
sectioning and image cytometry. 
A) Principle of serial vertical tumor sectioning and morphology mapping to annotate serial samples from 
tumor core (region 2) and invasion zone (regions 1 and 3). Arrow, direction of sectioning. B) Specific and 
isotype-controlled background staining for DNA damage response (DDR) markers (irradiated samples). 
Dashed rectangles, region of detail images. Scale bar, 10 µm. C) Work-flow for image segmentation and 
single cell cytometry. ROI, region of interest. D) Histogram analysis of nuclear size distribution to determine 
the cutoff for exclusion of nuclear fragments (i.e. apoptotic nuclei). Indicated variables and formula were 
used for Gaussian distribution fitting to define the intersection and separate fragmented from intact nuclei. 
Area binning of ~18,000 nuclear ROIs from 3 independent HT-1080 tumors including cores and invasion 
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zones. Similar distributions and curves were obtained for MV3 tumors resulting in the same cutoff (data 
not shown). E) Representative γH2AX, pChk2 and pATM/ATR substrate signal in sub-regions of HT-1080 
tumors before or shortly and 1 day after a single-dose irradiation. Representative maximum intensity 
projections from confocal 3D stacks. Red selections, ROIs of tumor nuclei. CI, collective invasion. Scale 
bar, 50 µm. F) Quantification of γH2AX and pChk2 signal intensity in MV3 tumors before and after a 
single-dose irradiation. Data originate from ~150-600 nuclei per invasion zone and tumor and ~1,000-
6,000 nuclei per core and tumor from 2 independent tumors, represented as medians, 25th/75th (box) and 
5th/95th percentiles (whiskers). Dashed lines visualize approximate dynamics of DNA damage response. 
Statistics, mixed model ANOVA (see methods section for details). G) Identification of biologically relevant 
effects from large datasets. Example plots derived from the Imer function after performing a mixed model 
ANOVA showing the distribution of mean of logvalues for different tumor sub-regions and tumors. Only 
data sets revealing similar directions and slopes were included for statistical analysis (right plot), whereas 
samples with disparate or noise-like behaviors (left plot) were considered not significant. 
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Supplementary Figure 4. Integrin expression profiles in HT-1080 and MV3 cells. 
(A,B) Surface expression pattern of integrin β and α chains on HT-1080 (A) and β chains on MV3 (B) 
cells determined by flow-cytometry. Black line, isotype control. Values, mean fluorescence (minus isotype 
values).
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Supplementary Figure 5. RNAi based integrin targeting in HT-1080 cells. 
(A-C) Downregulation of β1 and β3 integrins in HT-1080 cells by shRNA. A) Knockdown efficiency of β1 
integrin in dual-color HT-1080 cells (Western Blot), compared to non-transduced (NT) and empty vector 
(EV) transduced cells. β-tubulin, loading control. (B,C) Upregulation of β3 integrins after downregulation 
of β1 integrin (B) and efficient downregulation of both β1 and β3 integrins after β1/β3RNAi (C) determined 
by flow cytometry. Surface expression pattern of β1 and β3 integrins on β1RNAi cells or β1/β3RNAi cells 
(red lines) compared to cells transfected with empty vector (EV, blue lines). Black line, isotype control. 
Values, mean fluorescence (minus isotype values). Stability of β1/β3 downregulation was routinely 
verified, and no outlier behavior or drift of expression to other integrin β-chains was noted (data not 
shown). D) Reduction of β1 integrin adhesion epitope detected by FITC-conjugated mAb 4B4 on vector 
control (EV; left) and β1RNAi cells (right) after epitope saturation with unconjugated mAb 4B4 (3 µg/ml; 
blue line showing residual epitopes) compared with unspecific IgG1 (red line; total epitopes). Black line, 
isotype control staining (Iso). Values indicate mean fluorescence intensities. E) Experimental procedure 
for administration of anti-β1 integrin mAb 4B4 or IgG1 and sequential intravital imaging of the tumor 
response to integrin interference. Fluo, epifluorescence overview microscopy. MPM, subcellular-resolved 
multiphoton microscopy. F) Diminished phosphoErk signal (MAPK signaling) after β1/β3 integrin targeting 
(day 7). Histograms show the mean pixel fluorescence (MF) intensity of pErk from control (HT-1080 
wildtype) and β1/β3 integrin targeted tumors (T, dotted lines, identified by H2B-EGFP label) compared 
to pErk signal in the surrounding stroma (S), which further contained hair follicles (HF) with strong 
endogenous pErk expression. Ratio of tumor- and stroma-derived pErk intensity is displayed as medians, 
25th/75th (box) and 5th/95th percentiles (whiskers) determined from 10 independent regions of the 
according stroma region after exclusion of HF, with a ratio of 1.0 (red dashed line) when signal intensity 
of both regions was equal. Calibration bar, pixel intensity. Scale bars, 100 µm (overview), 10 µm (inset). 
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Supplementary Figure 6. Radiosensitization of HT-1080 tumor lesions by β1/β3 integrin RNA 
interference combined with antibody-based β1 integrin targeting. 
A) Topology and extent of the invasion zone in response to fractionated irradiation combined with single-
integrin (β1) or dual β1/β3 integrin interference. Epifluorescence (left) and 3D reconstructed z-projections 
from regions marked by dashed boxed using multiphoton microscopy (right) (day 13). White asterisks, 
apoptotic nuclei. Scale bars, 1 mm (left), 250 µm (right). B) Time-dependent tumor volume. Data show 
the means ± standard deviation from 3 to 4 independent tumors, with p-values for comparing irradiated 
integrin-targeted tumors to irradiated control tumors. *, significant p-value after Bonferroni correction for 
multiple comparisons (Bonferroni-corrected threshold was p=0.005). Statistics, Mann-Whitney test. C) 
Regression of tumor core and collective invasion (CI) zone after irradiation with or without integrin mono- 
or dual-interference. Data show the median, 25th/75th (box) and 5th/95th percentiles (whiskers) of day 13 
normalized to day 6 (Bonferroni-corrected threshold was p=0.025). Statistics, Mann-Whitney test. 
Supplementary Figure 7. Radiosensitization of sarcoma and melanoma tumors by dual  
antibody-based integrin interference. 
A) Protocol for administration of anti-β1 (4B4) and αV integrin (17E6) mAbs or IgG1 combined with 
fractionated irradiation and sequential intravital imaging of the tumor response. Fluo, epifluorescence 
overview microscopy. MPM, subcellular-resolved multiphoton microscopy. (B-H) Tumor morphology and 
quantification of radiosensitization assessed by intravital microscopy. (B,E) Time-dependent growth or 
regression of HT-1080 or MV3 lesions in response to the indicated treatment conditions. n.a., not analyzed 
due to humane endpoint after day 13 (tumor > 2cm3). Asterisks, regression tumor core. Arrowheads, 
tumor remnants. Scale bars, 1 mm. (C,F) Time-dependent tumor volume during and after treatment with 
IgG1 or mAb 4B4+17E6 with or without irradiation. Data show the means ± standard deviation from 3 to 
4 (HT-1080) or 3 to 5 (MV3) independent lesions. The indicated p-value compares IgG1/IR control with 
4B4/17E6 and IR (day 15). Statistics, Mann-Whitney test. (D,G) Mitotic frequencies in non-irradiated 
and irradiated tumor core and collective invasion (CI) zone. Data show the medians, 25th/75th (box) 
and 5th/95th percentiles (whiskers) from 7 to 23 independent fields from 4 (HT-1080) or 3-5 (MV3) 
independent tumors. Statistics, Mann-Whitney test. H) Long-term follow-up (day 26) after treatment with 
4B4 and 17E6 and irradiation, revealing minimal residual disease. Dotted grey line, position of former 
tumor. Box, position of right panel. Zoom shows surviving cells without mitotic activity (arrowheads) and 
cytoplasm-free, condensed nuclei of disintegrated cells (asterisks). 
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Supplementary Figure 8. Procedures and outcome of long-term therapy response monitoring after 
combining irradiation with single- or dual-targeted anti-integrin therapy. 
A) Treatment schemes for HT-1080 and MV3 tumors. Tumor cells were injected at day 0 resulting in an 
intradermally growing tumor located along the dorsal midline (dashed line). Example image, intradermal 
HT-1080 lesion. Time points of irradiation and antibody administration are indicated. B) Example tumor 
undergoing complete regression after therapy monitored longitudinally by whole-body fluorescence 
imaging. C) Dual-color detection of lung and lymph node metastases. Microscopic whole-organ screen 
(not shown) was followed by analysis of cryosections (shown). Scale bars, 100 µm (overview) and 10 µm 
(inset). D) Identification of minimal residual disease at the endpoint. The dorsal skin was screened from 
the deep fascia for presence or absence of fluorescent tumor remnants (left panel). In case of doubt sub-
regions were additionally sectioned for analysis by anti-EGFP immunohistochemistry (IHC) (right panel). 
Images show typical tumor-negative outcome. Scale bar, 100 µm. E) Examples of minimal residual lesions 
present at the tumor implantation site at the end point (day 180).Tumor remnants with strand-like pattern 
of green-fluorescent tumor nuclei (H2B-EGFP) followed by tissue sectioning and validation by anti-EGFP 
IHC. Dashed line, approximate position of tissue cross-section. Arrowheads, intact H2B-EGFP positive 
tumor nuclei. Right panel, validation of EGFP positive tumor remnants and positive anti-EGFP IHC side 
by side. Scale bars, 100 µm (overview) and 10 µm (details). 
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Genomic profiling of tumor material and sub-regional differences in therapy response 
revealed that a single lesion might suffer from intratumor heterogeneity. Human sarcoma 
xenografts grown in an imaging window in mice show clear compartmentalization, 
with a distinct tumor core and collective invasion zone, both exposed to differential 
environmental context and exhibiting diverging therapy response, thus displaying 
clear intratumor heterogeneity. To identify target genes in the invasion zone driving 
this heterogeneity, this chapter describes the establishment of intravital microscopy-
based 3D microdissection to isolate tumor core and invasion zone as separate fraction 
from live tumors, followed by RNA extraction and expression profiling through RNAseq. 
While tumor cores and invasion zones with a size range of 1 mm to <100 µm were 
successfully isolated and high-quality RNA was obtained from both tumor sub-regions, 
initial downstream analysis of RNAseq results suffered from the contained mixture of 
human tumor and stromal, murine RNA. However, upon further technical optimization 
of RNAseq performance and analysis, intravital microscopy-guided microdissection 
will become a valuable tool to analyze heterogeneity of spatially and functionally 
annotated tumor sub-regions. 
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Introduction
Tumor lesions usually appear as physical entity, however, histological analyses and emerging 
cancer genomics approaches combined with cancer research settings showed that cancerous 
lesions consist of distinct morphological, molecular and functional sub-regions1–4. By enabling 
adaptation responses, such intratumor heterogeneity may impact the biology and therapy 
response of cancer disease5–10. Several converging mechanisms can contribute to intratumor 
heterogeneity: Genetic diversity where distinct tumor sub-clones obtain additional private 
mutations compared to the initial tumor lesion, which might confer a survival advantage in 
selective environments, including contribution to therapeutic resistance, dissemination and 
metastasis formation5,6,11. Genetic heterogeneity can be identified by genome sequencing 
approaches and evaluation of tumor sub-clonality and is used to identify resistance 
mechanisms and, if possible, select suitable combinations of (targeted) therapy3,5,6,11,12. 
In addition, epigenetic heterogeneity such as differences in chromatin conformation, 
histone modifications and DNA methylation, can exist which originates either from genetic 
mutations that affect epigenetic regulators or is mediated by signals derived from the tumor 
microenvironment, including chromatin changes associated with cancer cell migration13–18. 
In contrast to genetic heterogeneity, epigenetic heterogeneity is modifiable and can occur 
transiently13. Furthermore, environment-derived signals reaching only tumor sub-regions 
may activate signaling cascades in cancer cells which contribute to intratumor heterogeneity 
without epigenetic reprogramming7,9,19–22. 
The invasion zone of tumor lesions contains migrating tumor cells which enter a 
microenvironment rich in extracellular matrix (ECM) components and various stromal 
cell types10,23,24. Compared to the tumor core, invading cancer cells thus receive distinct 
environmental input including mechanical and chemical stimuli, which together with chromatin 
changes to facilitate motility contribute to the development of intratumor heterogeneity and 
the distinction of two tumor sub-regions, i.e the tumor core and the invasion zone7,10,14,25,26. As 
shown in chapter 4 and 5 of this thesis for sarcoma and melanoma xenografts, this spatial 
heterogeneity of tumor core and invasion zone can be associated with functional heterogeneity 
shown by a differential response to integrin-targeting and radiotherapy with the invasion zone 
being radioresistant and capable to invade and survive independent of integrins (Fig. 1A). 
However, the molecular targets driving such invasion-associated heterogeneity and therapy 
failure remain to be dissected, which is necessary to identify new therapeutic targets and 
strategies to target the entire tumor lesion. 
Characterization of the environmental stimuli and downstream effects in the cancer cell 
population requires separation of both entities, followed by the employment of various 
techniques including gene expression profiling, investigation of epigenetic changes covering 
both, DNA and histone modification, or proteomic analyses21,27,28. But, as each method 
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depends upon distinct primary material, i.e. RNA, DNA or proteins, such multi-parametric 
analyses of sub-regions from the same lesion remain a technical challenge. However, since 
both, activation of signaling cascades and epigenetic modifications eventually converge in 
gene expression changes, which might be similarly reflected on protein level, gene expression 
analysis through RNAseq is a widely used, quantitative entry point to analyze intratumor 
heterogeneity and identify downstream modulators. Likewise the RNA sequence may reveal 
potential genetic mutations contributing to intratumor heterogeneity.29,30 
Current experimental approaches to dissect intratumor heterogeneity and identify differences 
in the disseminating cell fraction include expression profiling of tumor and/or metastatic 
specimens which are analyzed either directly or after dissolution and/or short-term culture 
using bulk or single-cell analyses31–33. However, thus far neither of these approaches addressed 
spatial and functional annotations of defined tumor-sub-regions. In contrast, the combination 
of orthotopic xenograft models, imaging windows and preclinical intravital microscopy 
constitutes an ideal setting to longitudinally monitor tumor growth and invasion, with the option 
for controlled interference or therapy application to observe effects at single-cell resolution, 
such as invasion associated radioresistance described in chapter 523,24,34,35. Expression of 
fluorescent markers allows clear identification of a tumor core and collective invasion zone 
in this model system. Therefore, combined with obvious heterogeneity between both sub-
regions, the intradermal invasion model was selected to establish a microscopy-guided 
microdissection approach for differential isolation and profiling of both sub-compartments, 
with the aim to identify mechanisms underlying the heterogeneity between tumor main mass 
and invading tumor cells, and the potential impact of the peritumor microenvironment. 
This chapter describes the technical establishment of the image-based microdissection 
approach followed by optimization of tissue preservation and RNA isolation procedure for 
subsequent expression profiling using RNAseq. Separated isolation of tumor main mass and 
invasion zones from untreated human HT-1080 sarcoma xenografts including subsequent 
RNA isolation were successfully achieved, introducing intravital microdissection for studies of 
intratumor heterogeneity. 
Material and Methods
Cells and cell culture 
Dual-color variants of human HT-1080 sarcoma cells36, expressing cytoplasmic DsRed2 and 
nuclear histone 2B (H2B)-EGFP37, were cultured in DMEM (Invitrogen) supplemented with 
10% fetal calf serum (Sigma Aldrich), penicillin and streptomycin (both 100 μg/mL; PAA), 
Hygromycin B (Invitrogen, 0.2 mg/mL) and G418 sulfate (Calbiochem, 0.2 mg/mL) at 37°C in 
a humidified 5% CO2 atmosphere. 
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Animal experiments
Animal procedures were approved by the Ethical Committee on Animal Experiments of the 
Radboud University, Nijmegen (The Netherlands) (RU-DEC 2011-040) and performed in the 
Central Animal Laboratory of the Radboud University Nijmegen, in accordance with the Dutch 
Animal Experimentation Act and the European FELASA protocol. 
Skin window model 
Titanium dorsal skin imaging windows were transplanted onto 10 to 14 week-old male athymic 
Balb/c nude mice (CANN.CG-FOXN1NU/CRL, Charles River), as described23. One day post-
surgery tumor cells (~5x105 cells in 4 µL PBS) were implanted into the dermis by image-guided 
microinjection. To monitor tumor progression live mice were anesthetized with isofluorane and 
stably mounted onto a temperature-controlled platform (37°C). Subsequently epifluorescence 
overviews of dual-color tumors were generated with a 4x objective (NA 0.3, Olympus).
Microscopy-based microdissection and tissue collection
Microscopy-guided microdissction was applied at day 6 after tumor implantation to intradermal 
xenograft lesions showing a well-developed invasion zone originating from the tumor core. As 
inclusion criteria, the tumor core showed volume increase compared to day 1 and a well-
developed neovascular network consistent with an established lesion. Mice were anesthetized 
by i.p. injection of 0.0875 mg/kg body weight (BW) atropine, 0.35 mg/kg BW xylacine and 7 
mg/kg BW ketamine. For reliable tumor dissection, mice were immobilized in a plastic tube 
with the skin-fold window exposed through a slit, fixed onto a metal holder which was placed 
onto a heating pad. To warm the mouse, the plastic tube was further surrounded by small 
bags containing warm water (~40°C). A coverslip was placed underneath the epidermal site 
of the imaging window as a stable support facilitating the microdissection. After removal of 
the imaging coverslip the exposed tissue was moisturized with 0.9% NaCl solution (Braun). 
Intravital microdissection was performed using a fluorescence stereomicroscope (Leica 
MZFLIII, 0125 N.A., EL6000external light source, GFP Plus and DsRed filter sets) at up to 800x 
magnification to reach oligocellular resolution. Tumor lesions were dissected with a micro-
knife (Micro-Knife 20° (0.120mm), #62091-08) and micro-hook (Micro-Hook 90° (0.25mm), 
#62091-18) connected to handle (#62090-00, Electron Microscopy Sciences). Subsequently 
dissected tissue was harvested and transferred using watchmaker tweezers (length 110mm, 
tip 0.06mm by 0.10mm, Aesculap).
Tissue samples were either collected in with RNAlater stabilization reagent (Qiagen) or snap-
frozen. For preservation in RNAlater stabilization reagent, prior to starting the dissection 
process DNase/RNase-free 1.5 ml reaction tubes (Thermo Fisher Scientific) were filled 
with the reagent (100 µL for tumor cores, 60 µL for invasion zones) and placed at room 
temperature. Microdissection was performed as quickly as possible to minimize surgery-
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imposed perturbation and gene expression alteration. Immediately after isolation tissue 
pieces were submerged in the respective amount of RNAlater stabilization reagent (one piece 
per reaction tube) and left at room temperature till microdissection was completed. After o/n 
incubation at 4°C samples were stored at -20°C until RNA isolation was performed. For snap-
frozen samples tissue pieces were put into an empty DNase/RNase-free 1.5 mL reaction tube 
and subsequently snap-frozen using a liquid nitrogen cooled mini mortar (Calpaclab). Frozen 
samples were stored in liquid nitrogen (short-term)/at -80°C (long-term).
RNA isolation
RNA isolation was performed using the RNeasy Miro kit (Qiagen). In brief, RNAlater 
stabilization reagent was aspirated and tissue pieces were lysed in freshly prepared RLT 
lysisbuffer containing β-mercaptoethanol (β-ME, Merck Millipore, 10 µL of 14.3 M β-ME 
per mL RLT buffer). Snap-frozen samples were thawed on ice prior to lysis. Tissue pieces 
larger than 1 mm3, including the tumor core, were lysed in 350 µL, and smaller tissue pieces, 
including the invasion zone, in 70 µL lysisbuffer. Tissue was disrupted and homogenized by 
repetitive resuspension, vortexing and mashing (using a 20-200 µL pipette tip). Subsequently 
non-homogenized debris was removed by centrifugation (3min, full-speed (21,130 x g)) and 
transfer of the supernatant to a new DNase/RNase-free 1.5 mL reaction tube, containing 1 
volume of 70% EtOH. Lysate and EtOH were carefully mixed and transfered, including any 
potential precipitate, to a RNeasy spin column placed in a 2 mL collection tube and processed 
according to the manufacturer's instruction until RNA elution (RNeasy Micro Handbook 
(version 12/2007) protocol "Purification of total RNA from animal and human tissues" steps 
5-12). After placing the spin column into a new 1.5 ml collection tube, RNA from tumor core 
samples was eluted using 14 µL DNase/RNase-free water, while invasion zone samples were 
eluted with a volume of 7 µL. Following application of nuclease-free water onto the filter of 
the column, collection tubes containing the column were incubated at 37°C for 1 min. After 1 
min centrifugation at full speed (21,130 x g) for elution, RNA samples were immediately put 
on ice. Subsequently for invasion zone samples elution was repeated by re-using the column 
and applying another 7 µL of nuclease-free water. Eventually RNA collected in both elution 
steps was pooled in one tube. Immediately after RNA extraction, RNA concentration was 
determined (NanoDrop 1000, Thermo Fisher Scientific) and samples to measure RNA quality 
(2100 Bioanalyzer, Agilent) were prepared. RNA samples were stored at -80°C. 
RNAsequencing
RNAseq was performed using the the SMART-seqII protocol, as described38. cDNA was 
synthesized according to the manufacturer’s protocol using the ultra low input RNA SMART-
seq v4 kit (Clontech) and subsequently sheared using a Biorupter Pico sonication system 
(Diagenode). To evaluate sonication efficiency, cDNA was analyzed on a 2100 Bioanalyzer. 
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To prepare the libraries for next generation sequencing the KAPA Hyper Prep Kit (KAPA 
Biosystems) was used applying the standard Illumina library preparation protocol. In brief, 
end-repair and A-tailing of the sonicated cDNA were performed in one reaction (30 min, 20°C) 
followed by heat-inactivation of the enzyme (30 min, 65°C). For barcoding, end-repaired and 
A-tailed samples were incubated with NEXTflex ChIP-seq adapters (Bioo Scientific) (15 min, 
20°C) followed by clean-up to remove remaining enzymes and adapters using AMPure XP 
beads (Beckman Coulter) with a sample to bead ratio of 1 : 0.8. cDNA libraries were amplified 
running 10 PCR cycles with the KAPA HIFI HotStart Kit (KAPA Biosystems) and subsequently 
cleaned using the Qiaquick PCR purification kit (QIAGEN). Selection of 300 bp fragments 
was achieved by an E-Gel electrophoresis system size selection approach (Thermo Fisher 
Scientific). After vacuum centrifugation (Savant DNA SpeedVac, Thermo Fisher Scientific), 
library concentration was determined fluorometrically (Qubit 2.0, Thermo Fisher Scientific) and 
average size of fragments was analyzed by automated electrophoresis (2100 Bioanalyzer). 
Next generation sequencing was performed on a NextSeq 500 platform (Illumina) with paired-
end reads, a medium sequencing depth of 30 million reads per end and 75 bp read length. 
Raw RNAseq data were cleaned from ribosomal RNA contamination using the Bowtie software 
package39 and reads with a quality score >15 were further analyzed. Processed reads were 
aligned to the human genome (hg19) using GSNAP40 with default options. Subsequently 
reads mapping uniquely to the human genome were re-aligned to the mouse genome (mm9) 
followed by removal of reads mapping to the mouse genome. Through application of the 
Xenome algorithm41 already cleaned reads derived from the previous step were assigned to 
the human and mouse genome k-mers (24 nt) to further remove contaminating mouse-derived 
reads. This additional processing step further improved selectivity for human and mouse 
mapping reads by 10%. Human-specific reads selected after the previous clean-up steps 
were counted and annotated to the human genome using Htseq-count42, followed by analysis 
of differential gene expression applying DESeq43 and using the R software environment. Cut-
offs to determine differentially expressed genes were as follows: i) expression threshold of 
minimum 20 counted reads per gene (corresponds to 0.6 mRNA molecules), ii) p value and 
FDR <0.05, and iii) fold change ≥1.5. Gene ontology (GO)-term analysis was performed using 
the DAVID online platform44,45. 
Results
To enable image-guided microdisscetion, cancer cells stably expressed fluorescent markers 
(H2B-EGFP and DsRed2), which allowed precise isolation of the cancer cell fraction by 3D 
fluorescence microscopy during dissection. HT-1080 sarcoma xenografts grown intradermally 
in the dorsal imaging window initiated deep tissue invasion by 2-3 days after implantation 
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(Fig. 1B). Initiation of the angiogenic switch in the tumor core, visible through the formation of 
new blood vessels occurred by day 5 to 6, coinciding with exponential growth (Fig. 1B). This 
resulted in a well defined tumor core of ~1.5 x 2 mm with lateral invasion zones of up to 1mm 
length. 
Cuts to perform the actual microdissection were made with so-called micro-knives having a 
blade width of 0.12 mm, while a micro-hook with a thickness of ≤0.25 mm was used to lift up 
the tumor tissue and separate it from the underlying epidermis (Fig. 1C). First, to physically 
separate both tumor sub-regions and minimize contamination of core cells in the invasion 
zone, occurring through physical perturbation onto the tumor core, two lateral incisions were 
made next to the core that approximately 1/8 to maximally 1/4 of an invasion strand became 
retained in the core fraction, including the critical transition zone (Fig. 1D, red dashed line). 
Due to the relative abundance of the tumor core volume, cross-contamination with invading 
cells was considered negligible. Subsequently, the invasion zone was separated from the 
surrounding tumor-free dermis by further circumferential incisions in parallel and orthogonal 
direction (Fig. 1D, yellow and blue dashed lines). To isolate the tumor core, further incisions 
were positioned at the lower and upper poles to retrieve the samples as a single tissue piece 
(Fig. 1D, green dashed lines). Overall, the combination of fluorescence microscopy-based 
guidance and employment of the micro-tools made it possible to separately isolate tumor 
core and invasion zones with minimal cross-contamination by dermal structures, as the lateral 
dermis and the underlying epidermis remained intact (Fig. 1E,F).
As standard procedure, maximum preservation of isolated tissue including integrity of nucleic 
acids was achieved by fast dissection (within ~10 min from initial cut perturbing blood circulation 
to isolation of final tissue piece) and direct sample transfer to RNA stabilization reagent. For 
both tumor sub-regions this yielded RNA with a quality index approximating the maximum 
score and hardly RNA degradation (Fig. 2A). In contrast, other preservation strategies, such 
as snap-freezing in liquid nitrogen, yielded inferior RNA quality (Fig. 2A). Concordant with size 
of the tissue chunks, amounts of RNA isolated per invasion zone sample were by 9-fold lower 
compared to the tumor core (Fig. 2B), though still sufficient to perform subsequent RNAseq 
(minimum amount ≥ 10ng), which was done for cores and invasion zones obtained from three 
human HT-1080 xenografts grown in three different mice. 
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Figure 1. Microscopy-guided microdissection of fluorescent human sarcoma xenografts in the 
mouse dermis.
A) Differential topology and functional heterogeneity of tumor core and invasion zone in sarcoma 
xenografts. B) Epifluorescence intravital microscopy of a HT-1080 sacroma xenograft in the mouse dermis, 
expressing H2B-EGFP and DsRed2, monitored through an imaging window. Arrowheads, neovessels. 
Scale bar, 100 µm. C) Setup and micro-tools to perform manual microdisscetion in the dermal imaging 
window. Scale bar, 200 µm. D) Step-wise xenograft dissection and removal of invasion zone and tumor 
core. Coloured, dashed lines and numbers in the first panel represent (order of) performed incisions. 
Arrows, location of incisions post-surgery. Zoom, clean dissection margin. Scale bar, 100 µm. E) Isolated 
tissue pieces containing tumor core or invasion zone. Upper panels, xenograft-derived H2B-EGFP signal. 
Lower panels, overlay brightfield and H2B-EGFP signal. Scale bar, 1 mm. F) Microdissection and tissue 
isolation are confined to the dermal tissue, leaving the deeper dermis and epidermis intact. Scale bar, 
100 µm.
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To minimize perturbation of RNA expression by disruption of the tumor microenvironment, 
isolated tumor-sub-regions were not subjected to any tissue digestion or cell sorting prior to 
preservation. Therefore, raw sequencing reads contained both, human (xenograft-derived) 
and murine (stromal) RNA. To separate human from murine sequences, data processing 
included steps to remove contaminating reads mapping to the mouse genome (see methods 
section for details). Eventually, the fraction of human-specific reads retrieved from the 
tumor core or invasion zone was 40% and 10%, respectively, while the remaining amount 
of reads mapped to both, the mouse and the human reference (Fig. 2C). The fraction of 
reads mapping uniquely to the mouse genome, which were excluded from further analyses, 
was negligible small (data not shown). Because fractions of human-specific reads differed 
for both sub-regions, which would have biased further analyses, differential gene expression 
was analyzed using both, unique human and human/mouse mapped reads. The according 
principal component analysis (PCA) plot, did not show any co-clustering of samples derived 
from the same tumor sub-region (Fig. 2D). However, two paired invasion zones from the 
same lesion mapped closer together, as expected based on their common origin (Fig. 2D). 
This indicated that not exclusively the factor “tumor sub-region” accounted for inter-sample 
differences but independent tumor samples generally exhibited significant differences in 
differentially expressed genes. 
As consequence of high variability observed in the PCA plot, differentially expressed genes 
in the respective sub-region were only obtained after lowering the expression cutoff from 50 
down to 20 minimum reads in at least one of the samples and fold-change from 2 to 1.5. Six 
genes were identified as commonly upregulated in the invasion zone compared to the tumor 
core, and three genes as consistently downregulated (Fig. 2E). Gene ontology (GO) analysis 
for the obtained hits revealed, that except for β3 integrin which becomes (among others) 
associated with the GO terms “cell migration” and “cell-matrix adhesion”, all differentially 
expressed genes have major functions in either endothelial or muscle tissue or the blood 
compartment and thus, very likely, originate from the mouse stroma.
These preliminary RNAseq data obtained from human cancer cells in a mouse background 
using a medium sequencing depths (~30 million reads), revealed major shortcomings in 
identifying cancer-cell specific hits, likely caused by cross-contamination with mouse-derived 
RNA. However, the identification of downregulated β3 integrin in the invasion zone, which is 
probably xenograft-derived, was consistent between all samples indicating general feasibility 
of differential dissection and RNAseq analysis of tumor sub-regions. 
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Figure 2. Extraction of high-quality RNA from tumor sub-regions and subsequent analysis of 
differentially regulated genes through RNAseq.
A) Measurement of RNA degradation to estimate RNA quality. Average RNA quality index (RQI) displayed 
as minimum to maximum plot from 17 core and 23 invasion zone samples. C, tumor core. I, invasion 
zone. RQI, 1=low quality, 10=high quality. B) Average amount of RNA obtained per isolated tumor sub-
region displayed as minimum to maximum plot from individual samples (27 cores, 34 invasion zones). C) 
Distribution of mapped reads among the mouse and human genome for each tumor sub-region derived 
from 3 independent xenografts. D) Principal component (PC) analysis of differentially regulated genes in 
tumor sub-regions from 3 independent xenografts. C, core. I, invasion zone. E) Differentially expressed 
(DE) genes in the invasion zone of 3 independent xenografts, displayed as Venn diagrams (top) and gene 
list with common DE genes and level of differential expression (bottom tables). T, tumor.
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Discussion
The here developed image-based microdissection approach allows to separately isolate small 
sub-regions of fluorescent human xenografts, here the tumor core and the invasion zone. In 
contrast to other strategies, including laser dissection microscopy, fine-needle aspiration or 
isolation of cancer cell sub-populations through in vitro and in vivo sub-culture of surgical 
specimens46–51, fluorescence-guided dissection using micro-tools enables i) isolation of 
clearly annotated sub-regions, through combination with intravital imaging23,24 also with known 
environmental context, ii) rapid collection of live tissue followed by immediate fixation and iii) 
avoids cellular reprogramming events caused by loss of the native environment upon tissue 
digestion or cell culture conditions52,53. 
Eventual aim of this study was to perform differential gene expression profiling of both sub-
regions to determine targets driving microenvironmental-induced intratumor heterogeneity. 
However, the preliminary transcriptome profiling by RNAseq shown here suffered from limited 
sensitivity and delivered largely inconclusive data. Only the downregulation of β3 integrin 
in the HT-1080 invasion zone can possibly be linked to a biological phenotype: as shown 
in chapter 5 blocking of αVβ3 integrin has no effect on the radiation-response of HT-1080 
tumors in the long-term observation setting (Chapter 5, Fig. 4C), which would make sense 
if the target is intrinsically downregulated. Additionally, down-regulation of β3 integrin in the 
invasion zone of HT-1080 tumors might partially explain ongoing dissemination after integrin-
targeting described in chapter 4, as invading cells might intrinsically adapt additional integrin-
independent migration modes. 
Since in vitro experiments using 3D spheroid-based invasion models resulted in almost 20 
differentially expressed and functionally validated hits when performing RNAseq of samples 
derived from the spheroid body vs. invading cells (data not shown), in vivo data most likely 
suffer from technical limitations precluding conclusive results rather than lack of differential 
gene expression patterns. A major confounding factor for the in vivo analysis is the contained 
mixture of human cancer cell RNA and contaminating stroma-derived murine RNA. Although 
processed reads of both tumor sub-regions could be separated into two categories, i.e. 
uniquely mapping to the human genome and mapping to both, human and mouse genome, 
reads belonging to the latter category could not be neglected: the fraction of mapped human 
reads and thus potential target genes was >30% smaller for invasion zone samples, which 
would have prohibited meaningful comparative expression profiling. To overcome these 
limitations, technical refinements need to be implemented. First, enhancing the sequencing 
depth by increasing the read length might allow more specific mapping of reads to either 
genome thereby cleaning the human RNA-derived reads from the murine RNA-derived 
reads. Although a first attempt including a switch from 43bp to 75bp length (maximum of the 
sequencing platform used here) did not affect the specificity (data not shown), switching to 
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another platform allowing reads up to 300bp still remains an option54. Second, the relative 
enrichment of fluorescent marker-derived RNA could be retrieved, to estimate the relative 
amount of human cancer cells in either isolated fraction. Prerequisite would be a standard 
generated by mixing defined proportions of digested stromal tissue and fluorescent tumor 
cells, followed by RNAseq to determine the amount of reads mapping to fluorescent markers 
for each defined stroma:tumor ratio. Eventually, reads mapping to both the human and mouse 
genome could be redivided, with the amount correlating with a certain number of fluoresecent 
marker reads being counted as human, while the remaining reads would be regarded as 
mouse-derived. 
Third, if bioinformatic strategies fail to reach further exclusion of contaminating murine RNA-
derived reads, physical removal of mouse-derived cells before RNA isolation would allow 
to increase specificity. The possibilities include enzymatic tissue digestion followed by 
fluorescence-activated cell sorting (FACS) of fluorescent and non-fluorescent cells31 or, in 
case of very small specimens, single cell aspiration of fluorescent tumor cells cells55 or single-
cell sequencing approaches combined with image-based selection of each individual cell56. 
However, as tissue digestion would introduce a delay between cell isolation and fixation, 
expression profiling after physical separation of human and murine cells may include artifacts 
caused by gene expression changes associated with tissue dissolution52. To overcome this, 
RNA polymerase inhibitors like α-amanitin & actinomycin D could be added to enzymatic 
solutions and sorting buffers31, delivering a valuable opportunity to physically separate mouse 
and human tissue while preserving the native expression profiles of tumor core and invasion 
zone immediately after tissue dissection for subsequent expression profiling including only 
human-specific reads. Apart from focusing on the tumor lesion, clear separation of human 
and mouse-derived hits would also enable in depth profiling of the according stroma, possibly 
combined with antibody-based enrichment for stromal cell subsets like endothelial cells (e.g 
CD31)57 or cancer associated fibroblasts (e.g. α-SMA)58. Eventually, independent of the final 
approach to resolve confounding similarity between human and mouse-derived reads, analysis 
of both, tumor sub-regions and the according stroma, will help to understand development of 
microenvironmentally- induced intratumor heterogeneity. 
Besides the spatial factor, another factor co-determining (the extent of) intratumor heterogeneity 
has not been investigated here, i.e. tumor progression over time. Although the incipient lesions 
used to establish the image-guided microdissection approach had undergone the angiogenic 
switch and onset of invasion, exponential growth had just initiated and invasion may persist till 
day 9 and thereafter23. Thus, as both sub-regions independently progress further, the level of 
heterogeneity in older lesions probably differs from incipient lesions. However, to investigate 
this, the microdissection of progressed xenografts requires further refinement: The internal 
pressure of the tumor core increases the larger it grows, and therefore passive drift of core 
cells into the invasion zone or rupture of the tumor main mass needs to be prevented, e.g. 
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through puncture of the tumor main mass followed by aspiration of tumor cells. Apart from 
that, additional optimization of the microscopy-based microdissection approach might allow to 
isolate sub-regions within the invasion zone, including leader and follower cells of a collective 
strand, individually detached cells or the transition zone between tumor core and invasion 
zone. As technically limiting factors the available microscopic magnification, size of the micro-
tools and the possibility to aspirate (single) cells will determine whether subsets of the invasion 
zone can be reliably isolated from defined niches intravitally.
Beyond RNAseq, the isolation strategy described here may also be suitable for assessing 
epigenetic or proteome changes in tumor sub-regions, and thereby derive multi-scale 
information on differences in invasion-associated reprogramming and therapy response 
of cancer cells47,59–62. As the invasion zone maximally consists of a few thousand cells, the 
applicability will depend upon the sensitivity of the detection strategy63–65. 
In summary differential gene expression analysis of tumor sub-regions including both the tumor 
and stromal cell fraction will eventually contribute to the identification of targets driving tumor 
cell reprogramming, dissemination or therapeutic resistance. Although technical shortcomings 
currently constitute relative bottlenecks, improved sensitivity of gene expression profiling and 
single-cell approaches will eventually help to resolve these issues to enable the identification 
of mechanisms underlying intratumor heterogeneity66–69. 
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Metastatic cancer progression is mediated by both single-cell and/or collective mechanisms, 
including local tissue invasion, entry into blood and/or lymph vessels, circulation, exit at 
distant sites and finally outgrowth of a metastatic lesion1. Simultaneously, with each step 
of the metastatic cascade, cancer cells enter and reciprocally interact with distinct micro-
environments, undergo adaptation, and likely adopt differential behavior, despite the fact 
that they usually derive from a single mutant cell clone2,3. Focusing on mesenchymal tumor 
types, in this thesis mechanisms of tumor cell dissemination and therapeutic resistance were 
investigated, using in vitro spheroid and in vivo xenograft models.
Besides cancer invasion and metastasis, collective cell movement contributes to cell 
migration in morphogenesis and tissue repair4. Chapter 2 addresses guidance mechanisms 
in collective migration, which comprise a fundamental feature to coordinate and maintain 
joint translocation of the moving cell groups with retained cell–cell contacts. Guidance 
principles employed during collective migration include the topography and/or stiffness of the 
environment (contact guidance), physical cues like fluid-flow induced shear stress or passive 
drift as well as chemical cytokine-based and electrical ion-channel stimulating cues, which 
are often present as a gradient. Subsequently migrating cell groups needs to integrate and 
prioritize guidance signals, which act in parallel and, combined with cell-intrinsic migration 
programs, steer and determine plasticity of (collective) migration. 
In chapter 3 in vitro experiments in 3D tissue cultures addressed whether and how topographic 
cues including matrix density and stiffness control single-cell and collective migration modes 
of mesenchymal sarcoma and melanoma cells. The data show that with increasing matrix 
density cells switched from individual to collective movement. Collective invasion is established 
for cells of epithelial origin but remains controversial for mesenchymal cell types which 
usually lack strong cell-cell cohesion and rather migrate individually in loose extracellular 
matrix (ECM). However, in confining ECM which forces leader cells to proteolytically cleave 
the dense matrix and generate tracks of least resistance, mesenchymal cells become 
“jammed” which subsequently promotes cell-cell junction formation and the acquisition of 
collective polarity. Thus, topographic confinement underlies a collective invasion phenotype 
of mesenchymal tumor cells. Accordingly, unconfined conditions (i.e. a loose matrix) support 
single cell migration, identifying matrix density as critical determinant for migration plasticity of 
mesenchymal cell types, which is further not affected by matrix rigidity. 
Apparently, the concept of confinement-induced collectivity overlaps with the concept of 
cell jamming: But, whereas the jamming concept describes the transition from a collectively 
mobile to a stable, non-moving state5,6, the results from 3D culture in mesenchymal cells 
indicate that confinement-induced collective movement still represents a partially jammed 
state, which is abandoned once cells fully individualize. Jammed rather than fluidized states in 
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confinement-induced collective migration include the initial phase prior to onset of migration, 
when leader cells have to cleave tracks which are not preexisting in randomly polymerized 
high-density 3D collagen matrices. Likewise, follower cells which pile up behind track-
forming leader cells and experience lateral geometric confinement resemble a jammed state. 
Accordingly, confinement-induced collective migration of both leader and follower cells should 
be appreciated as consequence of partial cell jamming.
In chapter 4 the collective invasion phenotype of mesenchymal tumor cells observed in 
vitro was confirmed in vivo when studying the process of sarcoma and melanoma invasion 
in the orthotopic dermal environment using single-cell resolved multiphoton microscopy. 
Accordingly, the interfaces present in vivo between tissue structures such as muscle fibers 
and blood vessels enabled the cells to maintain collective movement even in the absence of 
β1 and αVβ3 integrin-mediated cell-matrix anchorage, although integrin depletion generally 
went along with an increased probability towards single cell migration. This identifies integrin 
availability in cooperation with matrix density, as independent determinant of migration 
plasticity in mesenchymal cell types. Contradicting the common assumption that integrins 
are indispensable for metastatic dissemination7, integrin-independent individual and collective 
migration of sarcoma and melanoma cells further contributed to the formation of distant 
lung metastases and an even enhanced seeding frequency. However, as integrin-mediated 
anchorage comprises an essential source of pro-survival signals, similar to the primary tumor 
lesion disseminated cancer cells failed to grow out and develop macrometastases when 
integrins were not available. These findings suggest that collective migration represents 
an invasion mode of high cellular and molecular order that, after loss of integrin function, 
interconverts to single-cell dissemination and metastasis, similar to previous evidence from 
tumor explant models8. Therefore, application of integrin-targeted cancer therapies, which 
were designed based on established growth-and dissemination promoting properties of 
various integrin sub-types7, may be confounded by cell release and enhanced systemic 
dissemination, at least in mesenchymal tumor types. 
In chapter 5 the collective invasion niche of sarcoma and melanoma xenografts was 
further characterized by mapping its sensitivity towards genotoxic radiotherapy. Remarkably 
collective invasion strands were identified as radioresistant, whereas cells in the tumor core 
underwent apoptosis upon application of fractionated high-dose irradiation. Analysis of 
the DNA damage response (DDR) in both tumor sub-regions revealed similar amounts of 
irradiation-induced DNA double-strand breaks which were however cleared more rapidly and 
efficiently in the collective invasion zone. By comparison, persisting DDR signals in the tumor 
core indicated ill-fated attempts of DNA repair eventually followed by apoptosis induction. 
As mediators of anchorage-dependent pro-survival signals integrins have been implicated 
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in mediating radiation resistance9–12. As detailed in chapter 4, the emergence and survival 
of the invasion zones of sarcoma and melanoma xenografts were largely insensitive to β1 
and αVβ3 depletion, which accounts for the only integrin β subtypes expressed by the tumor 
models used. However, upon additional radiotherapy both the tumor core and the invading 
cell fraction underwent apoptosis followed by regression of the entire lesion, indicating that 
therapeutic resistance in the collective niche depends upon integrin-dependent pro-survival 
signaling and stimulation of DNA repair. Notably, single-chain integrin-targeting strategies 
to overcome radioresistance in (pre)clinical settings were reported as incompletely effective 
thus far13, which may result from compensation by other integrin family members. In contrast, 
dual-integrin targeting addressing all available β integrin sub-types as described in chapter 5 
effectively ablated invasion-associated radioresistance and successfully eradicated ≥ 80% of 
tumor lesions in a preclinical long-term study, hence introducing multiple integrin-targeting as 
successful strategy to (re)consider application of integrin-based anti-cancer therapy. 
Whereas chapter 3 identified the mechanism of confinement-induced collective invasion of 
mesenchymal sarcoma and melanoma tumors, chapter 4 and 5 subsequently revealed that, 
compared to the tumor core, this collective invasion zone exhibits remarkable differences 
regarding the dependency on integrin-mediated pro-survival signals as well as sensitivity 
to genotoxic treatment. Obviously, both tumor sub-regions differ in their organization and 
perception of the microenvironment and their cellular state (motile vs. static); however, which 
of these differences drive this sub-regional tumor heterogeneity and by which mechanism 
remains unresolved thus far. To address the molecular profiles of tumor sub-regions 
identified by intravital microscopy, chapter 6 describes the establishment of an image-based 
microdissection approach to separately isolate in live tissue tumor core and invasion zone 
of human sarcoma and melanoma xenografts grown in the mouse dermis for subsequent 
expression profiling by RNAseq. Whereas the separation and isolation of tumor sub-regions 
was technically successful, meaningful interpretation of global expression profiling data 
still suffered from the rather large amount of mouse stromal background contaminating the 
human cancer cell fraction. Thus further technical improvement of RNAseq procedures and 
in particular data processing is needed to better delineate gene candidates driving integrin 
dependency of radiation resistance and other oncogenic processes in the collective invasion 
zone.
Plasticity of migration – mechanisms and implications for metastasis formation
Similar to actomyosin-based single-cell migration, collective migration is plastic, i.e. it 
undergoes modification with altered intracellular signaling or an altered environment14. 
Accordingly, in this thesis (chapter 3 and 4) for two mesenchymal cancer cell models matrix 
density and integrin availability were identified as important modulators of migration plasticity, 
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stimulating either individual or collective migration. A similar range of migration mode plasticity 
has thus far primarily been reported for epithelial models: single-cell migration emerging after 
dissolution of cell-cell junctions follows two types of conversions that are currently known – 
the epithelial–mesenchymal transition (EMT) and the collective–amoeboid transition (CAT)15–
19. EMT is a well established molecular process that leads to the down-modulation of cell–
cell adhesion, whereby the migration machinery remains intact, which induces single-cell 
detachment and scattering from multicellular groups2,16,20. For mesenchymal cells, based on 
their intrinsic characteristics, the direction of migration mode conversion is actually reversed: 
they typically migrate as individualized cells but, as shown in chapter 3, switch to collective 
migration if they enter a confined matrix. Furthermore, as they readily switch back to single-
cell migration modes in unconfined environments, conversions happen rather instantaneous 
and are likely not regulated by cellular reprogramming events like EMT16. Beyond this, integrin 
depletion in confined conditions is another factor stimulating a conversion from collective 
movement to single cell detachment, which even broadens the range of migrational plasticity 
in mesenchymal cells. Whereas in epithelial models single-cell detachment is enabled by 
reduced cadherin expression, loss-of-function mutations in cadherin and catenin signaling 
pathways, or deregulated function of proteases degrading cadherins and other cell–cell 
adhesion molecules21–23, mechanisms regulating the switch towards single-cell migration after 
integrin loss in mesenchymal cells require further investigation. Fitting the broad range of 
implications of integrin-mediated downstream signaling24–26 it has been shown that via so-
called “adhesive cross-talk” integrins mediate upregulation of cadherins and thus stimulate 
formation of cadherin-based cell-cell adhesion27–29. Accordingly, loss of integrin function 
may promote the dissolution of cadherin-based junctions. Furthermore, integrins must be 
considered as further, direct or indirect, junctional gatekeepers. Thus far they have been 
shown to contribute to cell-cell attachment indirectly via intercellular deposits of the matrix 
components fibronectin or laminin30–32, or through interaction with laminins and the tetraspanin 
CD15133. Direct integrin-integrin-based cellular junctions have not been revealed yet but 
nevertheless numerous possibilities account for the interplay between integrin availability and 
switch between single-cell and collective migration modes in mesenchymal cells. 
CAT is the transition from collective invasion to amoeboid single-cell crawling after simultaneous 
weakening of cell–cell and cell–matrix interactions in epithelial and mesenchymal tumor cells 
in vitro8,18,19. The observation described in chapter 4, that decreased cellular elongation 
after integrin targeting in sarcoma and melanoma cells in vitro and in vivo follows the above-
mentioned switch from collective to single-cell migration, and consecutive cell rounding 
after detachment from the group, validates the presence of similar CAT mechanisms for 
mesenchymal models in vivo. Importantly, this intgrin-low to integrin-independent movement 
is still sufficient to execute the entire metastatic cascade, for which integrins were thus far 
described as indispensable7. Apart from ECM, the tumor micro-environment contains various 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Summary, Discussion and Implications  |  179
7
stromal cells34, which are able to form homo- and heterotypic junctions with cancer cells 
like N-cadherin-mediated interactions between cancer and endothelial cells or cadherin-23-
based adhesion between cancer cells and fibroblasts35,36. These interactions together with the 
cellular glycocalix may support friction-based force transmission as mechanism underlying 
integrin-independent movement37. Additionally, CD44 and discoidin domain receptors (DDRs) 
constitute alternative adhesion systems enabling migrating cells to interact with matrix 
components like collagens or hyaloronic acid38–41, potentially promoting integrin-independent 
migration. Via selectins expressed on endothelial cells, leukocytes and platelets cancer cells 
have numerous integrin-independent possibilities of interaction when crossing the endothelial 
barrier and entering the hematogeneous phase of the metastatic cascade7,42. Cluster 
formation with leukocytes and/or platelets not only protects disseminating cancer cells from 
shear stress but also promotes arrest in small capillaries of distant organs1,43–45, followed by 
extravasation. Granulae-release by platelets and selectin-based interactions between cancer 
cells and the endothelium might activate inflammatory pathways which increase permeability 
of the endothelial wall and thus facilitate extravasation46,47. Eventually, these mechanisms 
may coexist with integrin-dependent migration and dissemination, and gain dominance once 
integrin expression and function are downregulated. In aggregate, the results in this thesis 
indicate an important anchorage function for integrins, which limits cell dissemination and 
metastatic progression, consistent with enhanced dissemination after integrin targeting in 
certain other models48–50. 
Overall, both epithelial and mesenchymal models thus exhibit a broad range of migration 
plasticity and basically every described migration mode might contribute to metastatic 
dissemination. But, whereas collective migration increases efficiency with regard to metastatic 
outgrowth51–53, single cell migration and especially integrin-independent migration rather 
promote the seeding frequency with single cells persisting for weeks without dividing (dormancy 
phenotype)50,54. Beyond this, understanding of the signals maintained by simultaneous cell–
cell and cell–matrix communication during cancer cell invasion and secondary plasticity will be 
important in defining the cross-talk between strategies of invasion and resistance signaling55. 
Joint mechanisms of cancer invasion and resistance
Based on the multiple inputs from the tumor microenvironment and their overlapping signaling 
pathways, invasive tumor-cell migration and survival stimulation can be considered as 
interconnected cell functions. As a particular challenge, in collective invasion the joint signaling 
from tissue structures and cell–cell junctions may activate survival pathways not engaged in 
quiescent, non-invading tumor regions, eventually supporting resistance as shown in chapter 
5. Thereby, the residual niches that withstand targeting of conventional therapy can consist of 
a limited number of cells which, after surviving cycles of therapies, re-grow, initiate migration 
and thereby re-establish an invasive tumor. The signals required for both single-cell and 
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collective cancer invasion include the activation of integrins, cadherins, small GTPases Rac 
and Rho, as well as Ras pathways, and the engagement of intracellular signaling networks that 
include phosphatidylinositide 3-kinase (PI3K), mechanistic Target of Rapamycin (mTOR), Src- 
and mitogen-activated protein (MAP)- kinases55–61 (Fig. 1). Simultaneously, these pathways 
also control cell growth and survival24,55,60,62,63. 
Figure 1. Signaling pathways controlling tumour cell growth, survival and invasion.
Example pathways of p53, Ras GTPase, small Rho GTPases, integrins, growth factor receptors and 
cadherins with a dual role in controlling cell growth (upper row) and survival as well as cell migration and 
invasion (lower row). Migration effectors are marked in pink, survival effectors in purple, signaling hubs 
in bright green. Arrows indicate signaling direction. Bound to DNA, transcription factors. a-Act., a-actinin; 
cat, catenin; Cdc42, cell division cycle 42; CREB, cAMP response element-binding; CyclD1, cyclin D1; 
eIF, eukaryotic initiation factor; ERK, extracellular signal-related kinase; ETS, erythroblast transformation 
specific (transcription factor); FAK, focal adhesion kinase; GEF, guanine nucleotide exchange factor; 
GFR, growth factor receptor; GRB2, growth factor receptor-bound protein 2; ILK, integrin-linked kinase; 
Integ., integrin; JNK, Janus-kinase; MEK, mitogen-activated protein kinase/extracellular signal-regulated 
kinase kinase; MEKK, MEK kinase; MLC, myosin light chain; MLCPtase, MLC phosphatase; MRCK, 
myotonic dystrophy kinase-related Cdc42-binding kinase; NFκB, nuclear factor ‘kappa-light-chain-
enhance’ of activated B cells; PAK, p21-activated kinase; PINCH, particularly interesting Cys–His-rich 
protein; PKC, protein kinase C; PLCγ, phospholipase γ; PTEN, phosphatase and tensin homologue; 
ROCK, Rho-activated kinase; STAT, signal tranducer and activator of transcription; TIAM1, T-cell 
lymphoma invasion and metastasis 1; Vinc, vinculin; WASP, Wiskott–Aldrich syndrome protein; WAVE, 
WASPfamily Verprolin-homologous protein.
Figure also displayed and discussed in detail in: Alexander, S. & Friedl, P. Cancer invasion and resistance: 
Interconnected processes of disease progression and therapy failure. Trends Mol. Med. 18, 13–26 (2012).
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Consequently, druggable signaling hubs that may serve to target both tumor invasion and 
resistance include growth factor and chemokine signaling, integrin engagement, as well as 
downstream Ras/MAPKs, PI3K and mTOR signaling12,60,64–68. The effects of integrin-targeted 
therapy on metastatic dissemination and resistance in sarcoma and melanoma models have 
been investigated in chapter 4 and 5 of this thesis, however with increased dissemination 
after integrin targeting on the one hand but otherwise integrin-dependent radioresistance, 
responses were differential, requiring further elaboration of targeting strategies. 
Intratumor sub-regional heterogeneity – implications for (integrin-targeted) therapy
In a progressing tumor undergoing metastatic dissemination essentially each step of the 
metastatic cascade represents an anatomic and molecular “sub-compartment”, i.e. the primary 
tumor core, the invasion zone, circulating tumor cells (CTCs) and the metastatic lesion 1,2,69,70. 
The in vivo results in chapter 4 and 5 indicate that radiation and integrin-targeted therapy 
reach different efficacy for tumor sub-regions: radiotherapy causes regression of the tumor 
main mass while the invading cells survive with dissemination unaffected (Fig. 2). Similarly, 
upon integrin mono-targeting the tumor core and metastatic colonies in the lung have a major 
growth deficit and even may regress whereas the invasion zone remains largely intact but 
dissemination rate even increases (Fig. 2). These findings emphasize the need for preclinical 
therapy approaches, which dissect the therapy response for each step of the metastatic 
cascade, e.g. by using a combination of intravital imaging, blood sampling and microscopic 
metastasis screens. Conclusions about therapy efficiency based on the sole interpretation of 
effects observed for the primary lesion could lead to detrimental outcome in a patient: both 
the radiotherapy and integrin-targeting approach would have been interpreted as “successful” 
due to regressing bulk lesions, however applied in the patient resistant cell clones present in 
the invasive tumor margin or therapy-induced dormant, disseminated cells which may grow 
out after therapy completion may negatively impact prognosis. 
Beyond the joint mechanisms of cancer invasion and resistance, differences in the 
microenvironment of each tumor sub-region further account for differential therapeutic 
responses2,34,55,71–73. For tumors growing in the deep dermis or at the metastatic site, the 
core mainly consists of densely packed tumor cells interspersed with (neo)vessels and likely 
tumor associated fibroblasts74,75. Invading tumor cells may interact with stromal fibroblasts 
but additionally co-opt preexisting tissue structures including muscle fibers, blood vessel or 
nerve bundles, enclosed by a ligand-rich ECM74,76. In the blood stream cancer cells either 
interact with each other in CTC clusters or with platelets and/or immune cells, which also 
might facilitate intravascular arrest and extravasation at a distant site1,45,77. Support for 
improved cancer cell survival from the stroma, especially experienced by the disseminating 
cancer cell fraction, may result from differentially engaged receptor systems, e.g. integrins or 
DDRs in collagen-rich environments or CD44 interacting with selectins on endothelial cells or 
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leukocytes78,79. Eventually, the exposure to an increased ligand diversity and higher amount of 
engaged extracellular receptors with subsequent activation of downstream survival signaling 
cascades likely underlies increased survival of invading cancer cells compared to the tumor 
core and might also explain anoikis resistance observed after integrin-targeted therapy2,3,55. 
To unravel the exact mechanisms driving intratumor heterogeneity and differential 
therapy responses in sarcoma and melanoma lesions chapter 6 describes a microscopy-
guided microdissection approach to intravitally isolate different tumor and stromal sub- 
compartments for subsequent molecular profiling including gene expression or analysis of 
epigenetic modifications. To identify new therapeutic targets to overcome metastatic tumor 
cell dissemination, performing the profiling under therapeutic pressure might help to obtain 
local resistance mechanisms. Most likely this will result in combined approaches such as the 
combination of radiotherapy and dual (β1 and αVβ3) integrin targeting investigated in chapter 
5. To eliminate the invasion niche and prevent seeding to distant organs, combining DNA 
damage induction (irradiation) and anoikis-based mechanisms (integrin-targeting) reaches 
a level of apoptosis induction sufficient to eradicate the entire tumor lesion, including tumor 
main mass and invasion zone and further prevents lung metastasis (Fig.2). To further address 
compensatory upregulation by other integrins as resistance mechanism, which may contribute 
to the limited efficacy of clinical application of single-integrin targeting in cancer13,65,80, targeting 
approaches described in chapter 4 and 5 preceded generation of an integrin expression 
profile to subsequently target all expressed integrin β chains. Correspondingly, similar screens 
become included into innovative cancer therapy regimens, including multi-targeted kinase 
inhibition and immunotherapy, moving towards personalized treatment options65,81,82. 
Conclusion
The findings described in this thesis, employing 3D organotypic tissue culture and preclinical 
intravital microscopy, contribute to the mechanistic understanding of cancer invasion and 
metastasis. The results emphasize the contribution of the tumor microenvironment to metastatic 
progression and intratumor heterogeneity, and how invasion and the microenvironment jointly 
support cancer cell survival and resistance in mesenchymal tumor types. The here developed 
treatment strategy of combined radiotherapy and dual/multiple-integrin targeting should be 
considered as option to address radioresistance in the clinics, replacing approaches applying 
mono integrin-targeting. 
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Figure 2. Sub-regional tumor heterogeneity during metastatic cancer progression accounting for 
differential treatment response and the need for combination therapies.
Effects of local irradiation and integrin-targeted therapy on a tumor lesion undergoing metastatic 
dissemination. Tumor core, invasion zone, disseminating tumor cells and metastatic lesions respond 
differentially to the applied treatment, underlying therapy failure due to resistance development or 
enhanced dissemination. Only the combination of both therapeutic approaches reaches a level of 
apoptosis induction sufficient to kill the primary tumor and overcome metastatic dissemination.
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Kanker behoort wereldwijd tot de grootste doodsoorzaken, en is voornamelijk dodelijk door 
het vermogen van kankercellen om uitzaaiingen (metastasen) te vormen of door resistentie 
tegen therapieën te ontwikkelen. De progressie van een groeiende naar een metastaserende 
kanker verloopt via verschillende stappen: 1) de lokale invasie van migrerende kankercellen 
in het weefsel rondom de primaire tumor, 2) het binnendringen van tumorcellen in bloed en/
of lymfevaten, 3) het verlaten van de bloed en lymfevaten elders in het lichaam, en 4) de 
kolonisatie en de vorming van afstandsmetastasen in andere organen. Ondanks het feit dat 
metastaserende cellen waarschijnlijk allemaal afkomstig zijn van een enkele gemuteerde cel 
kloon, gedragen metastaserende kankercellen zich vaak anders dan de cellen in de primaire 
tumor. Deze verschillen kunnen worden veroorzaakt door variatie in cellulaire mechanismen 
die cellen gebruiken om de verschillende stappen van metastasen te bewerkstelligen. Een 
belangrijk verschil hierbij is de manier van celmigratie, waarbij cellen of als individuele 
cellen migreren, of als groepje cellen, ook wel genoemd collectieve celmigratie. Gedurende 
metastasering worden cellen bovendien blootgesteld aan verschillende milieus, waaraan 
ze zich zullen aanpassen, en hierdoor verdere veranderingen ondergaan. De focus van dit 
proefschrift is het gedrag van mesenchymale soorten kanker, die gekarakteriseerd worden 
door migratie als individuele cellen. In dit proefschrift wordt bestudeerd hoe deze tumorcellen 
zich uitzaaien en hoe zij resistentie tegen bestaande kanker therapieën ontwikkelen. Hiervoor 
werd gebruik gemaakt van zowel in vitro spheroid als in vivo xenograft modellen.
Collectieve cel migratie draagt bij aan het ontstaan van metastasen, maar is ook van belang 
tijdens embryonale ontwikkeling of bij het herstel van beschadigd weefsel. Hoofdstuk 2 
geeft een samenvatting van de mechanismes waarmee collectieve cel migratie de richting 
van migratie reguleert. Sturing van de celgroepen, waarbij de cellen met cel-cel bindingen 
contact houden, is essentieel om collectieve beweging van cellen onderling te coördineren. 
Mechanismes om migrerende celgroepen te sturen zijn onder ander afhankelijk van de 
topografie en/of stijfheid van de omgeving (sturing door middel van omgevingscontact) en 
van fysieke parameters zoals stroming van vloeistof. Vloeistofstromen kunnen actief cellen 
sturen via signalen afkomstig van frictiekrachten, of passief, door cellen mee te voeren. 
Voorts kunnen signalen van oplosbare moleculen of elektrische signalen, die ionkanalen 
stimuleren, betrokken zijn. Sturing door deze factoren wordt vaak bewerkstelligd doordat ze 
als gradiënt aanwezig zijn en op deze manier celgroepen heterogeen stimuleren en hierdoor 
sturen. Als een celgroep meerdere sturingssignalen tegelijk ontvangt, is het belangrijk deze te 
integreren en te prioriteren. Samen met de intrinsieke migratie programma's van de cellen zal 
dit uiteindelijk het karakter en de richting van collectieve migratie bepalen. 
In hoofdstuk 3 wordt met in vitro experimenten met 3D celkweek methoden onderzocht of 
en hoe de topografie van de omgeving, in het bijzonder de dichtheid en stijfheid, invloed 
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heeft op de individuele of collectieve migratie van mesenchymale sarcoom- en melanoom 
cellen. De resultaten laten zien dat toenemende dichtheid van de omgeving zorgt voor een 
switch van individuele naar collectieve migratie. Deze resultaten waren verrassend omdat 
collectieve migratie mechanismes een karakteristieke eigenschap is van kankercellen met 
een epitheliale oorsprong, terwijl individuele cel migratie typerend is voor mesenchymale 
cellen. Mesenchymale cellen vormen geen sterke cel-cel contacten en migreren dus in 
een omgeving met lage dichtheid als individuele cellen. Echter, zodra de dichtheid van de 
omgeving hoog is, en dus ruimte beperkt is, moeten cellen ruimte genereren via proteolyse 
waardoor er paden ontstaan, waarlangs vervolgens ook andere cellen migreren. Omdat 
alleen de voorste cellen van een celcollectief, genaamd "leider cellen" deze paden kunnen 
maken, en "volger cellen" hier achteraan bewegen, zullen er files ontstaan. Als gevolg 
hiervan vormen de cellen onderlinge cel-cel contacten, waardoor een collectieve polariteit 
opgebouwd wordt. Samenvattend laat dit hoofdstuk zien, dat topografische beperking ten 
grondslag ligt aan collectieve migratie van mesenchymale kankercellen terwijl een omgeving 
zonder ruimtelijke beperking individuele cel migratie bevordert. De dichtheid van de omgeving 
is daarom een bepalende factor om de migratie mechanisme van mesenchymale cellen te 
beïnvloeden. Stijfheid van de omgeving heeft echter geen effect op de manier van migratie 
van mesenchymale cellen. 
Hoofdstuk 4 laat zien dat de in vitro bevindingen uit hoofdstuk 3 ook in vivo worden 
waargenomen. Dit hoofdstuk beschrijft de implantatie van humane sarcoma en melanoom 
cellijnen als xenograft tumor in de dermis van een muis. Met behulp van multifotonen 
microscopie is de invasie van de kankercellen uit de primaire tumor in de orthotrope 
omgeving bestudeerd, waarbij ook collectieve migratie wordt waargenomen. Dit komt omdat 
de grensvlakken tussen weefselstructuren, die in vivo aanwezig zijn, zoals spiervezels of 
bloedvaten, ruimtelijk begrensde omgevingen vormen welke collectieve migratie mogelijk 
maken. Celmigratie is in veel gevallen afhankelijk van het vermogen van cellen om met 
behulp van bindingseiwitten, genaamd integrines, te binden aan de omliggende matrix. 
Hoofdstuk 4 laat echter zien dat collectieve invasie van sarcoom en melanoom cellen in vivo 
ook onafhankelijk van β1- en αVβ3 integrines kan plaatsvinden. De afwezigheid van deze 
integrines veroorzaakt wel een switch naar individuele migratie. Dus, naast dichtheid van 
de omgeving is ook de aanwezigheid van integrines een bepalende factor voor de migratie 
patroon van mesenchymale cel types. Omdat sarcoom en melanoom cellen in vivo blijkbaar 
zonder integrines het weefsel kunnen binnendringen, werd vervolgens onderzocht of de cellen 
ook metastasen kunnen vormen in afwezigheid van integrines. Hiervoor was de hypothese dat 
integrines absoluut noodzakelijk zijn voor de uitzaaiing van kankercellen. Het blijkt echter dat 
integrine-onafhankelijke individuele en collectieve invasie nog steeds tot uitzaaiing kan leiden 
en dat de frequentie van uitzaaiing zelfs verhoogd is vergeleken met cellen waarbij integrines 
nog aanwezig zijn. Omdat integrines ook van belang zijn voor de overleving van cellen, zijn de 
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primaire tumor en de metastasen wel geremd in hun groei. Gezien het belang van integrines 
voor overleving en groei, zijn voorheen kanker therapieën ontwikkeld, die integrines blokkeren 
en dus groei van de tumor remmen. Echter, zoals hoofdstuk 4 laat zien, is het mogelijk dat 
dergelijke therapieën, tenminste voor mesenchymale soorten kanker, leiden tot verhoogde 
uitzaaiing van enkele kankercellen, welke na voltooien van de therapie, kunnen uitgroeien tot 
makroskopische metastasen. 
In hoofstuk 5 is onderzocht of collectieve migratie van sarcoom en melanoom cellen 
in vivo leidt tot een veranderde gevoeligheid voor radiotherapie. Opmerkelijk was dat het 
deel van de tumor dat collectieve invasie ondergaat resistent is tegen de bestraling, terwijl 
cellen in de tumorkern apoptose ondergaan na een hoge dosis gefractioneerde bestraling. 
De hoeveelheid DNA schade na bestraling was vergelijkbaar in beide tumor fracties. Echter, 
analyse van de reactie op DNA-schade liet zien dat herstel van de DNA schade sneller en 
efficiënter is in de cellen uit de collectieve migratie zone. In de tumorkern waren tekenen 
te zien van een verstoorde DNA-schade respons, leidend tot celdood via apoptose. Omdat 
integrines belangrijk zijn voor adhesieafhankelijke overleving kunnen ze een rol spelen bij 
de resistentie tegen bestraling. In hoofdstuk 4, is al laten zien dat collectieve migratie en de 
overleving van migrerende sarcoom en melanoom cellen grotendeels onafhankelijk van β1 
en αVβ3 integrines is. Echter, als remming van integrines wordt gecombineerd met bestraling 
leidt dit tot apoptose van zowel de tumor kern als het collectief-invasieve deel, waardoor 
uiteindelijk regressie van de hele tumor optreedt. Samenvattend laat dit zien dat resistentie 
tegen bestraling in collectief-invasieve cellen, afhankelijk is van integrine-gemedieerde 
overlevingssignalen en stimulatie van herstel van DNA schade. Pogingen om resistentie 
tegen bestraling door middel van integrine interferentie als therapie te bestrijden, zijn tot nu 
toe onsuccesvol gebleken. Een mogelijke verklaring is dat de therapie was gericht tegen 
maar een integrine keten, welke door verhoogde expressie van een andere integrine keten 
gecompenseerd kon worden. De therapie beschreven in hoofdstuk 5 is gericht tegen twee 
integrine ketens, welke ook de enige zijn die in de gebruikte sarkoom en melanoom cel 
lijnen tot expressie komen. De remming van alle beschikbare integrines lijkt een effectieve 
strategie om resistentie tegen bestraling in collectief migrerende kankercellen aan te gaan. In 
overeenstemming hiermee werden in een lange-termijn studie ≥ 80% van de tumoren volledig 
geëlimineerd, wat een goede aanwijzing is om kanker therapiën, die tegen integrines zijn 
gericht, weer in overweging te nemen. 
Terwijl in hoofdstuk 3 ruimtelijke beperking als mechanisme werd geïdentificeerd om 
mesenchymale sarkoom en melanoom cellen collectief te laten migreren, laten hoofdstuk 
4 en 5 vervolgens zien, dat vergeleken met de tumorkern, de cellen die collectief invaderen, 
verschillend zijn wat betreft afhankelijkheid van integrine-gemedieerde overlevingssignalen 
en gevoeligheid voor bestraling. Blijkbaar zijn zowel organisatie als de waarneming van de 
omgeving verschillend voor beide tumor regio’s. Bovendien hebben ze een verschillende 
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status, namelijk bewegend vs. statisch. Welke van deze verschillen verantwoordelijk zijn voor 
de intra-tumor heterogeniteit is tot nu toe niet bekend. Een manier om dit uit te vinden, is het 
opstellen van een moleculair profiel van beide tumor regio’s (kern vs. collectieve invasie). 
Om deze reden beschrijft hoofdstuk 6 de ontwikkeling van een methode om de tumorkern 
en de invasie zone van sarkoom en melanoom xenografts in de muis dermis van elkaar 
te scheiden, en vervolgens te analyseren met behulp van RNA sequencing (RNAseq). 
Hoewel deze methode succesvol is opgezet, waren de verkregen resultaten moeilijk te 
interpreteren vanwege de hoge aanwezigheid van RNA uit het omliggend muisweefsel wat 
tot hoge achtergrond waarden leidde. Een technische verbetering van de zowel de RNAseq 
procedure en data analyse is daarom noodzakelijk om kandidaat genen te identificeren die 
de afhankelijkheid van integrines en resistentie tegen bestraling en andere oncologische 
processen in de collectieve migratie zone van melanoom en sarkoom cellen bepalen. Het 
uiteindelijke doel is om op deze manier nieuwe targets voor kanker therapiën te vinden en/of 
al bestaande therapiën door middel van combinaties te verbeteren.
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